日本臨牀　67/増刊4　パーキンソン病

出版社： 日本臨牀社
発行日： 2009-06-28
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： パーキンソン病　基礎・臨床研究のアップデート
電子書籍版： 2009-06-28 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,200 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

13,200 円(税込)

購入する

目次

  • 日本臨牀　67/増刊4　パーキンソン病

    ―目次―

    特集　パーキンソン病　基礎・臨床研究のアップデート

    ?． 総説 　 　
    　１． パーキンソン病の歴史的な流れ 　
    　２． パーキンソン病の疾患概念と分類 　
    　３． 我が国におけるパーキンソン病の疫学研究 　
    　４． 我が国におけるパーキンソン病病態研究の歩み 　

    II． 病因 　 　
    　１． 関連遺伝子 　 　
    　２． 環境因子 　 　
    　３． その他の因子 　 　
    　
    III． 病理・病態 　 　
    　１． 病態生理─無動、固縮、振戦、姿勢反射障害─ 　
    　２． 大脳基底核の神経回路とパーキンソン病における
    　　　　　病態神経生理 　
    　３． 神経病理学的特徴 　 　

    IV． 検査・診断 　 　
    　１． 診断基準 　
    　２． 臨床症状 　
    　３． 一般検査─電気生理学的検査、血液・尿・血清検査、
    　　　　　髄液検査など─ 　
    　４． 自律神経障害とその機能検査法 　 　
    　５． 神経心理学的検査 　
    　６． 画像検査 　 　
    　７． 関連疾患 　 　

    V． 治療 　 　
    　１． パーキンソン病治療ガイドライン
    　　　　　─我が国と欧米との比較─ 　
    　２． パーキンソン病の早期治療について 　
    　３． 非薬物療法 　 　
    　４． 薬物療法 　 　
    　５． 外科的治療 　 　
    　６． 脳刺激治療 　 　
    　７． 再生療法 　 　
    　８． 遺伝子治療 　 　
    　９． リハビリテーション 　 　
    　
    VI． 治療上の問題点と対策 　 　
    　１． 運動症状 　 　
    　２． 非運動症状 　 　
    　 心臓弁膜症 　

    VII． QOL 　 　
    　１． ＡＤＬ 　
    　２． 在宅医療 　
    　３． 教育活動-全国パーキンソン病友の会- 　
    　４． 患者の高齢化に対する長期治療計画 　


この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

序文

P.4 掲載の参考文献
1) Parkinson J : An Essay on the Shaking Palsy, Sherwood, Neely, and Jones, London, 1817.
 
2) 小阪憲司ほか : レビー小体病の臨床病理学的研究. 精神経誌 82 : 292-311, 1980.
 
3) Langston JW : The Parkinson's complex : Parkinsonism is just the tip of the iceberg. Ann Neurol 59 : 591-596, 2006.
PubMed
4) Toessl AJ : Gene therapy for Parkinson's disease : early data. Lancet 369 : 2056-2058, 2007.
 
5) 白水重尚ほか : 123I-MIBG心筋シンチグラフィによる心臓交感神経機能の検討. 臨床神経 34 : 402-404, 1994.
 
6) 葛原茂樹 : パーキンソン病治療の現状と展望. 臨床神経 48 : 835-843, 2008.
 
7) Murata M, et al : Zonisamide improves motor function in Parkinson disease. A randomized, double-blind study. Neurology 68 : 45-50, 2007.
PubMed
8) Gasser T : Update on the genetics of Parkinson's disease. Mov Disord 22 (Suppl 17) : S343-S350, 2007.
 

I 総説

P.10 掲載の参考文献
1) Parkinson J : An essay on the shaking palsy, Sherwood, Neely, and Jones, London, 1817 (in Arch Neurol Psychiatr 7 : 681-710, 1922).
 
2) Tretiakoff C : Contribution a l'etude de l'anatomie pathologique de locus niger de Soemmering avec queles deductions relatives a la pathologenie des traboules du tonus musculaire et de la maladie de Parkinson, These de Paris, no 293, 1919.
 
3) Kosaka K, et al : Diffuse type of Lewy body disease : progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree. A new disease? Clin Neuropathol 3 : 185-192, 1984.
PubMed
4) McKeith IG, et al : Consensus guidelines for the clinical and pathologic diagnosis with dementia with Lew bodies (DLB) : report of the Consortium on DLB International Workshop. Neurology 47 : 1113-1124, 1996.
 
5) Qualman SJ, et al : Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87 : 848-856, 1984.
PubMed
6) 菱川望ほか : Pure autonomic failure (PAF) の神経病理学的特徴. 神経内科 57 : 35-43, 2002.
 
7) Orimo S, et al : 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 189-194, 1999.
 
8) Langston JW, et al : Chronic parkinsonism in humans due to a product on meperidine-analog synthesis. Science 219 : 979-980, 1983.
PubMed
9) Polymeropoulos MH, et al : Mutation in alpha-synuclein gene identhied infamilies With Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
10) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
11) Birkmayer W, Hornykiewicz O : Der L-34-Dioxyphenylalanine (DOPA)-Effekt bei der Parkinson-Akinese. Wien Min Wochenschr 73 : 787-788, 1961.
 
12) Laitinen LV, et al : Lekselr s posteroventral pallidotomy in the treatment of Parkinson's disease. J Neurosurg 76 : 53-61, 1992.
PubMed
P.15 掲載の参考文献
1) 内藤寛, 葛原茂樹 : パーキンソン病の鑑別診断 日本臨牀 62 (9) : 1608-1616, 2004.
Medical*Online
2) Parkinson J : An Essay on the Shaking Palsy, Whittingham and Rowland for Sherwood, Neely and Jones, London, 1817.
 
3) 豊倉康夫ほか : パーキンソン病の原著と全訳, 三共, 1974.
 
4) Tretiakoff C : Contributions a l'etude de l'anatomie patholgique du locus niger de Soemmering avec quelques d6ductions relatives a la pathogenie des troubles de tonus musculaire et de la maladie de Parkinson, Thesis, Paris, 1919.
 
5) Lewy FH : Zur Pathologischen Anatomie der Paralysis Agitans. Dtsch Z Nervenheilkd 50 : 50, 1913.
 
6) Gibb WR, Lees AJ : The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51 : 745-752, 1988.
 
7) Goetz CG : Charcot on Parkinson's disease. Mov Disord l : 27-32, 1986.
 
8) 服部信孝ほか : 遺伝性パーキンソン病の病態と診断. MDSJ Letters 1 (1) : 6-8, 2008.
 
9) Gowers WR : AManual of Diseases of the Nervous System, Churchill, London, 1986.
 
10) Polymeropoulos MH, et al : Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
 
11) Warner TT, Schapira AH : Genetic and environmental factors in the cause of Parkinson's disease. Ann Neurol 53 (Supp13) : S16-S23, 2003.
PubMed
12) Langston JW : The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 59 (4) : 591-596, 2006.
PubMed
P.23 掲載の参考文献
1) 中島健二ほか : 日本におけるパーキンソン病の現状. 成人病と生活習慣病 38 : 882-886, 2008.
Medical*Online
2) Kusumi M, et al : Epidemiology of Parkinson's disease in Yonago City, Japan ; Comparison with a study carried out 12 years ago. Neuroepidemiology 15 : 201-207, 1996.
PubMed
3) 田代邦雄 : 本邦におけるParkinson病の疫学調査-総論-. 神経内科 57 : 467-470, 2002.
 
4) 伊藤和則ほか : 北海道 (岩見沢市) におけるParkinson病の疫学調査. 神経内科 57 : 492-497, 2002.
 
5) 山崎俊三ほか : 京都府におけるParkinson病の疫学調査-1978年調査と2001年調査の比較-. 神経内科 57 : 478-484, 2002.
 
6) 中川正法, 有里敬代 : 鹿児島県におけるParkinson病の疫学調査-1980年調査との比較検討-. 神経内科 57 : 471-474, 2002.
 
7) 楠見公義, 中島健二 : 鳥取県におけるパーキンソン病の疫学調査. 神経内科 57 : 475-477, 2002.
 
8) 中島健二, 楠見公義 : パーキンソン病の最近の疫学. Annual Review神経2008, p 370-378, 中外医学社, 2008.
 
9) Yamawaki M, et al : Changes in prevalence and incidence of Parkinson's disease in Japan during a quarter of a century. Neuroepidemiology. (in press)
 
10) Barbosa MT, et al : Parkinsonism and Parkinson's disease in the elderly : A community-based survey in Brazil (the Bambui study). Mov Disord 21 : 800-808, 2006.
PubMed
11) de Lau LM, Breteler MM : Epidemiology of Parkinson's disease. Lancet Neurol 5 : 525-535, 2006.
PubMed
12) Louis ED, Bennett DA : Mild Parkinsonian signs : An overview of an emerging concept. Mov Disord 22 : 1681-1688, 2007.
PubMed
13) 木村英紀, 加藤丈夫 : 山形県におけるParkinson病の疫学調査. 神経内科 57 : 485-491, 2002.
 
14) 三村将 : パーキンソン病におけるうつ状態-その診断と評価-. パーキンソン病-病因病態と治療, うつ・衝動制御障害 (山本光利編), p161-168, 中外医学社, 2008.
 
15) Nomura T, et al : Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Mov Disord 21 : 380-384, 2006.
PubMed
P.27 掲載の参考文献
1) Sano I, et al : Distribution of catechol compounds in human brain. Biochim Biophys Acta 32 : 586-587, 1959.
PubMed
2) Von Euler US : Assay of noradrenalin and adrenalin in extracts of nerves and tissues. Nature 162 (4119) : 570, 1948.
 
3) Von Euler US : Preparation, purification and evaluation of noradrenaline and adrenaline in organ extracts. Arch Int Pharmacodyn Ther 77 : 477-485, 1948.
PubMed
4) Carlsson A, et al : On the presence of 3-hydroxytyramine in brain. Science 127 : 471, 1958.
PubMed
5) 佐野勇 : 錐体外路系の生化学. 神経研究の進歩 5 : 42-48, 1960.
 
6) Ehringer H, Hornykiewicz O : Verteilung von noradrenalin und dopamin in gehirndes menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wochenschr 38 : 1236, 1960.
 
7) Birkmayer WZ, Hornykiewicz O : Der 3, 4-L-dioxyphenylalanin effekt bei der Parkinson a kinese. Wien Min Wochenschr 73 : 787, 1960.
 
8) Sano H : Biochemistry of the extrapyramidal system Shinkei Kennkyu No Shinpo, Advances in Neurological Sciences. (ISSN 0001-8724) Tokyo, October 1960 ; 5 : 42-48. Parkinsonism Relat Disord 6 : 3-6, 2000.
 
9) http://nobelprize.org/nobel-prizes/medicine/laureates/2000/carlsson-lecture.html
 
10) Nagatsu T, et al : Biopterin in human brain and urine from controls and parkinsonian patients : application of a new radioimmunoassay. Clin Chim Acta 109 : 305-311, 1981.
PubMed
11) Nagatsu T, et al : Biosynthesis of tetrahydrobiopterin in parkinsonian human brain. In : Advance in Neurology, Vol 45 (ed by Yahr MD, Bergmann KJ), p 223-226, Raven Press, New York, 1986.
 
12) Yamaguchi T, et al : Effects of tyrosine administration on serum biopterin in normal controls and patients with Parkinson's disease. Science 219 : 75-77, 1983.
PubMed
13) Narabayashi H, et al : Clinical effects of L-threo-3, 4-dihydroxyphenylserine in cases of parkinsonism and pure akinesia. In : Advance in Neurology, Vol 45 (ed by Yahr MD, Bergmann KD, p593-602, Raven Press, New York, 1986.
 
14) Mizuno Y, et al : Inhibition of mitochondrial NADH-ubiquinone oxidoreductase activity by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143 : 294-299, 1987.
PubMed
15) Mizuno Y, et al : Inhibition of mitochondrial alpha-ketoglutarate dehydrogenase by 1-methyl-4-phenylpyridinium ion. Biochem Biophys Res Commun 143 : 971-976, 1987.
PubMed
16) 白水重尚ほか : 123I-MIBG心筋シンチグラフィによる心臓交感神経機能の検討. 臨床神経 34 : 402-404, 1994.
 
17) 織茂智之 : パーキンソニズムおよびLewy小体型痴呆の鑑別診断におけるMIBG心筋シンチグラフィーの有用性. 神経内科 58 : 544-554, 2003.
 
18) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
19) Yamamura Y, et al : Paralysis agitans of early onset with marked diurnal fluctuation of symptoms. Neurology 23 : 239-244, 1973.
PubMed
20) Narabayashi H : Lessons from stereotaxic surgery using microelectrode techniques in understanding parkinsonism. Mt Sinai J Med 55 : 50-57, 1988.
PubMed

II 病因

P.34 掲載の参考文献
1) Maroteaux L, et al : Synuclein : a neuron-spechic protein localized to the nucleus and presynaptic nerve terminal. J Neurosci 8 : 2804-2815, 1988.
 
2) Ueda K, et al : Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc Natl Acad Sci USA 90 : 11282-11286, 1993.
PubMed
3) Polymeropoulos MH, et al : Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
PubMed
4) Recchia A, et al : Alpha-synuclein and Parkinson's disease. EASEB J 18 : 617-626, 2004.
PubMed
5) Kubo S, et al : A combinatorial code for the interaction of alpha-synuclein with membranes. J Biol Chem 280 : 31664-31672, 2005.
 
6) Ross CA Poirier MA : Protein aggregation and neurodegenerative disease. Nat Med (Suppl) : S10-S17, 2004.
 
7) Golbe L1, et al : A large kindred with autosomal dominant Parkinson's disease. Ann Neurol 27 : 276-282, 1990.
 
8) Choi JM, et al : Analysis of PARK genes in a Korean cohort of early-onset Parkinson disease. Neurogenetics 9 : 263-269, 2008.
 
9) Singleton AB, et al : Alpha-Synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003.
PubMed
10) Nishioka K. et al : Clinical heterogeneity of alpha-synuclein gene duplication in Parkinson's disease. Ann Neurol 59 : 298-309, 2006.
PubMed
11) Cohen J : Genomics. DNA duplications and deletions help determine health. Science 317 : 1315-1317, 2007.
PubMed
12) Obi T, et al : Clinicopathologic study of a SNCA gene duplication patient with Parkinson disease and dementia. Neurology 70 : 238-241, 2008.
PubMed
13) 戸田達史 : 孤発性パーキンソン病のゲノムワイドスクリーニング. ゲノム医学 8 : 105-110, 2008.
Medical*Online
14) Chen L, Feany MB : Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 8 : 657-663, 2005.
 
15) Hayashita-Kinoh H, et al : Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochem Biophys Res Commun 341 : 1088-1095, 2006.
PubMed
P.39 掲載の参考文献
1) Lucking C, et al : Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 342 : 1560-1567, 2000.
 
2) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 : 605-608, 1998.
 
3) Shimura H, et al : Familial Parkinson disease gene product parkin, is a ubiquitin-protein ligase. Nat Genet 25 : 302-305, 2000.
PubMed
4) Matsuda N, et al : Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281 : 3204-3209, 2006.
PubMed
5) Imai Y, et al : An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 : 891-902, 2001.
PubMed
6) Yang Y, et al : Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37 : 911-924, 2003.
 
7) Imai Y, et al : Pael receptor involved in dopamine metabolism in the nigrostriatal system. Neurosci Res 59 : 413-425, 2007.
PubMed
8) Olzmann JA, et al : Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 178 (6) : 1025-1038, 2007.
PubMed
9) Yang Y, et al : Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103 : 10793-10798, 2006.
PubMed
10) Deng H, et al : The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105 : 14503-14508, 2008.
 
11) Narendra D, et al : Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183 : 795-803, 2008.
PubMed
12) Jiang H, et al : Parkin increases dopamine uptake by enhancing the cell surface expression of dopamine transporter. J Biol Chem 279 : 54380-54386, 2004.
PubMed
13) Marazziti D, et al : Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor. Proc Natl Acad Sci USA 101 : 10189-10194, 2004.
PubMed
14) Marazziti D, et al : GPR37 associates with the dopamine transporter to modulate dopamine uptake and behavioral responses to dopaminergic drugs. Proc Natl Acad Sci USA 104 : 9846-9851, 2007.
PubMed
P.44 掲載の参考文献
1) Leroy E, et al : The ubiquitin pathway in Parkinson's disease. Nature 395 : 451-452, 1998.
PubMed
2) Lincoln S, et al : Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport 10 : 427-429, 1999.
PubMed
3) Maraganore DM, et al : Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53 : 1858-1860, 1999.
PubMed
4) Saigoh K, et al : Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 23 : 47-51, 1999.
PubMed
5) Setsuie R, Wada K : The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem Int 51 : 105-111, 2007.
PubMed
6) Mizuno Y, et al : Progress in familial Parkinson's disease. J Neural Transm Suppl 70 : 191-204, 2007.
 
7) Setsuie R, et al : Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease-associated UCH-L1 I93M mutant. Neurochem Int 50 : 119-129, 2007.
PubMed
8) Kabuta T, et al : Aberrant molecular properties shared by familial Parkinson's disease-aasociated mutant UCH-L1 and carbonyl-modified UCH-L1. Hum Mol Genet 17 : 1482-1496, 2008.
PubMed
9) Kabuta T, et al : Aberrant interaction between Parkinson's disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J Biol Chem 283 : 23731-23738, 2008.
PubMed
10) Osaka H, et al : Ubiquitin carboxy-temlinal hydrolase L1 binds to and stabilizes monoubiquitin in neurons. Hum Mol Genet 12 : 1945-1958, 2003.
PubMed
11) Nishikawa K, et al : Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304 : 176-183, 2003.
PubMed
12) Kabuta T, Wada K : Insights into links between familial and sporadic Parkinson's disease : Physical relationship between UCH-L1 variants and chaperone-mediated autophagy. Autophagy 4 : 827-829, 2008.
PubMed
13) Maraganore DM, et al : UCHL1 is a Parkinson's disease susceptibility gene. Ann Neurol 55 : 512-521, 2004.
PubMed
14) Healy DG, et al : UCHL-1 is not a Parkinson's disease susceptibility gene. Ann Neurol 59 : 627-633, 2006.
 
15) Liu Y, et al : The UCH-L1 gene encodes two opposing enzymatic activities that affect alphasynuclein degradation and Parkinson's disease suscepdbility. Cell 111 : 209-218, 2002.
PubMed
16) Castegna A, et al : Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I : creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1. Free Radic Biol Med 33 : 562-571, 2002.
PubMed
17) Choi J, et al : Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson'sand Alzheimer's diseases. J Biol Chem 279 : 13256-13264, 2004.
 
18) Gong B, et al : Ubiquitin hydrolase Uch-Ll rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell 126 : 775-788, 2006.
 
19) Sakurai M, et al : Reduction of memory in passive avoidance learning, exploratory behavior and synaptic plasticity in mice with a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. Eur J Neurosci 27 : 691-701, 2008.
PubMed
20) Metzger S, et al : The S18Y polymorphism in the UCHL1 gene is a genetic modifier in Huntington's disease. Neurogenetics 7 : 27-30, 2006.
PubMed
21) Wilkinson KD, et al : The neuron-specific protein PGP 9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246 : 670-672, 1989.
PubMed
22) Manago Y, et al : Potentiation of ATP-induced currents due to the activation of P2X receptors by ubiquitin carboxy-terminal hydrolase L1. J Neurochem 92 : 1061-1072, 2005.
 
23) Sakurai M, et al : Ubiquitin C-terminal hydrolase L1 regulates the morphology of neural progenitor cells and modulates their differentiation. J Cell Sci 119 (Pt 1) : 162-171, 2006.
 
24) Harada T, et al : Role of ubiquitin carboxy terminal hydrolase-L1 in neural cell apoptosis induced by ischemic retinal injury in vivo. Am J pathol 164 : 59-64, 2004.
PubMed
25) Kwon J, et al : Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am J Pathol 165 : 1367-1374, 2004.
PubMed
26) Sano Y, et al : Photoreceptor cell apoptosis in the retinal degeneration of Uchl3 deficient mice. Am J Pathol 169 : 132-141, 2006.
PubMed
27) Kim HJ, et al : Ubiquitin C-terminal hydrolase-L1 is a key regulator of tumor cell invasion and metastasis. Oncogene, 2008. (Epub ahead of print)
 
28) Rolen U, et al : The Ubiquitin C-terminal Hydrolase UCH-L1 regulates B-cell proliferation and integrin activation. J Cell Mol Med, 2008. (Epub ahead of print)
 
29) 田中章景, 祖父江元 : 神経疾患・腫瘍の統合分子医学. 生化学 79 : 121-130, 2007.
 
30) Lowe J, et al : Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 161 : 153-160, 1990.
PubMed
31) Das C, et al : Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc Natl Acad Sci USA 103 : 4675-4680, 2006.
PubMed
32) Johnston SC, et al : Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8 A resolution. EMBO J 16 : 3787-3796, 1997.
PubMed
33) Liu Y, et al : Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 10 : 837-846, 2003.
PubMed
34) Hirayama K, et al : Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening. Bioorg Med Chem 15 : 6810-6818, 2007.
PubMed
35) Setsuie R, et al : Ubiquitin dimers control the hydrolase activity of UCH-L3. Neurochem Int. (in press)
 
P.50 掲載の参考文献
1) Valente EM, et al : Hereditary early onset Parkinson's disease caused by mutations in PINK1. Science 304 : 1158-1160, 2004.
PubMed
2) Klein C, et al : Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6 : 652-662, 2007.
PubMed
3) Pridgeon JW, et al : PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5 : e172, 2007.
PubMed
4) Plun-Favreau H, et al : The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9 : 1243-1252, 2007.
PubMed
5) Gautier CA, et al : Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc Natl Acad Sci USA 105 : 11364-11369, 2008.
PubMed
6) Park J, et al : Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441 : 1157-1161, 2006.
PubMed
7) Clark IE, et al : Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441 : 1162-1166, 2006.
PubMed
8) Yang Y, et al : Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci USA 103 : 10793-10798, 2006.
PubMed
9) Deng H, et al : The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proc Natl Acad Sci USA 105 : 14503-14508, 2008.
 
10) Yang Y, et al : Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci USA 105 : 7070-7075, 2008.
PubMed
11) Bonifati V, et al : Early-onset parkinsonism associated with PINK1 mutations : frequency, genotypes, and phenotypes. Neurology 65 : 87-95, 2005.
PubMed
12) 山下拓史ほか : パーキンソン病-最近の進歩PINK1の機能-ミトコンドリア機能との関連性から. 最新医学 62 : 1649-1653, 2007.
 
13) Gandhi S, et al : PINK1 protein in normal human brain and Parkinson's disease. Brain 129 : 1720-1731, 2006.
PubMed
14) 山下拓史ほか : 発症後30年経過したPARK6の1例-脳機能画像による検討-. 臨床神経 48 : 662-665, 2008.
 
P.54 掲載の参考文献
1) Bonifati V, et al : Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299 : 256-259, 2003.
 
2) Hague S, et al : Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol 54 : 271-274, 2003.
PubMed
3) Clark LN, et al : Analysis of an early-onset Parkinson's disease cohort for DJ-1 mutations. Mov Disord 19 : 796-800, 2004.
 
4) Abou-Sleiman PM, et al : The role of pathogenic DJ-1 mutations in Parkinson's disease. Ann Neurol 54 : 283-286, 2003.
PubMed
5) Moore DJ, et al : Genetics of Parkinson's disease : what do mutations in DJ-1 tell us? Ann Neurol 54 : 281-282, 2003.
PubMed
6) Macedo MG, et al : The DJ-1L166P mutant protein associated with early onset Parkinson's disease is unstable and forms higher-order protein complexes. Hum Mol Genet 12 : 2807-2816, 2003.
 
7) Annesi G, et al : DJ-1 mutations and parkinsonism-dementia-amyotrophic lateral sclerosis complex. Ann Neurol 58 : 803-807, 2005.
PubMed
8) Nagakubo D, et al : DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231 : 509-513, 1997.
PubMed
9) Nishinaga H, et al : Expression profiles of genes in DJ-1 knockdown and L166P DJ-1 mutant cells. Neurosci Lett 390 : 54-59, 2005.
 
10) Kinumi T, et al : Cysteine-106 of DJ-1 is the most sensitive cysteine residue to hydrogen peroxide-mediated oxidation in vivo in human umbilical vein endothelial cells. Biochem Biophys Res Commun 317 : 722-728, 2004.
PubMed
11) Taira T, et al : DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5 : 213-218, 2004.
 
12) Yokota T, et al : Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312 : 1342-1348, 2003.
PubMed
13) Olzmann JA, et al : Familial Parkinson's disease-associated L166P mutation disrupts DJ-1 protein folding and function. J Biol Chem 279 : 8506-8515, 2004.
PubMed
14) Takahashi-Niki K, et al : Reduced anti-oxidative stress activities of DJ-1 mutants found in Parkinson's disease patients. Biochem Biophys Res Commun 320 : 389-397, 2004.
PubMed
15) Yang Y, et al : Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci USA 102 : 13670-13675, 2005.
PubMed
16) Meulener MC, et al : Mutational analysis of DJ-1 in Drosophila implicates functional inactivation by oxidative damage and aging. Proc Natl Acad Sci USA 103 : 12517-12522, 2006.
PubMed
17) Goldberg MS, et al : Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45 : 489-496, 2005.
PubMed
18) Kim RH, et al : Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydro-pyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102 : 5215-5220, 2005.
 
19) Chen L, et al : Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280 : 21418-21426, 2005.
PubMed
20) Choi J, et al : Oxidative damage of DJ-1 is linked to sporadic Parkinson and Alzheimer diseases. J Biol Chem 281 : 10816-10824, 2006.
PubMed
21) Bandopadhyay R, et al : The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson's disease. Brain 127 : 420-430, 2004.
PubMed
22) Tang B, et al : Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet 15 : 1816-1825, 2006.
PubMed
23) Moore DJ, et al : Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations. Hum Mol Genet 14 (1) : 71-84, 2005.
PubMed
24) Imai Y, et al : An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105 : 891-902, 2001.
PubMed
25) Inden M, et al : PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model. Neurobiol Dis 24 (1) : 144-158, 2006.
PubMed
26) Rizzu P, et al : DJ-1 colocalizes with tau inclusions : a link between parkinsonism and dementia. Ann Neurol 55 : 113-118, 2004.
PubMed
P.60 掲載の参考文献
1) Funayama M, et al : A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol 51 : 296-301, 2002.
PubMed
2) Paisan-Ruiz C, et al : Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 : 595-600, 2004.
PubMed
3) Zimprich A, et al : Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 : 601-607, 2004.
PubMed
4) Funayama M, et al : An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann Neurol 57 : 918-921, 2005.
PubMed
5) Greggio E, et al : The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283 : 16906-16914, 2008.
PubMed
6) Nichols WC, et al ; Parkinson Study Group-PROGENI investigators : Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease. Lancet 365 : 410-412, 2005.
 
7) Biskup S, et al : Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci 8 : 102, 2007.
PubMed
8) Biskup S, et al : Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60 : 557-569, 2006.
 
9) Melrose HL, et al : A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147 : 1047-1058, 2007.
PubMed
10) Meylan E, Tschopp J : The RIP kinases : crucial integrators of cellular stress. Trends Biochem Sci 30 : 151-159, 2005.
PubMed
11) Dachsel JC, et al : Identification of potential protein interactors of Lrrk2. Parkinsonism Relat Disord 13 : 382-385, 2007.
PubMed
12) Jaleel M, et al : LRRK2 phosphorylates moesin at threonine-558 : characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405 : 307-317, 2007.
PubMed
13) Imai Y, et al : Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J 27 : 2432-2443, 2008.
PubMed
14) Li X, et al : Leucine-rich repeat kinase 2 (LRRK2) /PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103 : 238-247, 2007.
PubMed
15) Ito G, et al : GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46 : 1380-1388, 2007.
 
16) Wang L, et al : The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci 28 : 3384-3391, 2008.
PubMed
17) Lee SB, et al : Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem Biophys Res Commun 358 : 534-539, 2007.
PubMed
18) Liu Z, et al : A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci USA 105 : 2693-2698, 2008.
 
P.65 掲載の参考文献
1) Klein C, Schlossmacher M : Parkinson disease, 10 years after its genetic revolution : Multiple clue to a complex disorder. Neurology 69 : 2093-2104, 2007.
 
2) Abou-Sleiman P, et al : Expanding insight of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 7 : 207-219, 2006.
PubMed
3) Najim Al-Din AS, et al : Pallido-pyramidal degeneration, supranuclear upgaze paresis and dementia : Kufor-Rakeb syndrome. Acta Neurol Scand 89 : 347-352, 1994.
PubMed
4) Williams D, et al : Kufor-Rakeb disease : Autosomal recessive, levodopa-responsive parkinsonism with pyramidal degeneration, supranuclear gaze palsy, and dementia. Mov Disord 20 : 1264-1271, 2005.
PubMed
5) Ramirez A, et al : Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase. Nat Genet 38 : 1184-1190, 2006.
PubMed
6) Fonzo A, et al : ATP13A2 missense mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology 68 : 1557-1562, 2007.
 
7) Ning YP, et al : PARK9-linked parkinsonism in Eastern Asia : Mutation detection in ATP13A2 and clinical phenotype. Neurology 70 : 1491-1493, 2008.
PubMed
8) Hampshire D, et al : Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36. J Med Genet 38 : 680-682, 2001.
PubMed
9) Lin CH, et al : Novel ATP13A2 variant associated with Parkinson disease in Taiwan and Singapore. Neurology 71 : 1727-1732, 2008.
PubMed
10) Guo JF, et al : Mutation analysis of Parkin, PINK1, DJ-1 and ATP13A2 genes in Chinese patients with autosomal recessive early-onset Parkinsonism. Mov Disord 23 : 2074-2079, 2008.
PubMed
11) Vilarifio-Guell C, et al : ATP13A2 variability in Parkinson disease. Hum Mutat 30 : 406-410, 2009.
 
12) Rakovic A, et al : Genetic association study of the P-type ATPase ATP13A2 in late-onset Parkinson's disease. Mov Disord 24 : 429-433, 2009.
 
13) Kanai K, et al : Preserved cardiac 123I-MIBG uptake and lack of severe autonomic dysfunction in a PARK9 patient. Mov Disord, 2009. (in press)
 
14) 久保紳一郎ほか : ATP13A2タンパク質の細胞内局在と機能に関する検討. 厚生労働科学研究補助金難治性疾患克服研究事業平成20年度神経変性疾患に関する調査研究班抄録集, 2008.
 
15) Komatsu M, et al : Loss of autophagy in the central nervous system causes neuro-degeneration in mice, Nature 441 : 880-884, 2006.
 
P.70 掲載の参考文献
1) Engelender S, et al : Synphilin-1 associates with alpha-synuclein and promotes the formation of cytosolic inclusions. Nat Genet 22 : 110-114, 1999.
PubMed
2) Ribeiro CS, et al : Synphilin-1 is developmentally localized to synaptic terminals, and its association with synaptic vesicles is modulated by alpha-synuclein. J Biol Chem 277 : 23927-23933, 2002.
PubMed
3) Marx FP, et al : Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Hum Mol Genet 12 : 1223-1231, 2003.
PubMed
4) Myhre R, et al : Genetic association study of synphilin-1 in idiopathic Parkinson's disease. BMC Med Genet 9 : 19, 2008.
 
5) Chung KK, et al : Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1 : implications for Lewy-body formation in Parkinson disease. Nat Med 7 : 1144-1150, 2001.
PubMed
6) Wakabayashi K, et al : Synphilin-1 is present in Lewy bodies in Parkinson's disease. Ann Neurol 47 : 521-523, 2000.
PubMed
7) Wakabayashi K et al : Immunocytochemical localization of synphilin-1, an alpha-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropathol 103 : 209-214, 2002.
PubMed
8) Lim KL, et al : Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1 : implications for Lewy body formation. J Neurosci 25 : 2002-2009, 2005.
PubMed
9) Nagano Y, et al : Siah-1 facilitates ubiquitination and degradation of synphilin-1. J Biol Chem 278 : 51504-51514, 2003.
PubMed
10) Liani E, et al : Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease. Proc Natl Acad Sci USA 101 : 5500-5505, 2004.
PubMed
11) Ito T, et al : Dorfin localizes to Lewy bodies and ubiquitylates synphilin-1. J Biol Chem 278 : 29106-29114, 2003.
PubMed
12) Franck T, et al : Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease. J Neural Transm 113 : 1903-1908, 2006.
PubMed
13) Tanji K, et al : NUB1 suppresses the formation of Lewy body-like inclusions by proteasomal degradation of synphilin-1. Arn J Pathol 169 : 553-565, 2006.
 
14) Marx FP, et al : The proteasomal subunit S6 ATPase is a novel synphilin-1 interacting protein-implications for Parkinson's disease. FASEB J 21 : 1759-1767, 2007.
PubMed
15) Avraham E, et al : Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH : implications for proteasomal function and Lewy body formation. J Biol Chem 280 : 42877-42886, 2005.
PubMed
16) Eyal A, et al : Synphilin-1A : an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients. Proc Natl Acad Sci USA 103 : 5917-5922, 2006.
PubMed
17) Jin HG, et al : Synphilin-1 transgenic mice exhibit mild motor impairments. Neurosci Lett 445 : 12-17, 2008.
PubMed
P.74 掲載の参考文献
1) Conrad C, et al : Genetic evidence for the involvement of tau in progressive supranuclear palsy. Ann Neurol 41 (2) : 277-281, 1997.
PubMed
2) Baker M, et al : Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 8 (4) : 711-715, 1999.
PubMed
3) Maraganore DM, et al : Case-Control study of the extended tau gene haplotype in Parkinson's disease. Ann Neurol 50 (5) : 658-661, 2001.
PubMed
4) de Silva R, et al : The tau locus is not significantly associated with pathologically confirmed sporadic Parkinson's disease. Neurosci Lett 330 (2) : 201-203, 2002.
 
5) Peplonska B, et al : Strong association between Saitohin gene polymorphism and tau haplotype in the Polish population. Neurosci Lett 348 (3) : 163-166, 2003.
PubMed
6) Levecque C, et al : Association of polymorphisms in the Tau and Saitohin genes with Parkinson's disease. J Neurol Neurosurg Psychiatry 75 (3) : 478-480, 2004.
PubMed
7) Kwok JB, et al : Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol 55 (3) : 329-334, 2004.
PubMed
8) Healy DG, et al : Tau gene and Parkinson's disease : a case-control study and meta-analysis. J Neurol Neurosurg Psychiatry 75 (7) : 962-965, 2004.
PubMed
9) Johansson A, et al : TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease. Neurodegener Dis 2 (1) : 28-35, 2005.
PubMed
10) Fidani L, et al : Association of the Tau haplotype with Parkinson's disease in the Greek population. Mov Disord 21 (7) : 1036-1039, 2006.
PubMed
11) Fung HC, et al : Association of tau haplotype-tagging polymorphisms with Parkinson's disease in diverse ethnic Parkinson's disease cohorts. Neurodegener Dis 3 (6) : 327-333, 2006.
PubMed
12) Zabetian CP, et al : Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease. Ann Neurol 62 (2) : 137-144, 2007.
PubMed
13) Goris A, et al : Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 62 (2) : 145-153, 2007.
PubMed
14) Tobin JE, etal : Haplotypes and gene expression implicate the MAPT region for Parkinson disease : the GenePD Study. Neurology 71 (1) : 28-34, 2008.
PubMed
15) Caffrey TM, et al : Haplotype-specific expression of exon 10 at the human MAPT locus. Hum Mol Genet 15 (24) : 3529-3537, 2006.
PubMed
P.77 掲載の参考文献
1) Kinoshita M : Diversity of septin scaffolds. Curr Opin Cell Biol 18 (1) : 54-60, 2006.
PubMed
2) Ihara M, et al : Sept4, a component of presynaptic scaffold and Lewy bodies, is required for the suppression of alpha-synuclein neurotoxicity. Neuron 53 (4) : 519-533, 2007.
PubMed
3) Ihara M, et al : Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathies. J Biol Chem 278 (26) : 24095-24102, 2003.
PubMed
4) Kinoshita A, et al : Identification of septins in neurofibrillary tangles in Alzheimer's disease. Am J pathol 153 (5) : 1551-1560, 1998.
PubMed
5) Zhang Y, et al : Parkin functions as an E2-dependent ubiquitin-protein ligase and promotes the degradation of the synaptic vesicle-associated protein CDCrel-1. Proc Natl Acad Sci USA 97 (24) : 13354-13359, 2000.
PubMed
6) Choi P, et al : SEPT5_v2 is a parkin-binding protein. Brain Res Mol Brain Res 117 (2) : 179-189, 2003.
PubMed
7) Kuhlenbaumer G, et al : Mutations in SEPT9 cause hereditary neuralgic amyotrophy. Nat Genet 37 (10) : 1044-1046, 2005.
PubMed
8) Woods WS, et al : Conformation-specific binding of alpha-synuclein to novel protein partners detected by phage display and NMR spectroscopy. J Biol Chem 282 (47) : 34555-34567, 2007.
PubMed
9) Sitz JH, et al : The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4. Neuroscience 157 (3) : 596-605, 2008.
PubMed
10) Shehadeh L, et al : Expression of Lewy body protein septin 4 in postmortem brain of Parkmson's disease and control subjects. Mov Disord 24 (2) : 204-210, 2009.
PubMed
11) Miller RM, et al : Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD. Exp Neurol 204 (1) : 421-432, 2007.
PubMed
P.82 掲載の参考文献
1) Vande Walle L, et al : The mitochondrial serine protease HtrA2/Omi : an overview. Cell Death Differ 15 : 453-460, 2008.
PubMed
2) Gupta S, et al : The C-terminal tail of presenilin regulates Omi/HtrA2 protease activity. J Biol Chem 279 : 45844-45854, 2004.
 
3) Park HJ, et al : Alzheimer's disease-associated amyloid beta interacts with the human serine protease HtrA2/Omi. Neurosci Lett 357 : 63-67, 2004.
PubMed
4) Jones JM, et al : Loss of Omi mitochondrial protease activity causes the neuromuscular disorder of mnd2 mutant mice. Nature 425 : 721-727, 2003.
PubMed
5) Martins LM, et al : Neuroprotective role of the Reaper-related serine protease HtrA2/Omi revealed by targeted deletion in mice. Mol Cell Biol 24 : 9848-9862, 2004.
PubMed
6) Strauss KM, et al : Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Hum Mol Genet 14 : 2099-2111, 2005.
PubMed
7) Kawamoto Y, et al : Accumulation of HtrA2/Omi in neuronal and glial inclusions in brains with alpha-synucleinopathies. J Neuropathol Exp Neurol 67 : 984-993, 2008.
PubMed
8) Simon-Sanchez J, Singleton AB : Sequencing analysis of OMI/HTRA2 shows previously reported pathogenic mutations in neurologically normal controls. Hum Mol Genet 17 : 1988-1993, 2008.
PubMed
9) Bogaerts V, et al : Genetic variability in the mitochondrial serine protease HTRA2 contributes to risk for Parkinson disease. Hum Mutat 29 : 832-840, 2008.
PubMed
10) Ross OA, et al : Genetic variation of Omi/HtrA2 and Parkinson's disease. Parkinsonism Relat Disord 14 : 539-543, 2008.
PubMed
11) Suzuki Y, et al : A serine protease, HtrA2, is released from the mitochondria and interacts with XIAP, inducing cell death. Mol Cell 8 : 613-621, 2001.
 
12) Plun- Favreau H, et al : The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat Cell Biol 9 : 1243-1252, 2007.
PubMed
13) Henchcliffe C, Beal MF : Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4 : 600-609, 2008.
PubMed
P.89 掲載の参考文献
1) Piccini P, et al : The role of inheritance in sporadic Parkinson's disease : evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 45 : 577-582, 1999.
PubMed
2) Sveinbjornsdottir S, et al : Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 343 : 1765-1770, 2000.
PubMed
3) Mizuta I, et al : Multiple candidate gene analysis identifiesα-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum Mol Genet 15 : 1151-1158, 2006.
 
4) Singleton A, et al : α-synuclein triplication causes Parkinson's disease. Science 302 : 841, 2003.
 
5) International HapMap Consortium : A second generation human haplotype map of over 3.1 million SNPs. Nature 449 : 851-861, 2007.
 
6) Maraganore DM, et al : High-resolution whole-genome association study of Parkinson disease. Am J Hum Genet 77 : 685-693, 2005.
PubMed
7) Fung HC, et al : Genome-wide genotyping in Parkinson's disease and neurologically normal controls : first stage analysis and public release of data. Lancet Neurol 5 : 911-916, 2006.
PubMed
8) Evangelou E, et al : Meta-analysis in genome-wide association datasets : strategies and application in Parkinson disease. PLoS ONE 2 : e196, 2007.
PubMed
9) Pankratz N, et al : Genomewide association study for susceptibility genes contributing to familial Parkinson disease. Hum Genet 72 : 593-605, 2009.
 
10) Aharon-Peretz J, et al : Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. N Engl J Med 351 : 1972-1977, 2004.
PubMed
11) Mitsui J, et al : Mutations for Gaucher disease confer high susceptibility to Parkinson disease. Arch Neurol. (in press)
 
12) Stefansson H, et al : Large recurrent microdeletions associated with schizophrenia. Nature 455 : 232-236, 2008.
PubMed
13) O'Donovan MC, et al : Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 40 : 1053-1055, 2008.
PubMed
P.94 掲載の参考文献
1) Ascherio A, et al : Pesticide exposure and risk for Parkinson's disease. Ann Neurol 60 : 197-203, 2006.
PubMed
2) Di Monte DA : The environment and Parkinson's disease : is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2 : 531-538, 2003.
PubMed
3) Betarbet R, et al : Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3 : 1301-1306, 2000.
 
4) Brighina L, et al : Alpha-synuclein, pesticides, and Parkinson disease : a case-control study. Neurology 70 : 1461- 1469, 2008.
 
5) Hatcher JM, et al : Parkinson's disease and pesticides : a toxicological perspective. Trends Pharmacol Sci 29 : 322-329, 2008.
PubMed
6) Brooks AI, et al : Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Res 823 : 1-10, 1999.
PubMed
7) Manning-Bog AB, et al : Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23 : 3095-3099, 2003.
PubMed
8) Fei Q, et al : Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem 283 : 3357-3364, 2008.
PubMed
9) Thiruchelvam M, et al : The nigrostriatal dopaminergic system as a preferential target of repeated exposures to combined paraquat and maneb : implications for Parkinson's disease. J Neurosci 20 : 9207-9214, 2000.
PubMed
10) Bhatt MH, et al : Acute and reversible parkinsonism due to organophosphate pesticide intoxication : five cases. Neurology 52 : 1467-1471, 1999.
PubMed
11) Sherer TB, et al : Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and alpha-synuclein aggregation. Exp Neurol 179 : 9-16, 2003.
 
12) Sherer TB, et al : Mechanism of toxicity in rotenone models of Parkinson's disease. J Neurosci 23 : 10756-10764, 2003.
PubMed
13) Chen YY, et al : GSK3beta and endoplasmic reticulum stress mediate rotenone-induced death of SK-N-MC neuroblastoma cells. Biochem Pharmacol 76 : 128-138, 2008.
 
14) Choi WS, et al : Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proc Natl Acad Sci USA 105 : 15136-15141, 2008.
 
15) Imamura K, et al : D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson's disease. J Neurosci Res 84 : 1376-1384, 2006.
 
16) Sherer TB, et al : Mechanism of toxicity of pesticides acting at complex I : relevance to environmental etiologies of Parkinson's disease. J Neurochem 100 : 1469-1479, 2007.
PubMed
17) Corrigan FM, et al : Diorthosubstituted polychlorinated biphenyls in caudate nucleus in Parkinson's disease. Exp Neurol 150 : 339-342, 1998.
PubMed
18) Sanchez-Ramos J, et al : Toxicity of dieldrin for dopaminergic neurons in mesencephalic cultures. Exp Neurol 150 : 263-271, 1998.
PubMed
19) Richardson JR, et al : Developmental exposure to the pesticide dieldrin alters the dopamine system and increases neurotoxicity in an animal model of Parkinson's disease. FASEB J 20 : 1695-1697, 2006.
 
P.100 掲載の参考文献
1) Hisanaga K, et al : Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 58 : 1580-1583, 2001.
 
2) Baba Y, et al : Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11 : 493-498, 2005.
PubMed
3) Poskanzer DC, Schwab RS : Cohort analysis of Parkinson's syndrome : evidence for a single aetiology related to subclinical infection about 1920. J Chronic Dis 46 : 961-973, 1963.
 
4) Martyn CN : Infection in childhood and neurological disease in adult 1ife. Br Med Bull 53 : 24-39, 1997.
 
5) 高橋三津雄, 山田達夫 : インフルエンザウイルスとパーキンソニズム. 神経内科 60 : 153-162, 2004.
 
6) Pavlovic J, et al : Resistance to influenza Virus and vesicular stomatitis virus conferred by expression of human MxA protein. J Virol 64 : 3370-3375, 1990.
 
7) Nomoto M, Igata A : Do parkinsonian patients have a greater resistance to common cold? J Neurol Neurosurg Psychiatry 46 : 1153-1154, 1983.
PubMed
8) 音成龍司, 伊賀崎伴彦 : Parkinson病と風邪. 仮説 : Parkinson病には, 風邪を起こす病原が関与しているのでは? 神経内科 69 : 171-176, 2008.
 
9) 朝長啓造ほか : パーキンソン病とボルナ病ウイルス感染. 遺伝子医学 2 : 347-349, 2000,
 
10) Roselli F, et al : Reversible Parkinsonian syndrome associated with anti-neuronal antibodies in acute EBV encephahtis : A case report. Parkinsonism Relat Disord 12 : 257-260, 2006.
PubMed
P.104 掲載の参考文献
1) Kionsky DJ, Ohsumi Y : Vacuolar import of proteins and organelles from the cytoplasm. Annu Rev Cell Dev Biol 15 : 1-32, 1999.
 
2) Ichimura Y, et al : Structural basis for sorting mechanism of p62 in selective autophagy. J Biol Chem 283 (33) : 22847-22857, 2008.
PubMed
3) Cuervo AM : Autophagy : many paths to the same end. Mol Cell Biochem 263 (1-2) : 55-72, 2004.
 
4) 吉田秀郎 : 小胞体ストレス応答の分子生物学. 生化学 76 : 617-630, 2004.
 
5) Goldberg MS, Lansbury Iγr Jr : Is there a cause-and-effect relationship between alpha-synuclein fibrillization and Parkinson's disease? Nat Cell Biol 2 (7) : El15-119, 2000.
 
6) Jana NR, et al : Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10 (10) : 1049-1059, 2001.
 
7) Hara T, et al : Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441 (7095) : 885-889, 2006.
PubMed
8) Komatsu M, et al : Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441 (7095) : 880-884, 2006.
PubMed
9) Bedford L, et al : Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lew-like inclusions resembling human pale bodies. J Neurosci 28 (33) : 8189-8198, 2008.
 
10) Wong HK et al : Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism. Hum Mol Genet 17 (20) : 3223-3235, 2008.
PubMed
11) Sarkar S, et al : A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17 (2) : 170-178, 2008.
 
P.109 掲載の参考文献
1) 小林理子, 武田篤 : パーキンソン病におけるミトコンドリア機能障害の意義. 医学のあゆみ 255 : 421-426, 2008.
 
2) Davis GC, et al : Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1 : 249-254, 1979.
PubMed
3) Mizuno Y, et al : Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem Biophys Res Commun 163 : 1450-1455, 1989.
PubMed
4) Hasegawa T, et al : Accelerated alpha-synuclein aggregation after differentiation of SH-SY5Y neuroblastoma cells. Brain Res 1013 : 51-59, 2004.
PubMed
5) Matsuzaki M, et al : Histochemical features of stress-induced aggregates in alpha-synuclein overexpressing cells. Brain Res 1004 : 83-90, 2004.
PubMed
6) Schapira AH : Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 7 : 97-109, 2008.
PubMed
7) Takeda A, et al : Mechanisms of neuronal death in synucleinopathy. J Biomed Biotechnol 2006 : 19365, 2006.
PubMed
8) Furukawa K, et al : Plasma membrane ion permeability induced by mutant alpha-synuclein contributes to the degeneration of neural cells. J Neurochem 97 : 1071-1077, 2006.
 
9) Hasegawa T, et al : Alpha-synuclein facilitates the toxicity of oxidized catechol metabolites : implications for selective neurodegeneration in Parkinson's disease. FEBS Lett 580 : 2147-2152, 2006.
PubMed
10) Fukae J, et al : Mitochondrial dysfunction in Parkinson's disease. Mitochondrion 7 : 58-62, 2007.
PubMed
11) Iaccarino C, et al : Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 16 : 1319-1326, 2007.
PubMed
12) Davidzon G, et al : Early-onset familial parkinsonism due to POLG mutations. Ann Neurol 59 : 859-862, 2006.
PubMed
13) Henchcliffe C, Beal MF : Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol 4 : 600-609, 2008.
PubMed
14) Shults CW, et al, Parkinson Study Group : Effects of coenzyme Q10 in early Parkinson disease : evidence of slowing of the functional decline. Arch Neurol 59 : 1541-1550, 2002.
 
15) Sugeno N, et al : Serine 129 phosphorylation of alpha-synuclein induces unfolded protein response-mediated cell death. J Biol Chem 283 : 23179-23188, 2008.
PubMed
P.115 掲載の参考文献
1) Lim KL : Ubiquitin-proteasome system dysfunction in Parkinson's disease : current evidence and controversies. Expert Rev Proteomics 4 : 769-781, 2007.
PubMed
2) 松田憲之 : ユビキチン系の異常に由来する遺伝子病一覧. 蛋白質核酸酵素 51 (10) (増刊号) : 1402-1407, 2006.
 
3) Shimura H, et al : Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25 : 302-305, 2000.
PubMed
4) Matsuda N, et al : Diverse effects of pathogenic mutations of Parkin that catalyze multiple monoubiquitylation in vitro. J Biol Chem 281 : 3204-3209, 2006.
PubMed
5) McNaught KS, et al : Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13 : 1437-1441, 2002.
PubMed
6) McNaught KS, et al : Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease. Ann Neurol 56 : 149-162, 2004.
PubMed
7) Manning-Bog AB, et al : Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol 60 : 256-260, 2006.
 
8) Bove J, et al : Proteasome inhibition and Parkinson's disease modeling. Ann Neurol 60 : 260-264, 2006.
PubMed
9) Kordower JH, et al : Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys. Ann Neurol 60 : 264-268, 2006.
 
10) Hampe C, et al : Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Hum Mol Genet 15 : 2059-2075, 2006.
PubMed
11) Lim KL, et al : Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1 : implications for Lewy body formation. J Neurosci 25 : 2002-2009, 2005.
PubMed
12) Olzmann JA, et al : Parkin-mediated K63-linked polyubiquitination targets misfolded DJ-1 to aggresomes via binding to HDAC6. J Cell Biol 178 : 1025-1038, 2007.
PubMed
13) Sato S, et al : Decline of striatal dopamine release in parkin-deficient mice shown by ex vivo autoradiography. J Neurosci Res 84 : 1350-1357, 2006.
PubMed
14) Bedford L, et al : Depletion of 26S proteasomes in mouse brain neurons causes neurodegeneration and Lewy-like inclusions resembling human pale bodies. J Neurosci 28 : 8189-8198, 2008.
PubMed
15) Komatsu M, et al : Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature 441 : 880-884, 2006.
PubMed
16) Komatsu M, et al : Homeostatic levels of p62 control cytoplasmic inclusion body formation in autophagy-deficient mice. Cell 131 : 1149-1163, 2007.
PubMed
17) Hara T, et al : Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 441 : 885-889, 2006.
PubMed
18) Bennett EJ, et al : Global changes to the ubiquitin system in Huntington's disease. Nature 448 : 704-708, 2007.
 
19) Newton K, et al : Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell 134 : 668-678, 2008.
PubMed
P.119 掲載の参考文献
1) Henchcliffe C, Beal MF : Excitotoxicity. Handb Clin Neurol 83 : 553-569, 2007.
PubMed
2) Lipton SA, Rosenberg PA : Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330 : 613-622, 1994.
PubMed
3) Conn PJ, et al : Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat Rev Neurosci 6 : 787-798, 2005.
PubMed
4) Hajnoczky G, et al : Mitochondrial calcium signalling and cell death : approaches for assessing the role of mitochondrial Ca2+ uptake in apoptosis. Cell Calcium 40 : 553-560, 2006.
PubMed
5) 分子神経薬理学 (ネスラーほか編, 樋口宗史ほか訳), p131-138, 西村書店, 2004.
 
6) Mungrue IN, Bredt DS : nNOS at a glance : implications for brain and brawn. J Cell Sci 117 : 2627-2629, 2004.
 
7) Siman R, et al : Calpain I activation is spechically related to excitatory amino acid induction of hippocampal damage. J Neurosci 9 : 1579-1590, 1989.
PubMed
8) Beal MF : Dose impairment of energy metabolism result in excitotoXic neuronal death in neurodegenerative illnesses? Ann Neurol 31 : 119-130, 1992.
 
9) Nafia I, et al : Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem 105 : 484-496, 2008.
PubMed
10) Leng Y, Chuang DM : Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitoto) dcity. J Neurosci 26 : 7502-7512, 2006.
 
11) Staropoli JF, et al : Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37 : 735-749, 2003.
PubMed
12) Nakao N, et al : Ablation of the subthalamic nucleus supports the survival of nigral dopaminergic neurons after nigrostriatal lesions induced by the mitochondrial toxin 3-nitropropionic acid. Ann Neurol 45 : 640-651, 1999.
PubMed
13) Maesawa S, et al : Long-term stimulation of the subthalamic nucleus in hemiparkinsonian rats : neuroprotection of dopaminergic neurons. J Neurosurg 100 : 679-687, 2004.
PubMed
14) Kaplitt MG, et al : Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease : an open label, phase I trial. Lancet 369 : 2097-2105, 2007.
PubMed
P.124 掲載の参考文献
1) Harman D : Aging : a theory based on free radical and radiation chemistry. J Gerontol 11 (3) : 298-300, 1956.
PubMed
2) Kitada T, et al : Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392 (6676) : 605-608, 1998.
 
3) Anglade P, et al : Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12 (3) : 603-610, 1997.
PubMed
4) Shamoto-Nagai M, et al : In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114 (12) : 1559-1567, 2007.
PubMed
5) Shamoto-Nagai M, et al : An inhibitor of mitochondrial complex I, rotenone, inactivates proteasome by oxidative modification and induces aggregation of oxidized proteins in SH-SY5Y cells. J Neurosci Res 74 (4) : 589-597, 2003.
 
6) Takanashi M, et al : Iron accumulation in the substantia nigra of autosomal recessive juvenile parkinsonism (ARJP). Parkinsonism Relat Disord 7 (4) : 311-314, 2001.
PubMed
7) Hattori N, et al : Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Ann Neurol 30 (4) : 563-571, 1991.
PubMed
8) Shimura-Miura H, et al : Increased 8-oxo-dGTPase in the mitochondria of substantia nigral neurons in Parkinson's disease. Ann Neurol 46 (6) : 920-924, 1999.
PubMed
9) Giasson BI, et al : Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290 (5493) : 985-989, 2000.
PubMed
10) McNaught KS, et al : Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease. Neurosci Lett 326 (3) : 155-158, 2002.
PubMed
P.129 掲載の参考文献
1) Nagatsu T, Sawada M : Inflammatory process in Parkinson's disease : role for cytokines. Curr Pharm Des 11 : 999-1016, 2005.
PubMed
2) Mogi M, Nagatsu T : Neurotrophins and cytokines in Parkinson's disease. Adv Neurol 80 : 135-139, 1999.
PubMed
3) Sawada M, et al : Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Supp1 (70) : 373-381, 2006.
 
4) McGeer PL, et al : Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer' s disease brains. Neurology 38 : 1285-1291, 1988.
PubMed
5) Knott C, et al : Inflammatory regulators in Parkinson's disease : iNOS, lipocortin-1, and cyclooxygenases-1 and-2. Mol Cell Neurosci 16 : 724-739, 2000.
PubMed
6) Imamura K, et al : Cytokine production of activated microglia and decrease in neurotrophic factors of neurons in the hippocampus of Lewy body disease brains. Acta Neuropathol 109 : 141-150, 2005.
PubMed
7) Langston JW, et al : Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Ann Neurol 46 : 598-605, 1999.
PubMed
8) Chen H, et al : Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60 : 1059-1064, 2003.
PubMed
9) Hald A, Lotharius J : Oxidative stress and inflammation in Parkinson's disease : is there a causal link? Exp Neurol 193 : 279-290, 2005.
 
10) Teismann P, et al : Cyclooxygenase-2 is instmmental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 100 : 5473-5478, 2003.
PubMed
11) Kukowska-Jastrzebska I, et al : The inflammatory reaction following 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine intoxication in mouse. Exp Neurol 156 : 50-61, 1999.
 
12) Aubin N, et al : Asprin and salicylate protect against MPTP-induced dopamine depletion in mice. J Neurochem 71 : 1635-1642, 1998.
 
13) Castano A, et al : Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70 : 1584-1592, 1998.
PubMed
14) Arimoto T, Bing G : Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 12 : 35-45, 2003.
PubMed
15) Le W, et al : Microglial activation and dopaminergic cell injury : an in vitro model relevant to Parkinson's disease. J Neurosci 21 : 8447-8455, 2001.
 
16) Feng ZH, et al : Cyclooxygenase-2-deficient mice are resistant to 1-methyl-4-phenyl 1, 2, 3, 6-tetrahydropyridine-induced damage of dopaminergic neurons in the substantia nigra. Neurosci Lett 329 : 354-358, 2002.
 
17) Wu DC, et al : NADPH oxidase mediates oxidative stress in the 1-methy1-4-phenyl-1, 2, 3, 6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci USA 100 : 6145-6150, 2003.
 
18) Casarejos MJ, et al : Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97 : 934-946, 2006.
PubMed
19) Solano RM, et al : Glial dysfunction in parkin null mice : effects of aging. J Neurosci 28 : 598-611, 2008.
PubMed
20) Kosaka K : Diffuse Lewy body disease. Neuropathology 20 (Suppl) : s73-78, 2000.
 
21) Kreutzberg GW : Microglia : a sensor for pathological events in the CNS. Trends Neurosci 19 : 312-318, 1996.
 
22) Sawada M, Suzuki H : Identification of two distinct subpopulation of microglia. Neurosci Protocol, 2009. (in press)
 
23) Hanish UK, Kettenmann H : Microglia : active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 10 : 1387-1394, 2007.
 
24) 澤田誠, 鈴木弘美 : 良いミクログリア, 悪いミクログリア. Dementia Japan 18 : 252-262, 2004.
 
25) Toyama H, et al : In vivo imaging of microglial activation using a peripheral benzodiazepine receptor ligand : [11C] PK-11195 and animal PET following ethanol injury in rat striatum. Ann Nucl Med 22 : 417-424, 2008.
PubMed
26) Sawada M : Importance of microglial imaging. Proc Brain Func Imaging Conference 23, 2009. (in press)
 

III 病理・病態

P.136 掲載の参考文献
1) Alexander GE, Crutcher MD : Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 13 : 266-271, 1990.
PubMed
2) DeLong MR : Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 : 281-285, 1990.
PubMed
3) Nambu A, et al : Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 : 111-117, 2002.
PubMed
4) 水野美邦, 中島八十一 : パーキンソン病 : 診断と治療の進歩病態と診断の進歩パーキンソン病における3大症候とその病態生理. 日内会誌 83 : 544-548, 1994.
 
5) Grafton ST, et al : Pallidotomy increases activity of motor association cortex in Parkinson's disease : a positron emission tomographic study. Ann Neurol 37 : 776-783, 1995.
PubMed
6) Haslinger B, et al : Event-related functional magnetic resonance imaging in Parkinson's disease before and after levodopa. Brain 124 : 558-570, 2001.
PubMed
7) Kikuchi A, et al : Hypoperfusion in the supplementary motor area, dorsolateral prefrontal cortex and insular cortex in Parkinson's disease. J Neurol Sci 193 : 29-36, 2001.
PubMed
8) Pfann KD, et al : Pallidotomy and bradykinesia : implications for basal ganglia function. Neurology 51 : 796-803, 1998.
PubMed
9) Vaillancourt DE, et al : Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease. Brain 127 : 491-504, 2004.
PubMed
10) Xia R, Rymer WZ : The role of shortening reaction in mediating rigidity in Parkinson's disease. Exp Brain Res 156 : 524-528, 2004.
PubMed
11) Shapiro MB, et al : Effects of STN DBS on rigidity in Parkinson's disease. IEEE Trans Neural Syst Rehabil Eng 15 : 173-181, 2007.
PubMed
12) Vitek JL, et al : Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53 : 558-569, 2003.
PubMed
13) Marsden CD : The mysterious motor function of the basal ganglia : the Robert Wartenberg Lecture. Neurology 32 : 514-539, 1982.
 
14) Delwaide PJ, et al : Some pathophysiological aspects of the parkinsonian rigidity. J Neural Transm Suppl 22 : 129-139, 1986.
PubMed
15) Tatton WG, Lee RG : Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients. Brain Res 100 : 671-676, 1975.
PubMed
16) Berardelli A, et al : Physiological mechanisms of rigidity in Parkinson's disease. J Neurol Neurosurg Psychiatry 46 : 45-53, 1983.
PubMed
17) Cody FW, et al : Observations on the genesis of the stretch reflex in Parkinson's disease. Brain 109 : 229-249, 1986.
PubMed
18) 橋本隆男 : 異常運動の臨床生理学. 日本臨牀 58 (10) : 1994-1999, 2000.
Medical*Online
19) Bergman H, et al : The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72 : 507-520, 1994.
PubMed
20) Plenz D, Kital ST : A basal ganglia pacemaker formed by the subthalamic nucleus and external globus pallidus. Nature 400 : 677-682, 1999.
PubMed
21) Blahak C, et al : Tremor reduction by subthalamic nucleus stimulation and medication in advanced Parkinson's disease. J Neurol 254 : 169-178, 2007.
PubMed
22) Koller WC : Pharmacologic treatment of parkinsonian tremor. Arch Neurol 43 : 126-127, 1986.
PubMed
23) Deuschl G, et al : The pathophysiology of parkinsonian tremor : a review. J Neurol 247 (Suppl 5) : V33-V48, 2000.
 
24) Fukuda M, et al : Thalamic stimulation for parkinsonian tremor : correlation between regional cerebral blood flow and physiological tremor characteristics. Neuroimage 21 : 608-615, 2004.
PubMed
25) Reichert WH, et al : Vestibular dysfunction in Parkinson disease. Neurology 32 : 1133-1138, 1982.
PubMed
26) Woolf NJ, Butcher LL : Cholinergic systems in the rat brain : IV. Descending projections of the pontomesencephalic tegmentum. Brain Res Bull 23 : 519-540, 1989.
PubMed
27) Shoushtarian M, Lithgow B : The relationship between electrovestibulography and Parkinson's disease severity. Conf Proc IEEE Eng Med Biol Soc 2007 : 2377-2380, 2007.
 
28) Nandi D, et al : Deep brain stimulation of the pedunculopontine region in the normal non-human primate. J Clin Neurosci 9 : 170-174, 2002.
PubMed
29) Visser JE, Bloem BR : Role of the basal ganglia in balance control. Neural Plast 12 : 161-174 ; discussion 263-272, 2005.
 
30) Westerberg BD, et al : The effects of posteroventral pallidotomy on balance function in patients with Parkinson's disease. Stereotact Funct Neurosurg 79 : 75-87, 2002.
PubMed
31) Vaugoyeau M, et al : Impaired vertical postural control and proprioceptive integration deficits in Parkinson's disease. Neuroscience 146 : 852-863, 2007.
PubMed
32) Takakusaki K, et al : Basal ganglia efferents to the brainstem centers controlling postural muscle tone and locomotion : a new concept for understanding motor disorders in basal ganglia dysfunction, Neuroscience 119 : 293-308, 2003.
 
33) Mak MK, et al : Sudden turn during walking is impaired in people with Parkinson's disease. Exp Brain Res 190 : 43-51, 2008.
PubMed
34) 高草木薫 : 進行性核上性麻痺 脚橋被蓋核と運動の制御. 神経精神薬理 19 : 349-356, 1997.
 
P.145 掲載の参考文献
1) Alexander GE, et al : Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci 9 : 357-381, 1986.
PubMed
2) Parent A, Hazrati LN : Functional anatomy of the basal ganglia. I. The cortico-basal ganglia-thalamo-cortical loop. Brain Res Rev 20 : 91-127, 1995.
PubMed
3) Alexander GE, Crutcher MD : Functional architecture of basal ganglia circuits : neural substrates of parallel processing. Trends Neurosci 13 : 266-271, 1990.
PubMed
4) Mink JW : The basal ganglia : focused selection and inhibition of competing motor programs. Prog Neurobiol 50 : 381-425, 1996.
PubMed
5) Mink JW, Thach WT : Basal ganglia intrinsic circuits and their role in behavior. Cur Opin Neurobiol 3 : 950-957, 1993.
 
6) Parent A, Hazrati LN : Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Rev 20 : 128-154, 1995.
PubMed
7) Nambu A, et al : Dual somatotopical representations in the primate subthalamic nucleus : evidence for ordered but reversed body-map transformations from the primary motor cortex and the supplementary motor area. J Neurosci 16 : 2671-2683, 1996.
PubMed
8) Nambu A, et al : Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. Neurosci Res 43 : 111-117, 2002.
PubMed
9) Nambu A, et al : Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey. J Neurophysiol 84 : 289-300, 2000.
PubMed
10) Albin RL, et al : The functional anatomy of basal ganglia disorders. Trends Neurosci 12 : 366-375, 1989.
PubMed
11) DeLong MR : Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13 : 281-285, 1990.
PubMed
12) Wichmann T, DeLong MR : Functional and pathophysiological models of the basal ganglia. Cur Opin Neurobiol 6 : 751-758, 1996.
 
P.149 掲載の参考文献
1) Takahashi H, et al : Ultrastructural relationship between Lewy bodies and pale bodies studied in locus ceruleus neurons of a non-parkinsonian patient. Neuropathology 14 : 73-80, 1994.
 
2) Wakabayashi K, et al : The Lewy body in Parkinson's disease : molecules implicated in the formation and degradation ofα-synuclein aggregates. Neuropathology 27 : 494-506, 2007.
 
3) Fujiwara H, et al : α-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4 : 160-164, 2002.
 
4) Hasegawa M, et al : Phosphorylated α-synuclein is ubiquitinated in α-synucleinopathy lesions. J Biol Chem 277 : 49071-49076, 2002.
 
5) Wakabayashi K et al : NACP/α-synuclein-positive mamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains. Acta Neuropathol 99 : 14-20, 2000.
 
6) Wakabayashi K, et al : Immunocytochemical localization of synphilin-1, an α-synuclein-associated protein, in neurodegenerative disorders. Acta Neuropatho1 103 : 209-214, 2002.
 
7) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
8) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 65 : 1863-1872, 2005.
PubMed
9) 高橋均 : パーキンソン病の病変はどこからはじまるのか? パーキンソン病-臨床の諸問題- (山本光利編), p59-68, 中外医学社, 2006.
 
10) Langston JW : The Parkinson's complex : parkinsonism is just the tip of the iceberg. Ann Neurol 59 : 591-596, 2006.
PubMed
11) Takahashi H, Wakabayashi K : Controversy : is Parkinson's disease a single disease entity? Yes. Parkinsonism Relat Disord 11 : S31-S37, 2005.
PubMed
P.154 掲載の参考文献
1) 若林孝一 : パーキンソン病の全身病理. パーキンソン病-病理学, 自律神経系研究の進歩- (山本光利編), p2-16, 中外医学社, 2004.
 
2) Wakabayashi K, Takahashi H : The intermediolateral nucleus and Clarke's column in Parkinson's disease. Acta Neuropathol 94 : 287-289, 1997.
PubMed
3) Braak H, et al : Parkinson's disease : lesions in dorsal horn layer I, involvement of parasympathetic and sympathetic pre-and postganglionic neurons. Acta Neuropathol 113 : 421-429, 2007.
PubMed
4) 若林孝一 : Parkinson病 : 末梢自律神経系におけるLewy小体の出現とその意義. 脳神経 41 : 965-971, 1989.
 
5) Wakabayashi K, Takahashi H : Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 38 (Suppl 2) : 2-7, 1997.
 
6) Orimo S, et al : Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 : 583-588, 2005.
PubMed
7) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
8) Kovari E, et al : Lewy body dysphagia. Acta Neuropathol 114 : 295-298, 2007.
PubMed
9) Takeda S, et al : Parkinson's disease with involvement of the parasympathetic ganglia. Acta Neuropathol 86 : 397-398, 1993.
PubMed
10) Qualman SJ, et al : Esophageal Lewy bodies associated with ganglion cell loss in achalasia. Similarity to Parkinson's disease. Gastroenterology 87 : 848-856, 1984.
PubMed
11) Kupsky WJ, et al : Parkinson's disease and megacolon : concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37 : 1253-1255, 1984.
 
12) Wakabayashi K, et al : Parkinson's disease : the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol 76 : 217-221, 1988.
 
13) Wakabayashi K, et al : Parkinson's disease : an immunohistochemical study of Lewy body-containing neurons in the enteric nervous system. Acta Neuropathol 79 : 581-583, 1990.
PubMed
14) Iwanaga K, et al : Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body disease. Neurology 52: 1269-1271, 1999.
PubMed
15) 織茂智之 : パーキンソン病およびレビー小体型認知症の早期診断法の確立とその病態機序に関する研究. 臨床神経 48 : 11-24, 2008.
 
16) Fumimura Y, et al : Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in Lewy body disease. J Neuropathol Exp Neurol 66 : 354-362, 2007.
PubMed
17) Dabby R, et al : Skin biopsy for assessment of autonomic denervation in Parkinson's disease. J Neural Transm 113 : 1169-1176, 2006.
PubMed
18) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008.
PubMed
19) Bloch A et al : α-Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32 : 284-295, 2006.
 
20) Klos KI, et al : α-Synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals. Neurology 66 : 1100-1102, 2006.
 
21) Braak H, et al : Gastric α-synuclein immunoreactive inclusions in Meissner'sand Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396 : 67-72, 2006.
 
22) Nishie M, et al : Accumulation of phosphorylatedα-synuclein in the brain and peripheral ganglia of patients with multiple system atrophy. Acta Neuropathol 107 : 292-298, 2004.
 
P.160 掲載の参考文献
1) Dampney RA : Functional organization of central pathways regulating the cardiovascular system. Physiol Rev 74 : 323-364, 1994.
PubMed
2) Owman C : Autonomic innervation of the cardiovascular system. In : Handbook of Chemical Neuroanatomy (ed by Bjorklund A, et al), p 327-389, Elsevier, Amsterdam, 1988.
 
3) Kawano H, et al : Histological study on the distribution of autonomic nerves in the human heart. Heart Vessels 18 : 32-39, 2003.
 
4) Orimo S, et al : Different histopathology accounting for a decrease in myocardial MIBG uptake in PD and MSA. Neurology 57 : 1140-1141, 2001.
PubMed
5) Amino T, et al : Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol 15 : 29-34, 2005.
PubMed
6) Mitsui J, et al : Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sic 243 : 101-104, 2006.
 
7) Orimo S, et al : Cardiac Sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 : 583-588, 2005.
PubMed
8) Orimo S, et al : Sympathetic cardiac denervation in Parkinson's disease and pure autonomic failure but not in multiple system atrophy. J Neurol Neurosurg Psychiatry 73 : 776-777, 2002.
PubMed
9) Braak H, et al : Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24 : 197-211, 2003.
PubMed
10) Orimo S, et al : Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 : 24-30, 2007.
PubMed
11) Fujishiro H, et al : Cardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov Disord 23 : 1085-1092, 2008.
PubMed
12) Orimo S, et al : Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20 : 1350-1353, 2005.
PubMed
13) Orimo S, et al : Cardiac sympathetic denervation in Parkinson's disease linked to SNCA duplication. Acta Neuropathol 116 : 575-577, 2008.
PubMed
14) Orimo S, et al : Degeneration of cardiac sympathetic nerve can occur in multiple system atrophy. Acta Neuropathol 113 : 81-86, 2007.
PubMed
15) Orimo S, et al : Axonal α-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson disease. Brain 131 : 642-650, 2008.
 

IV 検査・診断

P.169 掲載の参考文献
1) 柳澤信夫 : 厚生省特定疾患神経変性疾患調査研究班1995年度研究報告書 : 対象疾患診断基準, p22, 1996.
 
2) Hughes AJ, et al : Accuracy of clinical diagnosis of idiopathic Parkinson's disease : a clinico-pathological study of 100 cases. J Neurol Nuerosurg Psychiatry 55 : 181-184, 1992.
 
3) Paulson H, Stem M : Clinical manifestation of Parkinson's disease. In : Movement Disorders Neurologic Principles and Practice (ed by Watts RL, Koller WC), p 183, McGraw-Hill, New York, 1996.
 
4) Jankovic J, et al : Re-emergent tremor of Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 646-650, 1999.
PubMed
5) Barbeau A : Parkinson's disease : clinical features and etiopathology. In : Handbook of Clinical Neurology 49 (ed by Vinken PJ, et al), p 87, Elsevier Science Publishers BV, Amsterdam, 1986.
 
6) Narabayashi H : Akinesia in parkinsonism. In : Movement Disorders in Neurology and Neuropsychiatry, 2nd ed (ed by Joseph AB, Yang RR), p 185, Blackwell Science, Oxford, 1999.
 
7) Crithchley M : Arteriosclerotic parkinsonism. Brain 52 : 23, 1929.
 
8) Wilhelmsen KC, et al : Chromosome 17-linked dementia. In : Neuropathology of Dementing Disorders (ed by Markesbery WR), Arnold, London, 1998.
 
9) McKeith IG, et al : Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)-report of the consortium on DLB International workshop-. Neurology 47 : 1113-1124, 1996.
 
P.173 掲載の参考文献
1) Calne DB : Is idiopathic parkinsonism the consequence of an event or process? Neurology 44 : 5-10, 1994.
 
2) Morrish PK, et al : Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F] dopa PET. J Neurol Neurosurg Psychiatry 64 : 314-319, 1998.
 
3) Hilker R, et al : Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62 : 378-382, 2005.
PubMed
4) McGeer PL, et al : Aging and extrapyramidal function. Arch Neurol 34 : 33-35, 1977.
PubMed
5) Jellinger K : Overview of morphological changes in Parkinson's disease. Adv Neurol 45 : 1-18, 1986.
 
6) Bernheimer H, et al : Brain dopamine and the syndromes of Parldnson and Huntington. J Neurol Sci 20 : 415-455, 1973.
 
7) Lee CS, et al : In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47 : 493-503, 2000.
PubMed
8) Sawle GV, et al : Asymmetrical pre-synaptic and post-synaptic changes in the striatal dopamine projection in dopa naive parkinsonism. Brain 116 : 853-867, 1993.
PubMed
9) Lees AJ : The early detection of Parkinson's disease. In : International Workshop Berlin Parkinson's Disease (ed by Rinne UK, et al), p 156-170, Medicom, Bussum, 1991.
 
10) Gibb WR, Lees N : The relevance of the Lewy body to pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry 51 : 745-752, 1988.
 
11) Koller WC : When does Parkinson's disease begin? Neurology 42 (Suppl 4) : 27-31, 1992.
 
12) Burn DJ, Brooks DJ : Nigral dysfunction in drug-induced parkinsonism : an 18F-dopa PET study. Neurology 43 : 552-556, 1993.
PubMed
13) Gonera EG, et al : Symptoms and duration of the prodromal phase in Parkinson's disease. Mov Disord 12 : 871-876, 1997.
PubMed
14) Lees AJ : When did Ray Kennedy's Parkinson's disease begin? Mov Disord 7 : 110-116, 1992.
 
15) Shulman LM, et al : Internal tremor in patients with Parkinson's disease. Mov Disord 11 : 3-7, 1996.
PubMed
P.177 掲載の参考文献
1) Tolosa E, et al : The premotor phase of Parkinson's disease. Parkinsonism Relat Disord 13 : S2-S7, 2007.
PubMed
2) Kaye J, et al : Excess burden of constipation in Parkinson's disease : a pilot study. Mov Disord 21 : 1270-1273, 2006.
PubMed
3) Braak H, et al : Pathology associated with sporadic Parkinson's disease-where does it end? J Neural Transm Suppl (70) : 89-97, 2006.
 
4) Jackson M, et al : Lewy body dysphagia. J Neurol Neurosurg Psychiatry 58 : 756-758, 1995.
PubMed
5) Ross GW, et al : Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21 : 2062-2067, 2006.
PubMed
6) Jellinger KA : The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 248 : 167-172, 2006.
PubMed
7) Yoshimura N, et al : The amygdala of patients with Parkinson's disease is silent in response to fearful facial expressions. Neuroscience 131 : 523-534, 2005.
PubMed
8) Kobayakawa M, et al : Decision making in Parkinson's disease : Analysis of behavioral and physiological patterns in the Iowa gambling task. Mov Disord 23 : 547-552, 2008.
PubMed
9) Stiasny-Kolster K, et al : Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128 : 126-137, 2005.
PubMed
10) Nolano M, et al : Sensory deficit in Parkinson's disease : evidence of a cutaneous denervation. Brain 131 : 1903-1911, 2008.
PubMed
11) Berg D : Transcranial sonography in the early and differential diagnosis of Parkinson's disease. J Neural Transm Suppl 70 : 249-254, 2006.
PubMed
12) Okawa M, et al : Transcranial sonography of the substantia nigra in Japanese patients with Parkinson's disease or atypical parkinsonism : clinical potential and limitations. Intern Med 46 : 1527-1531, 2007.
PubMed
P.184 掲載の参考文献
1) 野元正弘 : コモン・マーモセット (小型のサル) の薬理学的研究への応用. 日薬理誌 106 : 11-18, 1995.
 
2) Bernheimer JM, et al : Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphorogical and neurochemical correlations. J Neurol Sci 20 : 415-455, 1973.
 
3) Fearnley JM, Lees AJ : Ageing and Parkinson's disease : Substantia nigra regional selectivity. Brain 114 : 2283-2301, 1991.
PubMed
4) Bezard E, et al : Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21 : 6853-6861, 2001.
 
5) Giladi N, et al : Hemiparkinsonism-hemiatrophy syndrome : clinical and neuroradiologic features. Neurology 40 : 1731-1734, 1990.
PubMed
6) Josephs KA, et al : Benign tremulous parkinsonism. Arch Neurol 63 : 354-357, 2006.
PubMed
7) Shahani BT, Young RR : Physiological and pharmacological aids in the differential diagnosis of tremor. J Neurol Neurosurg Psychiatry 39 : 772-783, 1976.
 
8) Calne DB, et al : Alzheimer's disease, Parkinson's disease, and motoneurone disease : abiotrophic interaction between ageing and environment? Lancet 2 (8515) : 1067-1070, 1986,
PubMed
9) Winkler M, et al : Unilateral injection of morphine into the nucleus accumbens induces akinesia and catalepsy, but no spontaneous muscular rigidity in rats. Naunyn Schmiedebergs Arch Pharmacol 318 : 143-147, 1982.
PubMed
10) Nomoto M, et al : The metabolic rate and vulnerability of dopaminergic neurons, and adenosine dynamics in the cerebral cortex, nucleus accumbens, caudate nucleus, and putamen of the common marmoset. J Neurol 247 (Suppl 5) : V16-V22, 2000.
 
11) Narabayashi H, et al : Cases of pure akinesia without rigidity and tremor and no effect by LDOPA therapy. In : Advances in Parkinsonism (ed by Birkmayer W, Hornykiewicz O), p 335, Roche, Basel, 1976.
 
12) 本間義章ほか : "L-dopa無効の純粋アキネジア" を呈した進行性核上性麻痺の1剖検例. 脳と神経 39 : 183-187, 1987.
 
13) Kolbe H, et al : Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release on to supersensitive postsynaptic receptors. Neurology 4 : 434-439, 1981.
PubMed
14) Djaldetti R, et al : Camptocormia (bent spine) in patients with Parkinson's disease-characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14 : 443-447, 1999.
PubMed
15) Parkes JD, et al : Bromocriptine treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 39 : 184-193, 1976.
PubMed
P.188 掲載の参考文献
1) Chaudhuri KR, et al : The non-motor symptom complex of Parkinson's disease : a comprehensive assessment is essential. Curr Neurol Neurosci Rep 5 : 275-283, 2005.
PubMed
2) Global Parkinson's Disease Survey Steering Committee : Factors impacting on quality of life in Parkinson's disease : results from an international survey. Mov Disord 17 : 60-67, 2002.
 
3) Wolters E, Braak H : Parkinson's disease : premotor clinico-pathological correlations. J Neural Transm Suppl 70 : 309-319, 2006.
PubMed
4) Boeve BF, et al : REM sleep behavior disorder in Parkinson's disease and dementia with Lewy bodies. J Geriatr Psychiatry Neurol 17 : 146-157, 2004.
PubMed
5) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB Consortium. Neurology 65 : 1863-1872, 2005.
PubMed
6) Levy G, et al : Combined effect of age and severity on the risk of dementia in Parkinson's disease. Ann Neurol 51 : 722-729, 2002.
PubMed
7) Myslobodsky M, et al : Are patients with Parkinson's disease suicidal? J Geriatr Psychiatry Neurol l4 : 120-124, 2001.
 
8) Iseki E, et al : Psychiatric symptoms typical of patients with dementia with Lewyy bodies-similarity to those of levodopa-induced psychosis. Acta Neuropsychiatr 14 : 237-241, 2002.
PubMed
9) Levy R, et al : Lewy bodies and response to tacrine in Alzheimer's disease. Lancet 343 : 176, 1994.
PubMed
10) Aarsland D, et al : Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 : 937-941, 2003.
PubMed
11) Emre M, et al : Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 : 2509-2518, 2004.
PubMed
12) Leroi I, et al : Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19 : 1-8, 2004.
 
13) 小阪憲司 : レビー小体型認知症と抑肝散. Geriatr Med 46 : 235-238, 2008.
Medical*Online
14) Ceravolo R et al : Paroxetine in Parkinson's disease : effects on motor and depressive symptoms. Neurology 55 : 1216-1218, 2000.
PubMed
15) Low PA, et al : Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA 277 : 1046-1051, 1997.
 
P.193 掲載の参考文献
1) 早原敏之 : パーキンソン病の診断. I. 臨床検査. パーキンソン病の臨床, p94-97, 新興医学出版社, 1996.
 
2) 出口一志ほか : 多系統萎縮症におけるclonidine経口負荷後のgrowth hormone分泌能-Parkinson病との比較-. 自律神経 39 : 438-444, 2002.
 
3) Sato S, et al : Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64 : 1081-1083, 2005.
PubMed
4) Dorsey ER, et al : Status of biological markers. In : Parkinson's disease, Diagnosis and Clinical Management, 2nd ed (ed by Factor SA, Weiner WJ), p 277-284, Demos Medical Publishing, New York, 2008.
 
5) Waragai M, et al : Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425 : 18-22, 2007.
PubMed
6) Abdo WF, et al : CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. Neurobiol Aging 28 : 742-747, 2007.
PubMed
7) 宮本智之ほか : Actigraphによるパーキンソン病の活動度と薬効の定量的評価. 自律神経 39 : 397-401, 2002.
Medical*Online
8) Nahm F, Freeman R : Sphincter electromyography and multiple system atrophy. Muscle Nerve 28 : 18-26, 2003.
PubMed
9) Shindo K, et al : Sympathetic sudomotor and vasoconstrictive neural function in patients with Parkinson's disease. Parldnsonism Relat Disord 14 : 548-552, 2008.
PubMed
10) 玉川聡, 辻貞俊 : Parkinson病での電気生理学的検査の意味. 神経内科 64 : 487-492, 2006.
 
11) Kodama Y, et al : Auditory brainstem responses in patients with autonomic failure with Parkinson's disease and multiple system atrophy. J Auton Nerv Syst 77 : 184-189, 1999.
PubMed
12) Sohn YH, et al : Dopaminergic influences on the P300 abnormality in Parkinson's disease. J Neurol Sci 158 : 83-87, 1998.
PubMed
13) Bonanni L, et al : EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain 131 : 690-705, 2008.
PubMed
14) Gagnon JF, et al : Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5 : 424-432, 2006.
PubMed
15) Ponsen MM, et al : Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56 : 173-181, 2004.
PubMed
P.198 掲載の参考文献
1) Orimo S, et al : 123I-metaiodobenzyl-guanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 189-194, 1999.
 
2) Goldstein DS : Dysautonomia in Parkinson's disease : neurocardiological abnormalities. Lancet Neurol 2 : 669-676, 2003.
PubMed
3) Biaggioni I, et al : Parkinson's disease. Autonomic neuronopathy with impaired cardiovascular regulation. Hypertension 49 : 21-22, 2007.
PubMed
4) Goldstein DS : Orthostatic hypotension as early finding in Parkinson's disease. Clin Auton Res 16 : 46-54, 2006.
PubMed
5) Goldstein DS, et al : Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension : independence from levodopa treatment. Hypertension 46 : 1333-1339, 2005.
PubMed
6) Bouhaddi M, et al : Impaired cardiovascular autonomic control in newly and long-teml-treated patients with Parkinson's disease : involvement of L-dopa therapy. Auton Neurosci 116 : 30-38, 2004.
 
7) Martignoni E, et al : Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism Relat Disord 12 : 195-204, 2006.
PubMed
8) 家田俊明 : 低血圧の症候. 食事性低血圧-新たな血圧異常の臨床 (高橋昭監, 長谷川康博, 古池保雄編), p31-33, 南山堂, 2004.
 
9) 長谷川康博 : Parkinson病の食事性低血圧. 神経内科 66 : 38-45, 2007.
 
10) Gilman S, et al : Consensus statement on the diagnosis of multiple system atrophy. Clin Auton Res 8 : 359-362, 1998.
PubMed
11) Gilman S, et al : Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71 : 670-676, 2008.
PubMed
12) 新美由紀 : 体位変換試験 : 血漿カテコールアミンなど. 自律神経機能検査, 第4版 (日本自律神経学会編), p 134-138, 文光堂, 2007.
 
13) 岡尚省ほか : パーキンソン病における心臓自律神経障害-123I-MIBGシンチグラフィーとValsalva試験による自律神経機能評価の対比-. 臨床神経 43 : 465-469, 2003.
 
14) 岡尚省 : 心電図RR間隔変動・血圧のfrequency-domain analysis. 自律神経機能検査, 第3版 (日本自律神経学会編), p51-54, 文光堂, 2000.
 
15) Kallio M, et al : Heart rate variability in patients with untreated Parkinson's disease. Eur J Neurol 7 : 667-672, 2000.
PubMed
16) Barbic F, et al : Early abnormalities of vascular and cardiac autonomic control in Parkinson's disease without orthostatic hypotension. Hypertension 49 : 120-126, 2007.
PubMed
17) 持尾聰一郎 : 心電図RR間隔変動 : CVを中心に. 自律神経機能検査, 第4版 (日本自律神経学会編), p159-163, 文光堂, 2007.
 
18) Shibata M, et al : Cardiac parasympathetic dysfunction concurrent with cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 276 : 79-83, 2008.
PubMed
19) 平山正昭 : 薬理学的検査 : ノルアドレナリン (NA) 静注試験 自律神経機能検査, 第4版 (日本自律神経学会編), p200-203, 文光堂, 2007.
 
20) Nakamura T, et al : Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 263 : 133-138, 2007.
PubMed
P.203 掲載の参考文献
1) 倉康夫ほか : PDの原著と全訳, 三共株式会社, 1974.
 
2) Braak H, et al : Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages). J Neurol 249 (Suppl 3) : 1-5, 2002.
 
3) Braak H, et al : Gastric alpha-synuclein immunoreactive inclusions in Meissner' s and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 396 : 67-72, 2006.
 
4) Camborova P, et al : The pacemaker activity of interstitial cells of Cajal and gastric electrical activity. Physiol Res 52 : 275-284, 2003.
PubMed
5) Cersosimo MG, Benarroch EE : Neural control of the gastrointestinal tract : implications for Parkinson disease. Mov Disord 23 : 1065-1075, 2008.
PubMed
6) 田山二朗 : 嚥下・食道機能検査. 自律神経機能検査第4版 (日本自律神経学会編), p303-308, 文光堂, 2007.
 
7) 楠裕明, 春間賢 : 胃排出機能検査. 自律神経機能検査第4版 (日本自律神経学会編), p309-312, 文光堂, 2007.
 
8) Suzuki A, et al : Impaired circadian rhythm of gastric myoelectrical actiVity in patients with multiple system atrophy. Clin Auton Res 15 : 368-372, 2005.
PubMed
9) Sakakibara Y, et al : Gastric myoelectrical differences between Parkinson's disease and multiple system atrophy. Mov Disord. (in press)
 
10) 榊原隆次ほか : 排便機能検査. 自律神経機能検査第4版 (日本自律神経学会編), p322-329, 文光堂, 2007.
 
11) Sakakibara R, et al : Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 115 : 443-460, 2008.
PubMed
12) Abbott RD, et al : Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 : 456-462, 2001.
PubMed
P.206 掲載の参考文献
1) Swinn L, et al : Sweating dysfunction in Parkinson's disease. Mov Disord 18 : 1459-1463, 2003.
PubMed
2) Wang SJ, et al : Sympathetic skin response and R-R interval variation in Parkinson's disease. Mov Disord 8 : 151-157, 1993.
 
3) De Marinis M, et al : Sympathetic skin response and cardiovascular autonomic function tests in Parkinson's disease and multiple system atrophy with autonomic failure. Mov Disord 15 : 1215-1220, 2000.
PubMed
4) Turkka JT, Myllyla W : Sweating dysfunction in Parkinson's disease. Eur Neurol 26 : 1-7, 1987.
 
5) Kihara M, et al : Assessment of sudomotor dysfunction in early Parkinson's disease. Eur Neurol 33 : 363-365, 1993.
PubMed
6) Raudino F : Non motor off in Parkinson's disease. Acta Neurol Scand 104 : 312-315, 2001.
PubMed
7) 吉岡雅之ほか : パーキンソン病の発汗機能障害と心臓交感神経機能障害の関連性について. 臨床神経学 41 : 61-67, 2004.
 
8) Hirashima F, et al : Sympathetic skin response in Parkinson's disease. Acta Neurol Scand 93 : 127-132, 1996.
PubMed
9) Kikkawa Y, et al : Cutaneous sympathetic function and cardiovascular function in patients with progressive supranuclear palsy and Parkinson's disease. Parkinsonism Relat Disord 10 : 101-106, 2003.
PubMed
10) 平山正昭 : 第5章非運動症状 6. パーキンソン病における発汗過多. パーキンソン病-臨床の諸問題- (山本光利編), p234-243, 中外医学社, 2006.
 
11) Hirayama M : Sweating dysfunctions in Parkinson's disease. J Neurol 253 (Suppl 7) : VII/42-VII/47, 2006.
 
12) Ikemura M, et al : Lewy body pathology involves cutaneous nerves. J Neuropathol Exp Neurol 67 : 945-953, 2008.
PubMed
13) Goetz CG, et al : Autonomic dysfunction in Parkinson's disease. Neurology 36 : 73-75, 1986.
PubMed
14) Sage JI, Mark MH : Drenching sweats as an off phenomenon in Parkinson's disease : treatment and relation to plasma levodopa profile. Ann Neurol 37 : 120-122, 1995.
PubMed
15) Witjas T, et al : Effects of chronic subthalamic stimulation on nonmotor fluctuations in Parkinson's Disease. Mov Disord 22 : 1729-1734, 2007.
PubMed
16) Pursiainen V, et al : Sweating in Parkinsonian patients with wearing-off. Mov Disord 22 : 828-832, 2007.
PubMed
P.211 掲載の参考文献
1) Trenkwalder C : Parkinsonism. In : Principles and Practice of Sleep Medicine, Fourth edition (ed by Kryger MH, et al), p 801-810, Elsevier Saunders, Philadelphia, 2005.
 
2) Silber MH : Sleep dysfunction in Parkinson's plus syndrome. In : Sleep and Movement Disorders (ed by Chokroverty S, et al), p 489-498, Butterworth-Heinemann, Philadelphia, 2003.
 
3) Aldrich MS, Jahnke B : Diagnostic value of video-EEG polysomnography. Neurology 41 : 1060-1066, 1991.
PubMed
4) Rechtschaffen A, Kales A (ed) : A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects, BIS/BRI, UCLA, Los Angeles, 1968.
 
5) Iber C, et al : The AASM Manual for the Scoring of Sleep and Associated Events-Rules, Terminology and Technical Specifications, American Academy of Sleep Medicine, Westchester, 2007.
 
6) 堀有行 : 1. Polysomnography (PSG) の基礎的知識 7) PSG所見の評価と報告書作成. 臨床睡眠検査マニュアル (日本睡眠学会編), p69-77, ライフ・サイエンス, 2006.
 
7) Chokroverty S (ed) : An overview of sleep. In : Sleep Disorders Medicine : Basic Science, Technical Considerations and Clinical Aspects, 2nd ed, p 7-20, Butterworth-Heinemann, Woburn, 1999.
 
8) Bonnet M, et al : ASDA report-EEG arousals : scoring rules and examples. Sleep 15 : 173-184, 1992.
 
9) Terzano MG, et al : Atlas, rules, and recording techniques for the scoring cyclic alternating pattern (CAP) in human sleep. Sleep Med 3 : 187-199, 2002.
PubMed
10) 睡眠呼吸障害研究会 (編) : 第2章病態. 成人の睡眠時無呼吸症候群診断と治療のためのガイドライン, p4, メディカルレビュー社, 2005.
 
11) The Report of an American Academy of Sleep Medicine Task Force : Sleep-related breathing disorders in adults : recommendations for syndrome definition and measurement techniques in clinical research. Sleep 22 : 667-689, 1999.
PubMed
12) Meoli AL, et al : Hypopnea in sleep-disordered breathing in adults. Sleep 24 : 469-470, 2001.
PubMed
13) American Academy of Sleep Medicine : Obstructive sleep apnea syndromes. In : International Classification of Sleep Disorders, Diagnostic and Coding Manual, 2nd ed, p 51-55, Westchester, 2005.
 
14) 宮本雅之ほか : 神経疾患と睡眠時無呼吸症候群. 医学のあゆみ 214 : 539-547, 2005.
Medical*Online
15) American Academy of Sleep Medicine : Periodic limb movement disorder. In : International Classification of Sleep Disorders. Diagnostic and Coding Manua1, 2nd ed, p 182-186, Westchester, 2005.
 
16) American Academy of Sleep Medicine : REM sleep behavior disorder (including parasomnia overlap disorder and status dissociatus). In : International Classification of Sleep Disorders. Diagnostic and Coding Manual, 2nd ed, p 148-152, Westchester, 2005.
 
17) Zhang J, et al : Diagnosis of REM sleep behavior disorder by video-polysomnographic study : Is one night enough? Sleep 31 : 1179-1185, 2008.
 
18) Carskadon MA, et al : Guidelines for the multiple sleep latency test (MSLT) : A standard measure of sleepiness. Sleep 9 : 519-524, 1986.
PubMed
19) Littner MR, et al ; Standards of Practice Committee of the American Academy of Sleep Medicine : Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 28 : 113-121, 2005.
PubMed
20) Richardson GS, et al : Excessive daytime sleepiness in man : multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol 45 : 621-627, 1978.
PubMed
21) American Academy of Sleep Medicine : Hypersomnias of central origin not due to a circadian rhythm sleep disorder, sleep related breathing disorder, or other cause of disturbed nocturnal sleep. In : International Classification of Sleep Disorders, Diagnostic and Coding Manual, 2nd ed, p 79-115, Westchester, 2005.
 
22) Mitler MM, et al : Maintenance of wakefulness test : A polysomnographic technique for evaluating treatment efficacy in patients with excessive somnolence. Electroencephalogr Clin Neurophysiol 53 : 658-661, 1982.
 
P.216 掲載の参考文献
1) 立花久大 : パーキンソン病の認知機能障害. 運動障害 14 : 77-85, 2004.
Medical*Online
2) 立花久大 : パーキンソン病の認知障害. 老年精神医学雑誌 19 : 1195-1202, 2008.
Medical*Online
3) 大槻美佳 : パーキンソン病の高次脳機能障害. Medical Rehabilitation 76 : 21-29, 2007.
 
4) Pagonabarraga J, et al : Parkinson's disease-cognitive rating scale : Anew cognitive scale specific for Parkinson's disease, Mov Disord 23 : 998-1005, 2008.
 
5) Zgaljardic DJ, et al : A review of the cognitive and behavioral sequelae of Parkinson's disease : relationship to frontostriatal circuitry. Cogn Behav Neurol 16 : 193-210, 2003.
PubMed
6) 加藤元一郎 : 高次脳機能障害各論8. 遂行機能障害, 注意障害A. 遂行機能障害とその検査. 神経内科 68 (Suppl 5) : 523-531, 2008.
 
7) Wilson BA, et al : Behavioral assessment of the dysexecutive syndrome, Themes Valley Test Company, Bury St. Edmunds, 1996.
 
8) Baddeley A : Working memory. Science 255 : 556-559, 1992.
PubMed
9) Wilson RS, et al : High speed scanning in parkinsonism. Cortex 16 : 67-72, 1980.
PubMed
10) Brown RG, et al : Dual task performance and processing resources in normal subjects and patients with Parkinson's disease. Brain 114 : 215-231, 1991.
PubMed
11) Dalrymple-Alford JC, et al : A central executive deficit in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57 : 360-367, 1994.
PubMed
12) 澁谷直美ほか : Parkinson病の記憶機能 : 神経心理学的検査と脳血流による検討. 日老医誌 38 (2) : 193-200, 2001.
 
13) Yamadori A, et al : Neurological basis of skill learning. Cogn Brain Res 5 : 49-54, 1996.
PubMed
14) Sharpe MM : Auditory attention in early Parkinson's disease : An impairment in focused attention. Neuropsychologia 30 : 101-106, 1992.
 
P.221 掲載の参考文献
1) 土谷邦秋 : 多系統萎縮症の提唱とGCIによる証明. Clin Neurosci 24 : 984-985, 2006.
 
2) Konagaya M, et al : Progressive cerebral atrophy in multiple system atrophy. J Neurol Sci 195 : 123-127, 2002.
PubMed
3) Seppi K, et al : Progression of putaminal degeneration in multiple system atrophy : A serial diffusion MR study. Neuroimage 31 : 240-245, 2006.
PubMed
4) Schocke MF, et al : Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease. Neuroimage 21 : 1443-1451, 2004.
PubMed
5) Shiga K et al : Local tissue anisotropy decreases in cerebellopetal fibers and pyramidal tract in multiple system atrophy. J Neurol 252 : 589-596, 2005.
PubMed
6) Lewinski F, et al : T2*-weighted MRI in diagnosis of multiple system atrophy. J Neurol 254 : 1184-1188, 2007.
 
7) Kraft E, et al : T2*-weighted MRI differentiates multiple system atrophy from Parkinson's disease. Neurology 59 : 1265-1267, 2002.
PubMed
8) Eckert T, et al : Differentiation of idiopathic Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and healthy controls using magnetization transfer imaging. Neuroimage 21 : 229-235, 2004.
PubMed
9) Naka H, et al : Magnetization transfer measurements of brain structures in patients With multiple system atrophy. Neuroimage 17 : 1572-1578, 2002.
PubMed
10) Schulz JB, et al : Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 45 : 65-74, 1999.
PubMed
11) Oba H, et al : New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 64 : 2050-2055, 2005.
PubMed
12) Rizzo G, et al : Diffusion-weighted brain imaging study of patients with clinical diagnosis of corticobasal degeneration, progressive supranuclear palsy and Parkinson's disease. Brain 131 : 2690-2700, 2008.
PubMed
13) Seppi K, et al : Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology 60 : 922-927, 2003.
 
P.226 掲載の参考文献
1) Orimo S, et al : 123I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease. J Neurol Neurosurg Psychiatry 67 : 189-194, 1999.
 
2) Yoshita M : Value of 123I-MIBG radioactivity in the differential diagnosis of DLB from AD. Neurology 66 : 1850-1854, 2006.
PubMed
3) Orimo S, et al : Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol 109 : 583-588, 2005.
PubMed
4) 織茂智之 : MIBG心筋シンチグラフィー. 内科 99 : 836-839, 2007.
 
5) Hamada K, et al : Onset age and severity of motor impairment are associated with reduction of myocardial 123I-MIBG uptake in Parkinson's disease. J Neurol Neurosurg Psychiatry 74 : 423-426, 2003.
PubMed
6) Saiki S, et al : Cardiac 123I-MIBG scintigraphy can assess the disease severity and phenotype of PD. J Neurol Sci 15 : 105-111, 2004.
 
7) Shindo K, et al : Analysis of the relationship between muscle sympathetic nerve activity and cardiac 123I-metaiodobenzylguanidine uptake in patients with Parkinson's disease. Mov Disord 20 : 1419-1424, 2005.
PubMed
8) Nakamura T, et al : Dobutamine stress test unmasks cardiac sympathetic denervation in Parkinson's disease. J Neurol Sci 263 : 133-138, 2007.
PubMed
9) Miyamoto T, et al : Reduced cardiac 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 67 : 2236-2238, 2006.
PubMed
10) Lee PH, et al : Correlation between cardiac 123I-MIBG and odor identification in patients with Parkinson's disease and multiple system atrophy. Mov Disord 78 : 1975-1977, 2006.
 
11) Kamiyama M, et al : Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. J Neurol Sci 264 : 22-26, 2008.
 
12) Orimo S, et al : Preserved cardiac sympathetic nerve accounts for normal cardiac uptake of MIBG in PARK2. Mov Disord 20 : 1350-1353, 2005.
PubMed
13) Tomiyama H, et al : Clinicogenetic study of mutations in LRRK2 exon41 in Parkinson's disease patients from 18 countries. Mov Disord 21 : 1102-1128, 2006.
 
14) Nishioka K, et al : Clinical heterogeneity of α-synuclein gene duplication in Parkinson's disease. Ann Neurol 59 : 298-309, 2006.
 
15) Hanyu H, et al : The role of 123I-metaiodobenzylguanidine myocardial scintigraphy in the diagnosis of Lewy body disease in patients with dementia in a memory clinic. Dement Geriatr Cogn Disord 22 : 379-384, 2006.
 
P.232 掲載の参考文献
1) Nandhagopal R, et al : Functional imaging in Parkinson disease. Neurology 70 : 1478-1488, 2008.
PubMed
2) Rinne UK, et al : Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord 5 : 55-59, 1990.
PubMed
3) Brooks DJ, et al : Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Ann Neurol 31 : 184-192, 1992.
PubMed
4) Shinotoh H, et al : Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration : a positron emission tomography study. J Neurol Neurosurg Psychiatry 56 : 467-472, 1993.
PubMed
5) Asanuma K, et al : Network modulation in the treatment of Parkinson's disease. Brain 129 : 2667-2678, 2006.
PubMed
6) Eckert T, et al : Quantification of Parkinson's disease-related network expression with ECD SPECT. Eur J Nucl Med Mol Imaging 34 : 496-501, 2007.
PubMed
7) Shinotoh H, et al : Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson's disease and progressive supranuclear palsy. Ann Neurol 46 : 62-69, 1999.
PubMed
8) Emre M, et al : Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 : 2509-2518, 2004.
PubMed
9) Ouchi Y, et al : Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 57 : 168-175, 2005.
PubMed
10) Parkinson Study Group : Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 : 1653-1661, 2002.
 
11) Whone AL, et al : Slower progression of Parkinson's disease with ropinirole versus levodopa : The REAL-PET study. Ann Neurol 54 : 93-101, 2003.
PubMed
12) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
13) Ravina B, et al : The role of radiotracer imaging in Parkinson disease. Neurology 64 : 208-215, 2005.
PubMed
14) Feigin A, et al : Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104 : 19559-19564, 2007.
PubMed
15) Eberling JL, et al : Results from a phase I safety trial of hAADC gene therapy for Parkinson's disease. Neurology 70 : 1980-1983, 2008.
PubMed
P.239 掲載の参考文献
1) Bruck A, et al : Striatal subregional 6- [18F] fluoro-L-dopa uptake in early Parkinson's disease : a two-year follow-up study. Mov Disord 21 : 958-963, 2006.
PubMed
2) Whone AL, et al : Slower progression of Parkinson's disease with ropinirole versus levodopa : The REAL-PET study. Ann Neurol 54 : 93-101, 2003.
PubMed
3) Cropley VL, et al : Pre-and post-synaptic dopamine imaging and its relation With frontostriatal cognitive function in Parkinson disease : PET studies with [11C] NNC 112 and [18F] FDOPA. Psychiatry Res 163 : 171-182, 2008.
PubMed
4) Kaasinen V, et al : Extrastriatal dopamine D (2) receptors in Parkinson's disease : a longitudinal study. J Neural Transm 110 : 591-601, 2003.
PubMed
5) Sawamoto N, et al : Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 131 : 1294-1302, 2008.
PubMed
6) 赫寛雄ほか : 脳血管性パーキンソニズムにおけるドパミンD2受容体結合能の検討. 臨床神経学 41 : 659-664, 2001.
 
7) Sovago J, et al : Positron emission tomographic evaluation of the putative dopamine-D3 receptor ligand, [11C] RGH-1756 in the monkey brain. Neurochem Int 45 : 609-617, 2004.
PubMed
8) Lee CS, et al : In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 47 : 493-503, 2000.
PubMed
9) Maeda T, et al : Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered 1-DOPA. Brain Res 1046 : 230-233, 2005.
 
10) Bohnen NI, et al : Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 26 : 1198-1212, 2006.
PubMed
11) 三品雅洋ほか : アデノシン受容体-ドパミンとの関連-. 臨床神経学 47 : 835-837, 2007.
 
12) Maetzler W, et al : [11C] PIB binding in Parkinson's disease dementia. Neuroimage 39 : 1027-1033, 2008.
PubMed
P.243 掲載の参考文献
1) Williams DR, et al : Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy : Richardson's syndrome and PSP-parkinsonism. Brain 128 : 1247-1258, 2005.
PubMed
2) Steele JC, et al : Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 10 : 333-359, 1964.
PubMed
3) Litvan I, et al : Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) : report of the NINDS-SPSP international workshop. Neurology 47 : 1-9, 1996.
PubMed
4) Litvan I, et al : Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewsld syndrome). Neurology 46 : 922-930, 1996.
PubMed
5) 船川格ほか : 進行性核上性麻痺の診断基準と重症度分類. 神経内科 56 : 124-130, 2002.
 
6) Hughes AJ, et al : The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 125 : 861-870, 2002.
 
7) Morris HR, et al : Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy. Brain 125 : 969-975, 2002.
PubMed
8) Williams DR, et al : Pure akinesia with gait freezing : a third clinical phenotype of progressive supranuclear palsy. Mov Disord 22 : 2235-2241, 2007.
PubMed
9) Imai H, Narabayashi H : Akinesia-conceming 2 cases of pure akinesia. Adv Neurol Sci (Tokyo) 18 : 787-794, 1974.
 
10) 湯浅龍彦ほか : 純粋アキネジアで初発し, その後経過において進行性核上性麻痺と診断された3例. 神経内科 26 : 460-467, 1987.
 
11) Quattrone A, et al : MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 246 : 214-221, 2008.
PubMed
12) Borroni B, et al : Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30 : 34-40, 2009.
PubMed
13) Borroni B, et al : Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71 : 1796-1803, 2008.
PubMed
14) Pittman AM, et al : Linkage disequilibrium fine mapping and haplotype association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. J Med Genet 42 : 837-846, 2005.
PubMed
15) Rademakers R, et al : High-density SNP haplotyping suggests altered regulation of tau gene expression in progressive supranuclear palsy. Hum Mol Genet 14 : 3281-3292, 2005.
PubMed
P.248 掲載の参考文献
1) Rebeiz JJ, et al : Corticodentatonigral degeneration with neuronal achromasia. Arch Neurol 18 : 20-33, 1968.
PubMed
2) Gibb WR, et al : Corticobasal degeneration. Brain 112 : 1171-1192, 1989.
PubMed
3) 森松光紀 : 進行性核上性麻痺, 大脳皮質基底核変性症. 日内会誌 92 : 1485-1492, 2003.
 
4) 田中真 : 大脳皮質基底核変性症Clinical Neuroscience 17 : 1395-1397, 1999.
 
5) Rinne JO, et al : Corticobasal degeneration : aclinical study of 36 cases. Brain 117 : 1183-1196, 1994.
 
6) 田中康文 : 頭頂葉内側面損傷と手の把握行動. 神経進歩 42 : 164-178, 1996.
 
7) Litvan I, et al : Movement Disorders Society Scientific Issues Committee report : SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18 : 467-486, 2003.
PubMed
8) Wenning GK, et al : Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 64 : 184-189, 1998.
PubMed
9) Geda YE, et al : Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 19 : 77-80, 2007.
 
10) Boeve BF, et al : Pathologic heterogeneity in clinically diagnosed corticobasal degeneration. Neurology 53 : 795-800, 1999.
PubMed
11) Llado A, et al : Clinicopathological and genetic correlates of frontotemporal lobar degeneration and corticobasal degeneration. J Neurol 255 : 488-494, 2008.
PubMed
12) Koyama M, et al : Imaging of corticobasal degeneration syndrome. Neuroradiology 49 : 905-912, 2007.
PubMed
13) Doran M, et al : Pathological heterogeneity of clinically diagnosed corticobasal degeneration. J Neurol Sci 216 : 127-134, 2003.
PubMed
P.254 掲載の参考文献
1) 阿部康二 (編) : 脊髄小脳変性症の臨床, 新興医学出版社, 1999.
 
2) Papp MI, et al : Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94 : 79-100, 1989.
PubMed
3) Gilman S, et al : Second consensus statement on the diagnosis of multiple system atrophy. Neurology 26 : 670-676, 2008.
 
4) Orimo S, et al : Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 : 642-650, 2008.
PubMed
5) Ito M, et al : Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy. J Neurol Neurosurg Psychiatry 78 : 722-728, 2007.
PubMed
6) Kollensperger M, et al : Diffusion weighted imaging best discriminates PD from MSA-P : A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord 22 : 1771-1776, 2007.
 
P.258 掲載の参考文献
1) Lewy FH : Paralysis agitans. I. Pathologische Anatomie. In : Handbuch der Neurologie (ed by Lewandowsky M), Vol 3, p 920-958, Springer, Berlin, 1912.
 
2) Greenfield JG, Bosanquet FD : The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry 10 : 213-226, 1953.
 
3) Kosaka K, et al : Presenile dementia with Alzheimer-, Pick-and Lewy body changes. Acta Neuropathol 36 : 221-233, 1976.
PubMed
4) Kosaka K : Lewy bodies in cerebral cortex, report of three cases. Acta Neuropathol 42 : 127-134, 1978.
PubMed
5) Kosaka K, Mehraein P : Dementia-Parkinsonism syndrome with numerous Lewy bodies and senile plaques in cerebral cortex. Arch Psychiatr Nervenkr 226 : 241-250, 1979.
PubMed
6) 小阪憲司ほか : Lewy小体病の臨床病理学的研究. 精神経誌 82 : 292-311, 1980.
 
7) Kosaka K, et al : Diffuse type of Lewy body disease. A progressive dementia with numerous cortical Lewy bodies and senile changes of various degree. A new disease? Clin Neuropathol 3 : 185-192, 1984.
PubMed
8) Kosaka K : Diffuse Lewy body disease in Japan. J Neurol 237 : 197-204, 1990.
PubMed
9) McKeith I, et al : Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewyy bodies (DLB). Neurology 47 : 1113-1124, 1996.
PubMed
10) McKeith IG, et al : Diagnosis and management of dementia with Lewy bodies : third report of the DLB consortium. Neurology 65 : 1863-1872, 2005.
PubMed
11) Kosaka K et al : Cerebral type of Lewy body disease. Neuropathology 17 : 32-35, 1996.
 
12) Polymeropoulos MH, et al : Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276 : 2045-2047, 1997.
 
13) Spillantini MG, et al : α-synuclein in Lewy bodies. Nature 388 : 839-840, 1997.
 
14) Masliah E, et al : Dopaminergic loss and inclusion body formation inα-synuclein mice implications for neurodegenerative disorders. Science 287 : 1265-1269, 2000.
 
15) Singleton AB, et al : α-synuclein locus triplication causes Parkinson's disease. Science 302 : 841, 2003.
 
P.262 掲載の参考文献
1) Hirano A, et al : Parkinsonism-dementia complex, an endemic disease on the island of Guam. Clinical features. Brain 84 : 642-661, 1961.
PubMed
2) Hirano A, et al : Parkinsonism-dementia complex, an endemic disease on the island of Guam. Pathological features. Brain 84 : 662-679, 1961.
PubMed
3) Galasko D, et al : Prevalence of dementia in Chamorros on Guam : relationship to age, gender, education, and APOE. Neurology 68 : 1772-1781, 2007.
PubMed
4) Kuzuhara S, et al : Familial amyotrophic lateral sclerosis and parkinsonism-dementia complex of the Kii peninsula of Japan : Clinical and neuropathological study and Tau analysis. Ann Neurol 49 : 501-511, 2001.
PubMed
5) 葛原茂樹 : 紀伊ALS再訪-ALS-parkinsonism-dementia complexとしての新しい概念, 疫学, 原因についての考察. Brain and Nerve 59 : 1065-1074, 2007.
 
6) 小久保康昌, 葛原茂樹 : 紀伊半島多発地域の筋萎縮性側索硬化症とパーキンソン認知症複合の臨床神経学的および神経病理学的検討. 臨床神経 41 : 769-774, 2001.
 
7) Kokubo Y, Kuzuhara S : Ophthalmomyiasis-like pigmentary retinopathy in ALS/PDC in the Kii peninsula of Japan. Neurology 60 : 1725-1726, 2003.
PubMed
8) Kokubo Y, Kuzuhara S : Neuroradiological study on amyotrophic lateral sclerosis and parkinsonism-dementia complex in the Kii peninsula of Japan. Arch Neurol 60 : 1257-1261, 2003.
 
9) Yamazaki M, et al : α-Synuclein inclusions in amygdala in the brains of patients with the parkinsonism-dementia complex of Guam. J Neuropathol Exp Neurol 59 : 585-591, 2000.
 
10) 谷口彰ほか : 紀伊半島の筋萎縮性側索硬化症/パーキンソン認知症複合のα-synuclein陽性構造の免疫組織化学的検討. 神経変性疾患に関する調査研究班2005年度研究報告書, p128-131, 2006.
 
11) Hasegawa M, et al : TDP-43 is deposited in the Guam parkinsonism-dementia complex brains. Brain 130 : 1386-1394, 2007.
PubMed
12) Kokubo Y, et al : Immunohistochemical study on phosphorylated TDP-43 protein in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula of Japan. Dement Geriatr Cogn Disord 26 (Suppl 1) : 87, 2008.
 
13) Tomiyama H, et al : Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan. Mov Disord 23 : 2344-2348, 2008.
PubMed
14) Sundar PD, et al : Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia. Hum Mol Genet 16 : 295-306, 2007.
PubMed
15) Morimoto S, et al : Increased oxidative stress in patients with amyotrophic lateral sclerosis/Parkinsonism-dementia complex in the Kii peninsula, Japan. Mov Disord 24 : 123-126, 2009.
PubMed
P.268 掲載の参考文献
1) Freidman JH, et al : Drug-induced parkinsonism. In : Drug Induced Movement Disorders, 2nd ed (ed by Factor SA, et al), p 103-139, Blackwell Futura, Massachusetts, 2005.
 
2) The Canadian Movement Disorder Group : Drugs that cause movement disorders http://www.cmdg.org/Movement_/drug/Drugsthatcausemovement/drugsthatcausemovement.htm
 
3) Ayd F : A survey of drug-induced extrapyramidal reactions. JAMA 175 : 1054-1060, 1961.
PubMed
4) Wilson J, MacLennan W : Drug-induced parkinsonism in the elderly. Age Aging 18 : 208-210, 1989.
PubMed
5) Factor SA, et al : Hsperidone and Parkinson's disease. Mov Disord 17 : 221-222, 2002.
PubMed
6) Tollefson GD, Kuntz AJ : Review of recent clinical studies with olanzapine. Br J psychiatry Suppl (37) : 30-35, 1999.
PubMed
7) Ravina B, et al : Donepezil for dementia in Parkinson's disease : a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76 : 934-939, 2005.
PubMed
8) Charness ME, et al : Frequent neurologic toxicity associated with amiodarone therapy. Neurology 34 : 669-671, 1984.
PubMed
P.271 掲載の参考文献
1) Critchley M : Arteriosclerotic parkinsonism. Brain 52 : 23-83, 1929.
 
2) Eadie MJ, Sutherland JM : Arteriosclerosis in parkinsonism. J Neurol Neurosurg Psychiatry 27 : 237-240, 1964.
PubMed
3) Yamanouchi H, Nagura H : Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke 28 : 965-969, 1997.
PubMed
4) 東儀英夫ほか : 血管性Parkinson症候群. 医学のあゆみ 186 : 69-73, 1998.
Medical*Online
5) 磯部千明, 安部隆志 : 血管性パーキンソニズム. 脳の科学 26 : 223-228, 2004.
 
P.275 掲載の参考文献
1) 井上尚英 : 重金属中毒による神経障害, 特に職業性マンガン中毒について. Brain and Nerve 59 : 581-589, 2007.
 
2) Pal PK, et al : Manganese neurotoxicity : a review of clinical features, imaging and pathology. Neurotoxicology 20 : 227-238, 1999.
PubMed
3) Olanow CW : Manganese-induced parkinsonism and Parkinson's disease. Ann N Y Acad Sci 1012 : 209-223, 2004.
PubMed
4) Inoue E, et al : Portal-systemic encephalopathy. Radiology 179 : 551-555, 1991.
PubMed
5) Brouillet EP, et al : Manganese injection into the rat striatum produces excitotoxic lesions by impairing energy metabolism. Exp Nerol 120 : 89-94, 1993.
 
6) Finkelstein Y, et al : Modulation of cholinergic systems by manganese. Neurotoxicology 28 : 1003-1014, 2007.
PubMed
7) Mena I : Manganese poisoning. In : Handbook of Clinical Neurology (ed by Vinken PJ, Bruyn G), p217-237, Elsevier North-Holland, Amsterdam, 1979.
 
8) Koller WC, et al : Effect of levodopa treatment for parkinsonism in welders : A double-blind study. Neurology 62 : 730-733, 2004.
PubMed
9) Shin YC, et al : High signal intensity on magnetic resonance imaging as a predictor of neurobehavioral performance of workers exposed to manganese. Neurotoxicology 28 : 257-262, 2007.
PubMed
10) Jiang Y, et al : Brain magnetic resonance imaging and manganese concentrations in red blood cells of smelting workers : search for biomarkers of manganese exposure. Neurotoxicology 28 : 126-135, 2007.
PubMed
11) 杉本久ほか : ガス (-酸化炭素中毒). 最新内科学体系臨床中毒, p223-236, 中山書店, 1994.
 
12) Parkinson RB, et al : White matter hyperintensities and neuropsychological outcome following carbon monoxide poisoning. Neurology 58 : 1525-1532, 2002.
PubMed
13) Murata T, et al : Neuronal damage in the interval form of CO poisoning determined by serial diffusion weighted magnetic resonance imaging plus 1H-magnetic resonance spectroscopy. J Neurol Neurosurg Psychiatry 71 : 250-253, 2001.
PubMed
14) Yoshii F, et al : Magnetic resonance imaging and 11C-N-methylspiperone/positron emission tomography studies in a patient with the interval form of carbon monoxide poisoning. J Neurol Sci 160 : 87-91, 1998.
 
15) Juurlink DN, et al : Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev (1) : CD002041, 2005.
PubMed
P.279 掲載の参考文献
1) Berger JR, Ross DB : Reversible Parkinson syndrome complicating postoperative hypoparathyroidism. Neurology 31 : 881-882, 1981.
PubMed
2) 顧艶紅, 児玉浩子 : Wilson病. 小児内科 38 (増刊号) : 161-162, 2006.
 
3) 百島祐貴, 藤原広和 : 浸透圧性脱髄症候群の画像診断. 神経内科 63 : 128-131, 2005.
 
4) Gocht A, Colmant HJ : Central pontine and extrapontine myelinolysis : areport of 58 cases. Clin Neuropathol 6 : 262-270, 1987.
 
5) 平野史倫ほか : パーキンソン症状を主症状とし, 完全寛解したpontine and extrapontine myelinolysisの1生存例. 臨床神経 32 : 1006-1012, 1992.
 
6) Lavy S, et al : Parkinsonism and hyperthyroidism. Eur Neurol 12 : 20-27, 1974.
PubMed
7) Davies JS, et al : Graves' disease presenting as hemiparkinsonism. J Endocrinol Invest 24 : 188-189, 2000.
 
8) Yoshida K, et al : GM1 gangliosidosis in adults : clinical and molecular analysis of 16 Japanese patients. Ann Neurol 31 : 328-332, 1992.
PubMed
9) Roze E, et al : Dystonia and parkinsonism in GM1 type 3 gangliosidosis. Mov Disord 20 : 1366-1369, 2005,
PubMed
10) 石川直将ほか : Marchiafava-Bignami病の臨床的検討. 昭和医学雑誌 68 : 232, 2008.
 
11) 相井平八郎, 亀山正邦 : 大脳基底核石灰化症について. 神経内科 16 : 585-594, 1982.
 
12) 門馬康二ほか : Fahr病の1例. 沖縄医学会雑誌 27 : 305-308, 1990.
 
P.284 掲載の参考文献
1) Jancovic J, Fahn S : Parkinsonism-plus syndromes and secondary parkinsonian disorders. In : Principles and Practice of Movement Disorders, p 260-263, Churchill Livingstone Elsevier, Philadelphia, 2007.
 
2) Von Economo C : Encephalitis lethargica. Wien Min Weshr 30 : 581-583, 1917.
 
3) Von Economo C : Die Encephalitis Lethargica, Franz Deuticke, Leipzig und Wein, 1918.
 
4) Ravenholt RT, Foege WH : 1918 influenza, encephalitis lethargica, parkinsonism. Lancet 2 : 860-864, 1982.
PubMed
5) Von Economo C : Encephalitis Lethargica : Its Sequelae and Treatment (Translated by Newman KO), Oxford University Press, London, 1931.
 
6) Dickman MS : von Economo encephalitis. Arch Neurology 58 : 1696-1698, 2001.
 
7) 森秀生 : 脳炎後パーキンソニズム. 別冊日本臨牀 神経症候群II, p32-35, 日本臨牀社, 1999.
 
8) Josephs KA, et al : Alpha-synuclein studies are negative in postencephalitic parkinsonism of von Economo. Neurology 59 : 645-646, 2002.
PubMed
9) Duvoisin RC, et al : Response of patients with postencephalitic parkinsonism to levodopa. J Neurol Neurosurg Psychiatry 35 : 487-495, 1972.
PubMed
10) Wenning G, et al : Spranuclear gaze palsy and eyelid apraxia in post-encephalitic parkinsonism. J Neural Transm 104 : 845-854, 1997.
PubMed
11) Gamboa ET, et al : Influenza virus antigen in postencephalic parkinsonism brain : detection by immnofluorescence. Arch Neurol 31 : 228-232, 1974.
 
12) Fahn S : Secondary Parkinsonism. In : Scientific Approaches to Clinical Neurology, vol. 2 (ed by Goldensohn ES, Appel SH), p 1159-1189, Lea and Febiger, Philadelphia, 1977.
 
13) Rail D, et al : Post-encephalitic Parkinsonism : current experience. J Neurol Neurosurg Psychiatry 44 : 670-676, 1981.
PubMed
14) Williams A, et al : Oligoclonal banding in the cerebrospinal fluid of patients With postencephalic Parkinsonism. J Neurol Neurosurg Psychiatry 42 : 790-792, 1979.
 
15) Howard RS, Lees AJ : Encephalitis lethargica. A report of four recent cases. Brain 110 (Pt 1) : 19-33, 1987.
 
16) Blunt ST, et al : Clinical features and management of two cases of encephalitis lethargica. Mov Disord 12 : 354-359, 1997.
 
17) Dale RC, et al : Encephalitis lethargica syndrome : 20 new cases and evidence of basal ganglia autoimmunity. Brain 127 : 21-33, 2004.
PubMed
18) Kirvan CA et al : Mimicry and auto-antibody-mediated neuronal cell signaling in Sydenham chorea. Nat Med 9 : 914-920, 2003.
 
19) Vincent A : Encephalitis lethargica : part of a spectrum of post-streptococcal autoimmune diseases? Brain 127 : 2-3, 2004.
PubMed
20) 木村朝昭ほか : 日本脳炎ウイルス. 別冊日本臨牀 神経症候群I, p465-468, 日本臨牀社, 1999.
 
21) 内藤寛ほか : S状結腸軸捻転症を繰り返した日本脳炎後パーキンソニズムの1例. 神経治療 25 : 157-162, 2008.
Medical*Online
P.289 掲載の参考文献
1) Kondo T : Brain tumor and parkinsonism. Nippon Rinsho 55 : 118-122, 1997.
PubMed
2) Margulies ME : Parkinsonism and brain tumor. J Nerv Ment Dis 117 : 550-552, 1953.
PubMed
3) Pohle T Krauss JK : Parkinsonism in children resulting from mesencephahc tumors. Mov Disord 14 : 842-846, 1999.
PubMed
4) Skiming JA, et al : Secondary parldnsonism : An unusual late complication of craniospinal radiotherapy given to a 16-month child. Med Pediatr Oncol 40 : 120-134, 2003.
 
5) Vhora S, et al : Pineal cavernous angioma presenting with Parkinsonism. J Clin Neurosci 8 : 263-266, 2001.
PubMed
6) Voermans NC, et al : Secondary parkinsonism in childhood : A rare complication after radiotherapy. Pediatr Neurol 34 : 495-498, 2006.
PubMed
7) Molho ES : Gliomatosis cerebri may present as an atypical parkinsonian syndrome. Mov Disord 19 : 341-344, 2004.
 
8) Cicarelli G, et al : Brain stem cystic astrocytoma presenting with pure parkmsonism. Mov Disord 14 : 364-366, 1999.
PubMed
9) Yoshikawa H, Abe T : Transient parkinsonism in bilateral striopallidodentate calcinosis. Pediatr Neurol 29 : 75-77, 2003.
PubMed
10) Yoshimura M, et al : Hemiparkinsonism associated with a mesencephalic tumor J Neurol Sci 197 : 89-92, 2002.
PubMed
11) Asada T, et al : Gliomatosis cerebri presenting as a parkinsonian syndrome. J Neuroimaging 17 : 269-271, 2007.
PubMed
12) Burkhardt K, et al : Pilocytic astrocytoma in the elderly. Clin Neuropathol 26 : 306-310, 2007.
PubMed
13) Ho BL, et al : Hemiparkinsonism secondary to an infiltrative astrocytoma. Neurologist 14 : 258-261, 2008.
 
14) Wenning GK, et al : Postoperative parkinsonian tremor in a patient with a frontal meningioma. Mov Disord 14 : 366-368, 1999.
 
15) Salvati M, et al : Parkinsonian syndrome in a patient with a pterional meningioma : case report and review of the literature. Clin Neurol Neurosurg 102 : 243-245, 2000.
 
16) Pramstaller PP, et al : Primary central nervous system lymphoma presenting with a parkinsonian syndrome of pure akinesia. J Neurol 246 : 934-938, 1999.
PubMed
17) Sanchez-Guerra M, et al : Primary brain lymphoma presenting as Parkinson's disease. Neuroradiology 43 : 36-40, 2001.
PubMed
18) Ertan S, et al : Parkinsonism caused by cavernoma located in basal ganglion. Parkinsonism Relat Disord 11 : 517-519, 2005.
PubMed
19) Pranzatelli MR, et al : Clinical spectrum of secondary parkinsonism in childhood : A reversible disorder. Pediatr Neurol 10 : 131-140, 1994.
PubMed

V 治療

P.300 掲載の参考文献
1) 日本神経学会治療ガイドライン作成小委員会 : 日本神経学会治療ガイドライン パーキンソン病治療ガイドライン2002. 臨床神経学 42 (5) : 421-494, 2002.
 
2) Olanow CW, et al : An algorithm (decision tree) for the management of Parkinson's disease (2001) : treatment guidehnes. Neurology 56 (11 Suppl 5) : S1-S88, 2001.
 
3) 日本神経学会「パーキンソン病治療ガイドライン」作成小委員会 : パーキンソン病治療ガイドライン-マスターエディション-, 医学書院, 2003.
 
4) Koller WC, et al : An algorithm for the management of Parkinson's disease. Neurology 44 (12 Suppl 10) : S1-S52, 1994.
 
5) Olanow CW, Koller WC : An algorithm (decision tree) for the management of Parkinson's disease : treatment guidelines. American Academy of Neurology. Neurology 50 (3 Suppl 3) : S1-S57, 1998.
 
6) Olanow CW, et al (柳澤信夫監, 久野貞子, 山本光利監訳) : パーキンソン病管理のアルゴリズム : 治療ガイドライン2001. Neurology 56 (11 Suppl 5) : S1-S88, 2001.
 
7) Goetz CG, et al : Management of Parkinson's disease : an evidence-based review. Mov Disord 17 (Suppl 4) : S1-S166, 2002.
 
8) Miyasaki JM, et al : Practice parameter : initiation of treatment for Parkinson's disease : an evidence-based review : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 (1) : 11-17, 2002.
 
9) Suchowersky O, et al : Practice parameter : diagnosis and prognosis of new onset Parkinson disease (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (7) : 968-975, 2006.
 
10) Suchowersky O, et al : Practice parameter : neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (7) : 976-982, 2006.
 
11) Pahwa R, et al : Practice parameter : treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (7) : 983-995, 2006.
 
12) Miyasaki JM, et al : Practice parameter : evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (7) : 996-1002, 2006.
 
P.306 掲載の参考文献
1) Grosset DG, Schapira AH : Timing the initiation of treatment in Parkinson's disease. J Neurol Neurosurg Psychiatry 79 : 615, 2008.
PubMed
2) de Jong GJ, et al : Factors that influence the occurrence of response variations in Parkinson's disease. Ann Neurol 22 : 4-7, 1987.
PubMed
3) Lesser RP, et al : Analysis of the clinical problems in parkinsonism and the complications of long-term levodopa therapy. Neurology 29 : 1253-1260, 1979.
PubMed
4) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
5) Grosset D, et al : A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 78 : 465-469, 2007.
PubMed
6) Asimakopoulos P, et al : Changes in quality of life in people with Parkinson's disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 79 : 716-718, 2008.
PubMed
7) 水野美邦 : 症候論よりみたParkinson病, Parkinsonismの概念, 定義と診断基準. 日本臨牀 55 (1) : 16-20, 1997.
Medical*Online
8) Oertel WH, et al : Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study. Mov Disord 21 : 343-353, 2006.
 
9) Bracco F, et al : The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease : final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18 : 733-746, 2004.
 
10) Parkinson Study Group : Pramipexole vs levodopa as initial treatment for Parkinson disease : A randomized controlled trial. JAMA 284 : 1931-1938, 2000.
 
11) Rascol O, et al : A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 342 : 1484-1491, 2000.
PubMed
12) Van Camp G, et al : Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363 : 1179-1183, 2004.
PubMed
13) Pinero A, et al : Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med 353 : 1976-1977, 2005.
PubMed
14) Stowe RL, et al : Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev (2) : CD006564, 2008.
PubMed
15) Parkinson Study Group : DATATOP : a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 46 : 1052- 1060, 1989.
 
16) Parkinson Study Group : Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 : 176-183, 1993.
 
17) Ward CD : Does selegiline delay progression of Parkinson's disease? Acritical re-evaluation of the DATATOP study. J Neurol Neurosurg Psychiatry 57 : 217-220, 1994.
 
18) Parkinson Study Group : A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 : 561-566, 2004.
 
19) Siderowf A, Stem M : Clinical trials With rasagiline : evidence for short-term and long-term effects. Neurology 66 : S80-S88, 2006.
 
20) Global Parkinson's Disease Survey Steering Committee : Factors impacting on quality of 1ife in Parkinson's disease : results from an international survey. Mov Disord 17 : 60-67, 2002.
 
P.311 掲載の参考文献
1) 楠見公義, 中島健二 : 我が国におけるパーキンソン病とパーキンソニズムの疫学. パーキンソン病-診断と治療- (柳澤信夫編), p10-16, 金原出版, 2000.
 
2) 日本神経学会 : 日本神経学会治療ガイドライン. パーキンソン病治療ガイドライン2002 (http://www.neurology-jp.org/guidelinem/neuro/parkinson/parkinson_index.html).
 
3) 新井雅信ほか : パーキンソン病患者におけるスポーツ習慣の効果. 臨床スポーツ医学 8 : 1200-1204, 1991.
 
4) Singh R, et al : Parkinson's disease and driving ability. J Neurol Neurosurg Psychiatry 78 : 363-366, 2007.
PubMed
5) Uc EY, et al : Impaired navigation in drivers with Parkinson's disease. Brain 130 : 2433-2440, 2007.
PubMed
6) Meindorfner C, et al : Driving in Parkinson's disease : mobility, accidents, and sudden onset of sleep at the wheel. Mov Disord 20 : 832-842, 2005.
PubMed
7) 松本光央ほか : 高齢者の運転の実態と今後の展望について. 老年精神医学雑誌 16 : 815-821, 2005.
Medical*Online
8) 串田一博ほか : 骨折の予防と予後-大腿骨頸部骨折. 最新骨粗鬆症, p565-572, ライフサイエンス出版, 1999.
 
9) Grisso JA, et al : Risk factors for hip fracture among elderly patients with Parkinson's disease. J Neurol Sci 182 : 89-93, 2001.
 
10) Sato Y, et al : High prevalence of vitamin D deficiency and reduced bone mass in Parkinson's disease. Neurology 49 : 1273-1278, 1997.
PubMed
11) 吉岡勝 : 患者さんの骨密度減少と脊柱病変. 難病と在宅ケア 9 : 47-50, 2003.
Medical*Online
12) 安部和夫, 高島千敬 : パーキンソン病の患者さんのための住まいの工夫-家屋改修のポイント, 星和書店, 2004.
 
13) 湯浅龍彦ほか : パーキンソン病における熱性ストレス症候群-それはより本質的な問題である-. 医療 61 : 449-457, 2007.
Medical*Online
14) Yoneyama T, et al : Oral care reduces pneumonia in older patients in nursing homes. J Am Geriatr Soc 50 : 430-433, 2002.
PubMed
15) Kirchgatterer A, et al : Long-term outcome following placement of percutaneous endoscopic gastrostomy in younger and older patients. Scand J Gastroenterol 42 : 271-276, 2007.
PubMed
P.317 掲載の参考文献
1) Olanow CW, et al : An algorithm (decision tree) for the management of Parkinson's disease (2001) : treatment guidelines. Neurology 56 : S1-S88, 2001.
PubMed
2) Goodwin VA, et al : The effectiveness of exercise interventions for people with Parkinson's disease : a systematic review and meta-analysis. Mov Disord 23 : 631-640, 2008.
PubMed
3) Fisher BE, et al : The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. Arch Phys Med Rehabil 89 : 1221-1229, 2008.
PubMed
4) Kuroda K, et al : The effectiveness of exercise interventions for people with Parkinson's disease : a systematic review and meta-analysis. Mov Disord 23 : 631-640, 2008.
 
5) Hausdorff JM, et al : Gait variability and basal ganglia disorders : stride-to-stride variabilities of gait cycle timing in Parkinson's disease and Huntington s disease. Mov Disord 13 : 428-437, 1998.
PubMed
6) Hanakawa T : Neuroimaging of standing and walking : Special emphasis on Parkinsonian gait. Parkinsonism Relat Disord 12 : S70-S75, 2006.
 
7) Rubinstein TC, et al : The power of cueing to circumvent dopamine deficits : a review of physical therapy treatment of gait disturbances in Parkinson's disease. Mov Disord 17 : 1148-1160, 2002.
PubMed
8) Jiang Y, Norman KE : Effects of visual and auditory cues on gait initiation in people with Parkinson's disease. Clin Rehabil 20 : 36-45, 2006.
PubMed
9) Hausdorff JM, et al : Rhythmic auditory stimulation modulates gait variability in Parkinson's disease. Eur J Neurosci 26 : 2369-2375, 2007.
PubMed
10) Marchese R, et al : The role of sensory cues in rehabilitation of parkinsonian patients : a comparison of two physical therapy protocols. Mov Disord 15 : 879-883, 2000.
PubMed
11) Nieuwboer A, et al : Cueing training in the home improves gait-related mobility in Parkinson's disease : the RESCUE trial. J Neurol Neurosurg Psychiatry 78 : 134-140, 2007.
 
12) Miyai I, et al : Long-term effect of body weight-supported treadmill training in Parkinson's disease : a randomized controlled trial. Arch Phys Med Rehabil 83 : 1370-1373, 2002.
PubMed
13) Cakit BD, et al : The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease. Clin Rehabil 21 : 698-705, 2007.
PubMed
14) Kurtis Y, et al : Does treadmill training improve lower-extremity tasks in Parkinson disease? A randomized controlled tria1. Clin J Sport Med 18 : 289-291, 2008.
 
15) Canning CG, et al : Multiple-task walking training in people with mild to moderate Parkinson's disease : a pilot study. Clin Rehabil 22 : 226-233, 2008.
PubMed
16) Gauthier L, et al : The benefits of group occupational therapy for Parkinson's disease. Am J Occup Ther 41 : 360-365, 1987.
PubMed
17) Scott S, Caird FI : Speech therapy for Parkinson's disease. J Neurol Neurosurg Psychiatry 46 : 140-144, 1983.
PubMed
18) Ramig LO, et al : Intensive voice treatment (LSVT) for patients with Parkinson's disease : a 2 year follow up. J Neurol Neurosurg Psychiatry 71 : 493-498, 2001.
PubMed
P.323 掲載の参考文献
1) 介護支援専門員テキスト編集委員会 : 四訂介護支援専門員基本テキスト, 長寿社会開発センター, 2007.
 
2) 難病対策研究会 : 難病対策提要, 太陽美術, 2005.
 
3) 障害者福祉研究会 : 新訂身体障害者認定基準及び認定要領「補訂版」解釈と運用, 中央法規 2005.
 
P.327 掲載の参考文献
1) Parkinson J : An Essay on The Shaking Palsy, Sherwood Neely and Jones, London, 1817.
 
2) 柏原健一 : パーキンソン病とやせ. パーキンソン病 臨床の諸問題 (山本光利編), p228-231, 中外医学社, 2006.
 
3) Chen H, et al : Weight loss in Parkinson's disease. Ann Neurol 53 : 676-679, 2003.
PubMed
4) Uc EY, et al : Predictors of weight loss in Parkinson's disease. Mov Disord 21 : 930-936, 2007.
 
5) たんぱく質. 厚生労働省策定 日本人の食事摂取基準 [2005年版] (第一出版編集部編), p39-49, 第一出版, 2005.
 
6) Mena I, Cotzias GC : Protein intake and treatment of Parkinson's disease. N Engl J Med 292 : 181-184, 1975.
PubMed
7) Carter JH, et al : Amount and distribution of dietary protein affects clinical response to levodopa in Parkinson's disease. Neurology 39 : 552-556, 1989.
PubMed
8) Riley D, Lang AE : Practical application of a low-protein diet for Parkinson's disease. Neurology 38 : 1026-1031, 1988.
PubMed
9) Puvi-Rajasingham S, Mathias CJ : Effect of meal size on post-prandial blood pressure and on postural hypotension in primary autonomic failure. Clin Auton Res 6 : 111-114, 1996.
PubMed
10) Kuipers HMM, et al : The influence of food temperature on postprandial blood pressure reduction and its relation to substance-P in healthy elderly subjects. J Am Geriatr Soc 39 : 181-184, 1991.
 
11) Mathias CJ, Bannister R (ed) : Postprandial hypotension. In : Autonomic Failure : A Textbook of Clinical Disorders of Autonomic Nervous System, 4th ed, p 283-295, Oxford University Press, Oxford, 1999.
 
12) 新美由紀 : 6食事性低血圧の治療 食事療法. 知っていますか? 食事性低血圧 (高橋昭監, 長谷川康博, 古池保雄編), p221-225, 南山堂, 2004.
 
13) Kempster PA, et al : Motor effects of broad beans (Vicia faba) in Parkinson's disease ; single dose studies. Asia Pac J Clin Nutr 2 : 85-89, 1993.
PubMed
14) Kempster PA, Wahlqvist ML : Dietary factors in the management of Parkinson's disease. Nutr Rev 52 : 51-58, 1994.
PubMed
P.332 掲載の参考文献
1) Miyasaki JM, et al : Practice parameter : initiation of treatment for Parkinson's disease : an evidence-based review : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 58 : 11-17, 2002.
 
2) Olanow CW, et al : An algorithm (decision tree) for the management of Parkinson's disease : treatment guidelines. Neurology 56 (Suppl 5) : S1-S88, 2001.
 
3) 水野美邦ほか, 日本神経学会パーキンソン病治療ガイドライン作成小委員会 : パーキンソン病ガイドライン. 臨床神経 42 : 428-494, 2002.
 
4) Management of Parkinson's disease : an evidence-based review. Mov Disord 17 (Suppl 4) : S1-S166, 2002.
 
5) Goetz CG, et al : Evidence-based medical review update : pharmacological and surgical treatments of Parkinson's disease : 2001 to 2004. Mov Disord 20 (5) : 523-539, 2005.
PubMed
6) Horstink M, et al : Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I : early (uncomplicated) Parldnson's disease. Eur J Neurol 13 : 1170-1185, 2006.
PubMed
7) Horstink M, et al : Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II : late (complicated) Parkinson's disease. Eur J Neurol 13 : 1186-1202, 2006.
PubMed
8) Parkinson Study Group : Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 : 1653-1661, 2002.
 
9) Schapira AH, Olanow CW : Neuroprotection in Parkinson disease : mysteries, myths, and misconceptions. JAMA 291 (3) : 358-364, 2004.
PubMed
10) Larsen JP, Boas J : The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability : an interim analysis of a Norwegian-Danish 5-year study. Norwegian-Danish Study Group. Mov Disord 12 : 175-182, 1997.
 
11) Palhagen S, et al : Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 51 : 520-525, 1998.
 
12) Palhagen S, et al : Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 : 1200-1206, 2006.
PubMed
13) Parkinson Study Group : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
 
14) Homykiewicz O : Dopamine miracle : From brain homogenate to dopamine replacement. Mov Disord 17 : 501-508, 2002.
 
15) Fahn S : Levodopa in the treatment of Parkinson's disease. J Neural Transm Suppl (71) : 1-15, 2006.
PubMed
16) Koller WC : Selegiline monotherapy in the treatment of Parkinson's disease. Neurology 47 : 196S-199S, 1996.
 
17) Shannon KM, et al : Amantadine and motor fluctuations in chronic Parkinson's disease. Clin Neuropharmacol 10 : 522-526, 1987.
PubMed
18) Verhagen Metman L, et al : Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 : 1323-1326, 1998.
PubMed
19) Ruottinen HM, Rinne UK : Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60 : 36-40, 1996.
 
20) Parkinson Study Group : Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 : 747-755, 1997.
 
P.337 掲載の参考文献
1) DeLong MR Juncos JL : Parkinson's disease and other extrapyramidal movement disorders. In : Harrison's Principles of Internal Medicine, 17th ed (ed by Fauci AS, et al), p 2549-2559, McGraw-Hill, New York, 2008.
 
2) 大槻純男 : 血液脳関門におけるモノアミン関連トランスポーターの役割. Clinical Neuroscience 26 : 1077-1080, 2008.
 
3) 水野美邦, 金沢章 : 各論パーキンソン病治療ガイドライン-マスターエディション (日本神経学会「パーキンソン病治療ガイドライン」作成小委員会編), p322-342, 医学書院, 2003.
 
4) 出村信隆 : パーキンソン病治療薬としてのCOMT阻害剤コムタン(R) の薬理と臨床プロフィール. 薬理と治療 36 : 155-163, 2008.
Medical*Online
5) 久野貞子ほか : L-ドーパ. パーキンソン病治療ガイドライン-マスターエディション (日本神経学会「パーキンソン病治療ガイドライン」作成小委員会編), p6-28, 医学書院, 2003.
 
6) Montastruc JL, et al : A randomized controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up. J Neurol Neurosurg Psychiat 57 : 1034-1038, 1994.
PubMed
7) Rinne UK, et al : Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications : results of a double-blind Ievodopa controlled tria1. The PKDS009 Study Group. Drugs 55 (Suppl 1) : 23-30, 1998.
 
8) Rascol O, et al : A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 : 1484-1491, 2000.
PubMed
9) Parkinson Study Group : Pramipexole vs Levodopa as initial treatment for Parkinson disease. A randomized controlled trial. JAMA 284 (15) : 1931-1938, 2000.
 
10) 水野美邦, 金沢章 : 総論パーキンソン病治療ガイドライン-マスターエディション (日本神経学会「パーキンソン病治療ガイドライン」作成小委員会編), p310-321, 医学書院, 2003.
 
11) Godwin-Austen RB, et al : Effects of L-dopa in Parkinson's disease. Lancet ii : 165-168, 1969.
 
12) 加瀬正夫ほか : 特発性パーキンソニズムに対するCarbidopa・L-Dopa併用療法とL-Dopa単独療法の二重盲検法による比較検討. 医学のあゆみ 101 : 796-813, 1977.
 
13) 水野美邦ほか : パーキンソン病に対するL-ドーパおよびBenserazide (RO4-4602) の併用効果 : 二重盲検法によるL-ドーパ単独療法と併用療法の比較. 神経研究の進歩 21 : 159-186, 1977.
 
P.340 掲載の参考文献
1) Chase TN, Oh JD : Striatal mechanisms and pathogenesis of Parkinsonian signs and motor complications. Ann Neurol 47 (Suppl 1) : S122-S130, 2000.
 
2) 水野美邦ほか : パーキンソン病治療ガイドライン2002. 臨床神経 42 : 430-494, 2002.
 
3) Melamed E, et al : Levodopa toxicity and apoptosis. Ann Neurol 44 (Suppl 1) : S149-154, 1998.
 
4) Poewe WH, Lees AI, Stern GM : Low-dose L-dopa therapy in Parkinson's disease : A 6-year follow-up study. Neurology 36 : 1528-1530, 1986.
 
5) Quinn N, et al : Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1 : 65-68, 1986.
 
6) Fahn S, et al : Levodopa and the progression of Parkinson's disease. N Engl J Med 351 : 2498-2508, 2004.
PubMed
7) Hoehn MM, Yahr MD : Parkinsonism : onset, progression and mortality. Neurology 17 : 427-442, 1967.
PubMed
8) Kitagawa M, Tashiro K : Low-dose levodopa therapy in Japanese patients with Parkinson's disease : Aretrospective study. Intern Med 44 : 939-943, 2005.
 
9) Katzenschlager R, et al : Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71 : 474-480, 2008.
PubMed
10) Kurlan R : "Levodopa phobia" : A new iatrogenic cause of disability in Parkinson disease. Neurology 64 : 923-924, 2005.
PubMed
P.344 掲載の参考文献
1) Calne DB, et al : Bromocriptine in Parkinsonism. Br Med J 4 : 442-444, 1974.
PubMed
2) Foley P, et al : Dopamine receptor agonists in the therapy of Parkinson's disease. J Neural Transm 111 : 1375-1446, 2004.
PubMed
3) 森川裕司 : パーロデル2.5mgの健常人における血漿中薬物動態データ, ノバルティスファーマ 社内資料, 1998.
 
4) Friis ML, et al : Transfer of bromocriptine across the blood-brain barrier in man. Acta Neurol Scand 59 : 88-95, 1979.
PubMed
5) Lieberman A, et al : Long-term efficacy of bromocriptine in Parkinson disease. Neurology 30 : 518-523, 1980.
PubMed
6) Teychenne PF, et al : Bromocriptine : low-dose therapy in Parkinson disease. Neurology 32 : 577-583, 1982.
PubMed
7) 豊倉康夫, 岩田誠ほか : パーキンソン症候群に対するプロモクリプチンの臨床的有用性-多施設二重盲検法による塩酸アマンタジンとの比較試験-. 臨床評価 12 : 369-401, 1984.
 
8) 豊倉康夫, 水野美邦ほか : パーキンソン症候群に対するプロモクリプチンの治療効果-レボドーパとの併用治療法における二重盲検法によるプラセボとの比較試験-. 臨床評価 12 : 403-443, 1984.
 
9) 豊倉康夫ほか : パーキンソニズムに対するBromocriptineの3年間の長期投与試験. 臨牀と研究 61 : 2338-2346, 1984.
Medical*Online
10) Nakanishi T, et al : Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients. Final report. Eur Neurol 32 (Suppl 1) : 9-22, 1992.
 
11) Ogawa N, et al : Nationwide multicenter prospective study on the long-term effects of bromocriptine for Parkinson's disease. Final report of a ten-year follow-up. Eur Neurol 38 (Suppl 2) : 37-49, 1997.
 
12) Montastruc JL, et al : A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease : a five year follow up. J Neurol Neurosurg Psychiatry 57 : 1034-1038, 1994.
PubMed
13) 青野敏弘ほか : ブロモクリプチンの副作用と対策. ブロモクリプチンの臨床 (高倉公朋, 水野正彦編), p136-145, 中外医学社, 1985.
 
14) Serratrice J, et al : Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev 10 : 334-336, 2002.
PubMed
15) Yamashiro K, et al : The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23 : 935-941, 2008.
PubMed
16) Tan LC, et al : Bromocriptine use and the risk of valvular heart disease. Mov Disord 24 : 344-349, 2009.
PubMed
P.349 掲載の参考文献
1) Rubin A, et al : Physiologic disposition of pergolide. Clin Pharmacol Ther 30 : 258-265, 1981.
PubMed
2) Thalamas C, et al : Pergolide : multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol 28 : 120-125, 2005.
PubMed
3) Bonuccelli U, Pavese N : Role of dopamine agonists in Parkinson's disease : an update. Expert Rev Neurother 7 : 1391-1399, 2007.
PubMed
4) 山本光利 : パーキンソン病治療におけるペルゴリドのスターター・パックを使用した亜急性漸増法. Geriatr Med 37 : 127-134, 1999.
 
5) 楢林博太郎ほか : パーキンソン病に対するpergolide mesilate (LY127809) の臨床的有用性の検討-bromocriptine mesilateを対照薬とした二重盲検群間比較試験医学と薬学 27 : 147-211, 1992.
 
6) Barone P, et al : Pergolide monotherapy in the treatment of early PD : arandomized, controlled study. Pergolide Monotherapy Study Group. Neurology 53 : 573-579, 1999.
 
7) Boas J, et al : The levodopa dose-sparing capacity of pergolide compared with that of bromocriptine in a open-label, crossover study. Eur J Neurol 3 : 44-49, 1996.
 
8) Oertel WH, et al : Pergolide versus levodopa monotherapy in early Parkinson's disease patients : The PELMOPET study. Mov Disord 21 : 343-353, 2006.
 
9) Pezzoli G, et al : A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease. Neurology 45 (3 Suppl 3) : S22-S27, 1995.
 
10) Lieberman AN, et al : Further studies with pergolide in Parkinson disease. Neurology 32 : 1181-1184, 1982.
PubMed
11) Stowe RL, et al : Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev (2) : CDOO6564, 2008.
PubMed
12) Pritchett AM, et al : Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 : 1280-1286, 2002.
PubMed
13) Yamashiro K, et al : The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23 : 935-941, 2008.
PubMed
14) Yamamoto M, et al : Dopamine agonists and cardiac valvulopathy in Parkinson disease : a case-control study. Neurology 67 : 1225-1229, 2006.
PubMed
15) Singh JP, et al : Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am J Cardiol 83 : 897-902, 1999.
PubMed
P.354 掲載の参考文献
1) 野元正弘 : Evidence based medicineに基づく治療 : ドパミンアゴニスト. 神経研究の進歩 44 : 601-610, 2000.
 
2) Pritchett AM, et al : Valvular heart disease in patients taking pergolide. Mayo Clin Proc 77 : 1280-1286, 2002.
PubMed
3) Schade R, et al : Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 : 29-38, 2007.
PubMed
4) Zanettini R, et al : Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 : 39-46, 2007.
PubMed
5) 日本神経学会 : ドパミンアゴニスト使用上の注意 (http://www.neurology-jp.org/news/0704_dopamin/0704_dopamin.html).
 
6) 浅井美由紀, 黒山政一 : パーキンソン病治療薬. 薬局 58 : 557-574, 2007.
 
7) 長谷川一子 : ドパミンアゴニスト. 脳の科学 26 (増刊号) : 288-296, 2004.
 
8) 「カベルゴリンのパーキンソン病に係る用法・用量について」, 薬食審査発第0829001号, 平成20年8月29日付.
 
9) Rinne UK, et al : Cabergoline in the treatrnent of early Parkinson's disease : results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. Neurology 48 : 363-368, 1997.
 
10) Rinne UK, et al : Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drug 55 (Suppl 1) : 23-30, 1998.
 
11) Bracco F, et al : The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease final results of a 5-year, double-blinded, levodopa-controlled study. CNS Drugs 18 : 733-746, 2004.
 
12) 柳澤信夫ほか : CG-101 (カベルゴリン) のパーキンソン病L-DOPA非併用例に対する臨床的有効性の検討-メシル酸プロモクリプチンを対照薬とした第III相多施設二重盲検比較試験-. 臨床医薬 12 (17) : 3719-3755, 1996.
 
13) Geminiani G, et al : Cabergoline in Parkinson's disease complicated by motor fructuations. Mov Disord 11 : 495-500, 1996.
PubMed
14) Steiger MJ, et al : Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. J Neurol 243 : 68-72, 1996.
PubMed
15) 柳澤信夫ほか : CG-101 (カベルゴリン) のパーキンソン病L-DOPA併用例に対する臨床的有効性の検討-メシル酸プロモクリプチンを対照薬とした第III相多施設二重盲検比較試験-. 臨床医薬 12 (17) : 3757-3798, 1996.
 
16) Ghantani T, et al : Comparative audit of pergolide and cabergoline therapy in the treatment of nocturnal 'off periods causing sleep disruption in Parkinson's disease. Eur J Neurol 8 (Suppl 1) : 8-11, 2001.
 
17) 柳澤信夫ほか : CG-101 (カベルゴリン) のパーキンソン病に対する長期投与試験. 臨床医薬 12 (17) : 3799-3823, 1996.
Medical*Online
18) EMEAプレリリース (http://www.emea.europa.eu/pdfs/human/press/pr/32239508en.pdf).
 
P.358 掲載の参考文献
1) Anden NE, et al : Effects of B-HT 920 and B-HT 933 on dopamine and noradrenaline autoreceptors in the rat brain. Acta Pharmacol Toxicol (Copenh) 52 : 51-56, 1983.
 
2) Eriksson E, et al : The putative dopamine autoreceptor agonist B-HT 920 decreases nigral dopamine cell firing rate and prolactin release in rat. Life Sci 36 : 1819-1827, 1985.
PubMed
3) Cichini G, et al : B-HT 920 and B-HT 958 : Presynaptic effects on electrically evoked 3H-dopamine release from slices of rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 335 : 28-31, 1987.
 
4) Pichler L, et al : The dopamine autoreceptor agonist B-HT 920 inhibits in vivo dopamine release into the cerebroventricular system of cats. Eur J Pharmacol 135 : 239-242, 1987.
PubMed
5) Hinzen D, et al : The dopamine autoreceptor agonist B-HT 920 stimulates denervated postsynaptic brain dopamine receptors in rodent and promate models of Parkinson's disease : a novel approach to treatment. Eur J Pharmacol 131 : 75-86, 1986.
 
6) Hjorth S, Carlsson A : Postsynaptic dopamine (DA) receptor stimulation properties of the putative DA autoreceptor-selective agonist B-HT 920 uncovered by co-treatment with the D-1 agonist SK & F3839. Psychopharmacology (Berl) 93 : 534-537, 1987.
 
7) Anden NE, Grabowska-Anden M : Stimulation of D1 dopamine receptors reveals direct effects of the preferential dopamine autoreceptor agonist B-HT 920 on postsynaptic dopamine receptors. Acta Physiol Scand 134 : 285-290, 1988.
PubMed
8) Pifl C, Hornykiewicz O : Postsynaptic dopamine agonist properties of B-HT 920 as revealed by concomitant D-1 receptor stimulation. Eur J Pharmacol 146 : 189-191, 1988,
PubMed
9) 中西孝雄ほか : B-HT 920 (塩酸タリペキソール) のパーキンソン病に対する臨床評価-メシル酸プロモクリプチンを対照とした第III相多施設二重盲検比較試験-. 臨床評価 21 : 59-110, 1993.
 
10) Kitamura Y, et al : Inhibitory effects of talipexole and pramipexole on MIPTP-induced dopamine reduction in the striatum of C57BL/6N mice. Jpn J Pharmacol 74 : 51-57, 1997.
PubMed
11) Kitamura Y, et al : Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model. Jpn J pharmacol 78 : 23-29, 1998.
PubMed
12) Kondo T, et al : Talipexole protects dopaminergic neuron from methamphetamine toxicity in C57BL/6N mouse. Neurosci Lett 247 : 143-146, 1998.
PubMed
13) Kitamura Y, et al : Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells. Mol Pharmacol 54 : 1046-1054, 1998.
PubMed
14) Takata K, et al : Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole. Brain Res 872 : 236-241, 2000.
PubMed
15) Kakimura J, et al : Release and aggregation of cytochrome C and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417 : 59-67, 2001.
PubMed
P.363 掲載の参考文献
1) Bouthenet ML, et al : Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry : comparison with dopamine D2 receptor mRNA. Brain Res 564 : 203-219, 1991.
PubMed
2) Parkinson Study Group : Pramipexole vs levodopa as initial treatment for Parkinson disease : A randomized controlled trial. Parkinson Study Group. JAMA 284 : 1931-1938, 2000.
 
3) Holloway RG, et al : Pramipexole vs levodopa as initial treatment for Parkinson disease : a 4-year randomized controlled tria1. Arch Neurol 61 : 1044-1053, 2004.
 
4) Moller JC, et al : Long-term efficacy and safety of pramipexole in advanced Parkinson's disease : results from European multicenter trial. Mov Disord 20 : 602-610, 2005.
PubMed
5) Powe WH, et al : Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease : a double-blind, double dummy, randomized controlled trial. Lancet Neurol 6 : 513-520, 2007.
 
6) Mizuno Y, et al : Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease. Mov Disord 18 : 1149-1156, 2003.
PubMed
7) Hanna PA, et al : Switching from pergolide to pramipexole in Parkinson's disease. J Neural Transm 108 : 63-70, 2001.
PubMed
8) Reichmann H, et al : Changing dopamine agonist treatment in Parkinson's disease : experiences with switching to pramipexole. J Neural Transm Suppl, 17-25, 2006.
PubMed
9) Pogarell O, et al : Pramipexole in patients with Parkinson's disease and marked drug resistant tremor : a randomized, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 72 : 713-720, 2002.
PubMed
10) Rektorova I, et al : Pramipexole and pergolide in the treatment of depression in Parkinson's disease : a national multicentre prospective randomized study. Eur J Neurol 10 : 399-406, 2003.
PubMed
11) Lemke MR, et al : Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci 248 : 266-270, 2006.
PubMed
12) Kumru H, et al : Increase in body weight after pramipexole treatment in Parkinson's disease. Mov Disord 21 : 1972-1974, 2006.
PubMed
13) Weintraub D, et al : Association of dopamine agonist use with impulse control disorders in Parkinson's disease. Arch Neurol 63 : 969-973, 2006.
PubMed
14) Izumi Y, et al : Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity. Eur J Pharmacol 557 : 132-140, 2007.
PubMed
15) Parkinson Study Group : Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 : 1653-1661, 2002.
 
P.367 掲載の参考文献
1) Coldwell MC, et al : Comparison of the functional potencies of ropinirole and other dopamine receptor agonists at human D2 (long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells. Br J Pharmacol 127 : 1696-1702, 1999.
PubMed
2) Eden RJ, et al : Preclinical pharmacology of ropinirole (SK & F 101468-A) a novel dopamine D2 agonist. Pharmacol Biochem Behav 38 : 147-154, 1991.
 
3) Hoglinger GU, et al : Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7 : 726-735, 2004.
PubMed
4) Rascol O, et al : A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342 : 1484-1491, 2000.
PubMed
5) Hauser RA, et al : Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Mov Disord 22 : 2409-2417, 2007.
PubMed
6) Korczyn AD, et al : A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. Neurology 53 : 364-370, 1999.
PubMed
7) Lieberman A, et al : Amulticenter trial of ropinirole as adjunct treatment for Parkinson's disease. Neurology 51 : 1057-1062, 1998.
 
8) Mizuno Y, et al : Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease : STRONG study. Mov Disord 22 : 1860-1865, 2007.
PubMed
9) Suzuki K, et al : Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson's disease. J Neurol Sci 271 : 47-52, 2008.
PubMed
10) Schade R, et al : Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356 : 29-38, 2007.
PubMed
11) Zanettini R, et al : Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 : 39-46, 2007.
PubMed
P.372 掲載の参考文献
1) Olanow CW, et al : The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 38 : 771-777, 1995.
PubMed
2) Parkinson Study Group : A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 : 561-566, 2004.
 
3) Birkmayer W, et al : Implications of combined treatment with 'Madopar' and L-deprenyl in Parkinson's disease. A long-term study. Lancet i : 439-443, 1977.
 
4) The Parkinson Study Group : Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 328 : 176-183, 1993.
 
5) Ebadi M, et al : Neuroprotective actions of selegiline. J Neurosci Res 67 : 285-289, 2002.
PubMed
6) Bainbridge JL, et al : Elucidating the mechanism of action and potential interactions of MAO-B inhibitors. Neurol Clin 26 (Suppl) : 85-96, 2008.
 
7) Kushleika J, et al : Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease. Ann Neurol 39 : 278-281, 1996.
 
8) Salo Pr, Tatton WG : Deprenyl reduces the death of motor neurons caused by axotomy. J Neurosci Res 31 : 394-400, 1992.
 
9) Biagini G, et al : L-deprenyl increases GFAP immunoreactivity selectively in activated astrocytes in rat brain. Neuroreport 5 : 955-958, 1993.
 
10) Palhagen S, et al : Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66 : 1200-1206, 2006.
PubMed
11) Hamaue N, et al : Selegiline effects on bradykinesia and dopamine levels in a rat model of Parkinson's disease induced by Japanese encephalitis virus. Biog Amines 16 : 523-530, 2001.
 
12) Ogata A, et al : Isatin, an endogenous MAO inhibitor, improves bradykinesia and dopamine levels in a rat model of Parkinson's disease by Japanese encephalitis virus. J Nerol Sci 206 : 79-83, 2003.
 
13) 山下拓史, 松本昌泰 : エンタカポン導入後にいったん改善したwearing-off現象がセレギリン投与を中止したところ悪化した1例. 神経内科 70 : 221-222, 2009.
 
14) Giladi N : Medical treatment of freezing of gait. Mov Disord 23 (Suppl 2) : 482-488, 2008.
 
15) 野村哲志ほか : Parkinson病の睡眠障害に対するselegilineの効果. 神経治療 24 : 583-587, 2007.
Medical*Online
P.377 掲載の参考文献
1) Rosenmund KW, et al : Uber Oxy-und Dioxyphenyl-serin und die Mutterstubstanz des Adrenalins. Ber Dtsch Chem Gew 52 : 1734-1749, 1919.
 
2) Inagaki C, et al : Inhibitory effect of (+) threo-3, 4-dihydroxy-phenylserine (DOPS) on decarboxylation of (-) threo-dops, Jpn J pharmacol 26 : 380-382, 1976.
PubMed
3) 楢林博太郎ほか : パーキンソン病におけるL-DOPSの治療効果-レボドーパ基礎治療例におけるプラセボを対照薬とした二重盲検比較法による検討-. 臨床評価 (Clin Eval) 15 : 423-457, 1987.
 
4) 中野友貴ほか : 家族性アミロイドポリニューロパチーに対するL-threo-3, 4-dihydroxyphenylserineの臨床効果. 薬理と治療 15 : 533-548, 1987.
Medical*Online
5) 祖父江逸郎ほか : Shy-Drager症候群および関連疾患に対するL-threo-3, 4-dihydroxyphenylserine (L-DOPS) の薬効評価. 医学のあゆみ 141 (6) : 353-378, 1987.
Medical*Online
6) 田中千賀子ほか : L-threo-DOPSの基礎薬理学. 神経精神薬理 7 (12) : 779-793, 1985.
 
7) 赤嶺俊彦ほか : L-DOPS細粒剤のパーキンソン病に対する臨床効果. 薬理と治療 15 : 445-452, 1987.
Medical*Online
8) 片山宗一 : パーキンソン病に対するL-DOPS長期投与の臨床効果. 薬理と治療 15 : 463-469, 1987.
Medical*Online
9) 楢林博太郎, 横地房子ほか : パーキンソン病におけるL-threo-3, 4-dihydroxyphenylserine療法の効果の分析. 脳と神経 43 (3) : 263-268, 1991.
 
10) Narabayashi H, Mizuno R : Norepinephrine Deficiency and Its Treatment with L-threo-DOPS in Parkinson's Disease and Related Disorders, The Parthenon Publishing Group, New York, 1993.
 
11) Freeman R, et al : The treatment of neurogenic orthostatic hypotension in autonomic failure with 3,4-DL-threo-dihydroxyphenylserine. Neurology 47 : 1414-1420, 1996.
 
12) Yamamoto M, et al : Result of long-term administration of L-threo-3, 4-dihydroxyphenylserine in patients with pure akinesia as an early symptom of progressive supranuclear palsy. Clin Neuropharmacol 20 : 371-373, 1997.
PubMed
13) Goldstein DS : L-Dihydroxyphenylserine (L-DOPS) : a norepinephrine prodrug. Cardiovasc Drug Rev 24 (3-4) : 189-203, 2006.
PubMed
P.384 掲載の参考文献
1) Schwab RS, et al : Amantadine in the treatment of Parkinson's disease. JAMA 208 (7) : 1168-1170, 1969.
PubMed
2) Farnebo LO, et al : Dopamine and noradrenaline releasing action of amantadine in the central and peripheral nervous system : a possible mode of action in Parkinson's disease. Eur J Pharmacol 16 (1) : 27-38, 1971.
PubMed
3) Arai A, et al : Amantadine increases L-DOPA-derived extracellular dopamine in the striatum of 6-hydroxydopamine-lesioned rats. Brain Res 972 (1-2) : 229-234, 2003.
 
4) Heimans RL, et al : Effects of amantadine on uptake and release of dopamine by a particulate fraction of rat basal ganglia. J Pharm Pharmacol 24 (11) : 875-879, 1972.
PubMed
5) Scatton B, et al : Increased synthesis and release of dopamine in the striatum of the rat after amantadine treatment. Eur J Pharmacol 13 (1) : 131-133, 1970.
PubMed
6) 小林清隆ほか : 健常人におけるシンメトレル錠の血中動態および尿排泄について. 薬理と治療 12 : 195-203, 1984.
 
7) Wu MJ, et al : Amantadine hydrochloride pharmacokinetics in patients with impaired renal function. Clin Nephrol 17 (1) : 19-23, 1982.
 
8) Horadam VW, et al : Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 94 (4 pt 1) : 454-458, 1981.
 
9) Nishikawa N, et al : Plasma amantadine concentrations in patients with Parkinson's disease. Parkinsonism Relat Disord, 2008. (Epub ahead of print)
 
10) 日本神経学会「パーキンソン病治療ガイドライン」作成小委員会 : パーキンソン病治療ガイドライン-マスターエディション (日本神経学会監), 医学書院, 2003.
 
11) Factor SA, Molho ES : Transient benefit of amantadine in Parkinson's disease : the facts about the myth. Mov Disord 14 (3) : 515-517, 1999.
PubMed
12) ノバルティスファーマ株式会社 : 医薬品インタビューフォーム (改訂7版), 1999 (11月).
 
13) Greenamyre JT, O'Brien CF : N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol 48 (9) : 977-981, 1991.
PubMed
14) Verhagen Metman L, et al : Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 50 (5) : 1323-1326, 1998.
PubMed
15) Pahwa R, et al : Practice Parameter : treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 (7) : 983-995, 2006.
 
16) Snow BJ, et al : The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease : a double-blind, placebo-controlled study. Clin Neuropharmacol 23 (2) : 82-85, 2000.
PubMed
17) Uitti RJ, et al : Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 46 (6) : 1551-1556, 1996.
PubMed
18) Inzelberg R, et al : Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 21 (9) : 1375-1379, 2006.
PubMed
19) Wenk GL et al : MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293 (3) : 267-270, 1995.
PubMed
20) Blanchet PJ, et al : Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dysldnesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. J Pharmacol Exp Ther 290 (3) : 1034-1040, 1999.
 
P.389 掲載の参考文献
1) 堀内恵美子 : 抗コリン薬, L-DOPS, Amantadine. 脳の科学 2004年増刊号 : 302-305, 2004.
 
2) Cunningham RW, et al : The pharmacology of 3- (N-piperidyl)-1-phenyl-1-cyclohexyl-1-propanol HCl- (artane) and related compounds ; new antispasmodic agents. J pharmacol Exp Ther 96 : 151-165, 1949.
 
3) Doshay LJ, Constable K : Artane therapy for parkinsonism. JAMA 140 : 1317-1322, 1949.
 
4) Doshay LJ, et al : Five year follow-up of treatment with trihexyphenidyl (Artane). JAMA 154 : 1334-1336, 1954.
 
5) 水野美邦 : パーキンソン病. p129-130, 星和書店, 1984.
 
6) 谷脇考恭, 後藤幾生 : 症状による治療薬の使い方-長期治療の観点からL-DOPAおよび抗コリン剤. 綜合臨牀 39 : 2443-2447, 1990.
 
7) Anticholinergic therapies in the treatment of Parkinson's disease. Mov Disord 17 (Suppl 4) : S7-S12, 2002.
 
8) 高柳一成ほか : アセチルコリン及びアドレナリン受容体機構の問題点とその検討. 日薬理誌 100 : 279-292, 1992.
Medical*Online
9) 近藤智善, 羽島浩三 : 抗パーキンソン剤 a) 抗コリン薬. 医薬ジャーナル 31 : 2992-2997, 1995.
 
10) Schrag A, et al : Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord 14 : 252-255, 1999.
PubMed
11) 東琢哉 : 抗コリン薬. パーキンソン病治療ガイドライン-マスターエディション (日本神経学会「パーキンソン病治療ガイドライン」作成小委員会編), 医学書院, 2003.
 
12) 村田美穂 : Evidence Based Medicineに基づく治療 : 抗コリン剤・塩酸アマンタジン. 神経研究の進歩 44 : 611-615, 2000.
 
13) 安藤一也ほか : Parkinson病に対するL-DOPAの効果-二重盲検法によるTrihexyphenidylとの比較実験を中心として-. 医学のあゆみ 75 : 95-105, 1970.
 
14) 平山恵三ほか : Parkinson症候群に対するL-DOPAならびにTrihexyphenidylの治療効果. 神経研究の進歩 15 : 267-285, 1971.
 
15) 中村重信 : パーキンソン病の治療とその機序 a) 抗コリン薬. 治療学 22 : 269-272, 1989.
 
16) Norris JW, Vas CJ : Methixene hydrochloride and parkinsonian tremor. Acta Neurol Scandinav 43 : 535-538, 1967.
 
P.394 掲載の参考文献
1) Assal F, et al : Tolcapone and fulminant hepatitis. Lancet 352 : 958, 1998.
PubMed
2) Colosimo C : The rise and fall of tolcapone. J Neurol 246 : 880-882, 1999.
PubMed
3) Sawle GV, et al : The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism : implications for levodopa therapy of Parkinson's disease. Neurology 44 : 1292-1297, 1994.
PubMed
4) Parkinson Study Group : Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42 : 747-755, 1997.
 
5) Rinne UK, et al : Entacapone enhances the response to levodopa in Parkinsonian patients with motor fluctuations. Neurology 51 : 1309-1314, 1998.
PubMed
6) Larsen Jp : The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 10 : 137-146, 2003.
PubMed
7) Mizuno Y, et al : Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients. Mov Disord 22 : 75-80, 2007.
PubMed
8) 総合製品概要-末梢COMT阻害薬コムタン錠100mg-, ノバルティスファーマ株式会社, 2008年3月.
 
9) 野元正弘 (監) : L-dopa血中濃度の推移をイメージした治療戦略-末梢COMT阻害薬コムタン錠100mg-, ノバルティスファーマ株式会社, 2008年10月.
 
10) 藤本健一 : Parkinson病治療におけるCOMT阻害薬の位置付け. 神経治療 24 : 533-539, 2007.
Medical*Online
11) Olanow CW, et al : An algorithm (decision tree) for the management of Parkinson's disease (2001) : treatment guidelines. Neurology 56 (Suppl 5) : S1-S88, 2001.
 
12) パーキンソン病ガイドライン作成小委員会 : パーキンソン病治療ガイドライン2002. 臨床神経 42 : 430-494, 2002.
 
P.398 掲載の参考文献
1) Voon V, et al : Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol 64 (2) : 212-216, 2007.
PubMed
2) EMEA recommends new warnings and contraindications for ergot-derived dopamine agonists, European Medicines Agency Press office, London, 2008. http://www.emea.europa.eu/pdfs/human/press/pr/32239508en.pdf
 
3) Lees AJ : Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. BMJ 311 (7020) : 1602-1607, 1995.
 
4) Olanow CW, et al : Effect of selegiline on mortality in patients with Parkinson's disease : a meta-analysis. Neurology 51 : 825-830, 1998.
PubMed
5) Media releases, Patients with early Parkinson's disease show better symptom control and improvements in daily activities with Stalevo than levodopa/carbidopa, Novartis, April 15, 2008. http://www.novartis.com/newsroom/media-releases/en/2008/1209170.shtml
 
P.405 掲載の参考文献
1) 村田美穂 : 薬物治療 : 我が国初の新規治療薬の開発に向けて-新規抗パーキンソン病薬ゾニサミドの開発-. 最新医学 62 (7) : 40-45, 2007.
 
2) Murata M, et al : Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci Res 41 : 397-399, 2001.
PubMed
3) Murata M, et al : Zonisamide improves motor function in Parkinson disease. A randomized, double-blind study. Neurology 68 : 45-50, 2007.
PubMed
4) Seino M, Ito T : Zonisamide. In : Epilepsy : A Comprehensive Textbook (ed by Engel J Jr, Pedlly TA), p 1619-1626, Lippincott-Raven, Philadelphia, 1997.
 
5) Okada M, et al : Effects of zonisamide on dopaminergic system. Epilepsy Res 22 : 193-205, 1995.
PubMed
6) Murata M : Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 10 : 687-693, 2004.
PubMed
7) 村田美穂 : 日本発の新しい抗パーキンソン作用薬ゾニサミドの臨床研究班, 平成15-17年度総合研究報告書, 2006年3月.
 
8) 村田美穂 : 新規抗パーキンソン病薬ゾニサミドの神経保護作用に関する臨床研究班, 平成19年度総括・分担研究報告書, 2008年3月.
 
9) Asanuma M, et al : Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci Res 60 : 106-113, 2008.
PubMed
P.409 掲載の参考文献
1) Stocchi E et al : Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease. Arch Neurol 62 : 905-910, 2005.
 
2) Mori A Shindou T : Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors. A potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology 61 (Suppl 6) : S44-S48, 2003.
 
3) Lewyitt PA et al : Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces "off" time in Parkinson's disease : a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol 63 : 295-302, 2008.
 
4) Kanda T, et al : Adenosine A2A antagonist : a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol 43 : 507-513, 1998.
 
5) Calon F, et al : Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias. Brain 127 : 1075-1084, 2004.
PubMed
6) Maeda T, et al : Serotonergic hyperinnervation into the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. Brain Res 1046 : 230-233, 2005.
PubMed
7) Olanow CW, McNaught KS : Ubiquitin-proteasome system and Parkinson's disease. Mov Disord 21 : 1806-1823, 2006.
PubMed
8) Whitton PS : Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 150 : 963-976, 2007.
PubMed
9) Ravina BM, et al : Neuroprotective agents for clinical trials in Parkinson's disease. Neurology 60 : 1234-1240, 2003.
PubMed
P.412 掲載の参考文献
1) Horstink M, et al : Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II : late (complicated) Parkinson's disease. Eur J Neurol 13 : 1186-1202, 2006.
PubMed
2) Deuschl G, et al : A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med 355 : 896-908, 2006.
PubMed
3) 深谷親ほか : パーキンソン病の定位・機能神経外科的治療. 医学のあゆみ 225 : 406-410, 2008.
Medical*Online
4) Katayama Y, et al : Subthalamic nucleus stimulation for Parkinson disease : benefits observed in levodopa-intolerant patients. J Neurosurg 95 : 213-221, 2001.
PubMed
5) Krack P, et al : Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 : 1925-1934, 2003.
PubMed
6) Limousin P, et al : Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 339 : 1105-1111, 1998.
PubMed
7) The Deep-Brain Stimulation for Parkinson's Disease Study Group : Deep-brain stimulation of the subthalamic nucleus or the pars intema of the globus pallidus in Parkinson's disease. N Engl J Med 345 : 956-963, 2001.
 
8) Katayama Y, et al : Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease. Stereotact Funct Neurosurg 84 : 176-179, 2006.
PubMed
9) Yamamoto T, et al : Deep brain stimulation for the treatment of parkinsonian, essential, and poststroke tremor : asuitable stimulation method and changes in effective stimulation intensity. J Neurosurg 101 : 201-209, 2004.
 
10) Burchiel KJ, et al : Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease : results of a randomized, blinded pilot study. Neurosurgery 45 : 1375-1382, 1999.
PubMed
11) Bejjani BP, et al : Deep brain stimulation in Parkinson's disease : opposite effects of stimulation in the pallidum. Mov Disord 13 : 969-970, 1998.
PubMed
12) Krack P, et al : Opposite motor effects of pallidal stimulation in Parkinson's disease. Ann Neurol 43 : 180-192, 1998.
PubMed
13) Stefani A, et al : Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130 : 1596-1607, 2007.
PubMed
14) Freed CR, et al : Transplantation of embryonic dopamine neurons for severe Parldnson's disease. N Engl J Med 344 : 710-719, 2001.
PubMed
15) Olanow CW, et al : A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 : 403-414, 2003.
PubMed
16) Roy NS, et al : Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 12 : 1259-1268, 2006.
PubMed
17) Fukuda H, et al : Fluorescence-activated cell sorting-based purification of embryonic stem cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 24 : 763-771, 2006.
PubMed
18) Takahashi K, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007.
PubMed
19) Itakura T, et al : Autologous transplantation of the cervical sympathetic ganglion into the parkinsonian brain : case report. Neurosurgery 35 : 155-157, 1994.
PubMed
20) Nakao N, et al : Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease. Brain Res Rev 52 : 244-256, 2006.
PubMed
21) Date I, et al : Chromaffin cell survival and host dopaminergic fiber recovery in a patient with Parkinson's disease treated by cografts of adrenal medulla and pretransected peripheral nerve. Case report. J Neurosurg 84 : 685-689, 1996.
 
P.417 掲載の参考文献
1) Spiegel EA, et al : Stereotactic apparatus for operations on the human brain. Science 106 : 349-350, 1947.
 
2) Svennilson E, et al : Treatment of parkinsonism by stereotactic thermolesions in the pallidal region. A clinical evaluation of 81 cases. Acta Psychiatr Neurol Scand 35 : 358-377, 1960.
 
3) Siegfried J, Lippitz B : Chronic electrical stimulation of the VL-VPL complex and of the pallidum in the treatment of movement disorders : personal experience since 1982. Stereotact Funct Neurosurg 62 : 71-75, 1994.
 
4) Ogura M, et al : The effect and mechanism of chronic electrical stimulation of the globus pallidus for treatment of Parkinson's disease. J Neurosurg 100 : 997-1001, 2004.
PubMed
5) Kumar R, et al : Deep brain stimulation of the globus pallidus interna in advanced Parkinson's disease. Neurology 55 (Suppl 6) : S34-S39, 2000.
 
6) The Deep-Brain Stimulation for Parkinson's Disease Study Group : Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 345 : 956-963, 2001.
PubMed
7) Tronnier VM, et al : Pallidal stimulation : an alternative to pallidotomy? J Neurosurg 87 : 700-705, 1997.
PubMed
8) Volkmann J, et al : Bilateral high-frequency stimulation of the internal globus pallidus in advanced Parkinson's disease. Ann Neurol 44 : 953-961, 1998.
PubMed
9) Bejjani B, et al : Pallidal stimulation for Parkinson's disease. Two targets? Neurology 49 : 1564-1569, 1997.
PubMed
10) Rodriguez-Oroz MC, et al : Bilateral deep brain stimulation in Parkinson's disease : a multicentre study with 4 years follw-up. Brain 128 : 2240-2249, 2005.
 
11) Krack P, et al : Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 : 1925-1934, 2003.
PubMed
12) Minguez-Castellanos A, et al : Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease : target related effect or selection bias? J Neurol Neurosurg Psychiatry 76 : 34-39, 2005.
 
13) Peppe A, et al : Stimulation of the subthalamic nucleus compared with the globus pallidus intemus in patients with Parkinson disease. J Neurosurg 101 : 195-200, 2004.
PubMed
14) Mazzone P, et al : Implantation of human pedunculopontine nucleus : a safe and clinically relevant target in Parkinson's disease. Neuroreport 17 : 1877-1881, 2005.
PubMed
15) Jeffrey E, et al : Motor cortex stimulation in patients with Parkinson disease : 12-month follow-up in 4 patients. J Neurosurg 109 : 133-139, 2008.
 
P.422 掲載の参考文献
1) 川崎隆ほか : 不確帯, Forel H野の術中微小電極記録. 機能的脳神経外科 47 : 150-153, 2008.
 
2) 高田昌彦ほか : 皮質-視床下核投射の機能的意義. 脳の科学 24 : 437-444, 2002.
 
3) Herzog J, et al : Most effective stimulation site in subthalamic deep brain stimulation for Parkinson's disease. Mov Disord 9 : 1050-1054, 2004.
PubMed
4) Limousin P, et al : Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus Stimulation. Lancet 345 : 91-95, 1995.
PubMed
5) Hamani C, et al : Bilateral subthalamic nucleus stimulation for Parkinson's disease : a systematic review of the clinical literature. Neurosurgery 62 (Suppl 2) : 863-874, 2008.
 
6) Kleiner-Fisman G, et al : Subthalamic nucleus deep brain stimulation : summary and metaanalysis of outcomes. Mov Disord (Suppl 14) : S290-S304, 2006.
 
7) Rodriguez-Oroz MC, et al : Bilateral deep brain stimulation in Parkinson's disease : a multicentre study with 4 years follow-up. Brain 128 : 2240-2249, 2005.
PubMed
8) Krack P, et al : Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 349 : 1925-1934, 2003.
PubMed
9) Schtipbach WM, et al : Stimulation of the subthalamic nucleus in Parkinson's disease : a 5 year follow up. J Neurol Neurosurg Psychiatry 76 : 1640-1644, 2005.
 
10) Welter ML, et al : Clinical predictive factors of subthalamic stimulation in Parkinson's disease. Brain 125 : 575-583, 2002.
PubMed
11) Schupbach WM, et al : Neurosurgery at an earlier stage of Parkinson disease : a randomized, controlled trial. Neurology 68 : 267-271, 2007.
PubMed
12) Saint-Cyr JA, et al : Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 123 : 2091-2108, 2000.
PubMed
13) Drapier D, et al : Does subthalamic nucleus stimulation induce apathy in Parkinson's disease? J Neurol 253 : 1083-1091, 2006.
PubMed
14) Takeshita S, et al : Effect of subthalamic stimulation on mood state in Parkinson's disease : evaluation of previous facts and problems. Neurosurg Rev 28 : 179-186, 2005.
 
P.427 掲載の参考文献
1) Pascual-Leone A, et al : Akinesia in Parkinson's disease. II. Effects of subthreshold repetitive transcranial motor cortex stimulation. Neurology 44 : 892-898, 1994.
PubMed
2) Mally J, Stone TW : Improvement in Parkinsonian symptoms after repetitive transcranial magnetic stimulation. J Neurol Sci 162 : 179-184, 1999.
PubMed
3) Mally J, Stone TW : Therapeutic and "dose-dependent" effect of repetitive microelectroshock induced by transcranial magnetic stimulation in Parkinson's disease. J Neurosci Res 57 : 935-940, 1999.
PubMed
4) Siebner HR, et al : Repetitive transcranial magnetic stimulation has a beneficial effect on bradykinesia in Parkinson's disease. Neuroreport 10 : 589-594, 1999.
 
5) Siebner HR, et al : Short-term motor improvement after sub-threshold 5-Hz repetitive transcranial magnetic stimulation of the primary motor hand area in Parkinson's disease. J Neurol Sci 178 : 91-94, 2000.
PubMed
6) Shimamoto H, et al : Therapeutic effect of repetitive transcranial magnetic stimulation in Parkinson's disease. Rinsho Shinkeigaku 39 : 1264-1267, 1999.
PubMed
7) de Groot M, et al : Contralateral and ipsilateral repetitive transcranial magnetic stimulation in Parkinson patients. Nervenarzt 72 : 932-938, 2001.
PubMed
8) Sommer M, et al : Repetitive paired-pulse transcranial magnetic stimulation affects corticospinal excitability and finger tapping in Parkinson's disease. Clin Neurophysiol 113 : 944-950, 2002.
PubMed
9) Khedr EM, et al : Therapeutic effect of repetitive transcranial magnetic stimulation on motor function in Parkinson's disease patients. Eur J Neurol 10 : 567-572, 2003.
PubMed
10) Ikeguchi M, et al : Effects of successive repetitive transcranial magnetic stimulation on motor performances and brain perfusion in idiopathic Parkinson's disease. J Neurol Sci 209 : 41-46, 2003.
PubMed
11) Lefaucheur JP, et al : Improvement of motor performance and modulation of cortical excitability by repetitive transcranial magnetic stimulation of the motor cortex in Parkinson's disease. Clin Neurophysiol 115 : 2530-2541, 2004.
PubMed
12) Lomarev MP, et al : Placebo-controlled study of rTMS for the treatment of Parkinson's disease. Mov Disord 21 : 325-331, 2006.
PubMed
13) Khedr EM, et al : Effect of daily repetitive transcranial magnetic stimulation on motor performance in Parkinson's disease. Mov Disord 21 : 2201-2205, 2006.
PubMed
14) Ghabra MB, et al : Simultaneous repetitive transcranial magnetic stimulation does not speed fine movement in PD. Neurology 52 : 768-770, 1999.
 
15) Tergau F, et al : Lack of clinical improvement in patients with Parkinson's disease after low and high frequency repetitive transcranial magnetic stimulation. Electroencephalogr Clin Neurophysiol Suppl 51 : 281-288, 1999.
PubMed
16) Koch G, et al : rTMS of supplementary motor area modulates therapy-induced dyskinesias in Parkinson disease. Neurology 65 : 623-625, 2005.
PubMed
17) Brusa L, et al : Low frequency rTMS of the SMA transiently ameliorates peak-dose L1D in Parkinson's disease. Clin Neurophysiol 117 : 1917-1921, 2006.
 
18) Boylan LS, et al : Repetitive transcranial magnetic stimulation to SMA worsens complex movements in Parkinson's disease. Clin Neurophysiol 112 : 259-264, 2001.
PubMed
19) Okabe S, et al : 0.2-Hz repetitive transcranial magnetic stimulation has no add-on effects as compared to a realistic sham stimulation in Parkinson's disease. Mov Disord 18 : 382-388, 2003.
 
20) Hamada M, et al : High frequency rTMS over the supplementary motor area for treatment of Parkinson's disease. Mov Disord 23 : 1524-1531, 2008.
PubMed
P.433 掲載の参考文献
1) Pittenger MF, et al : Multilineage potential of adult human mesenchymal stem cells. Science 284 : 143-147, 1999.
PubMed
2) Mezey E, et al : Turning blood into brain : cells bearing neuronal antigens generated in vivo from bone marrow. Science 290 : 1779-1782, 2000.
PubMed
3) Makino S, et al : Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 103 : 697-705, 1999.
PubMed
4) Chen J, et al : Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci 189 : 49-57, 2001.
PubMed
5) Li Y, et al : Human marrow stromal cell therapy for stroke in rat : neurotrophins and functional recovery. Neurology 59 : 514-523, 2002.
PubMed
6) Ohta M, et al : Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation. Exp Neurol 187 (2) : 266-278, 2004.
PubMed
7) Lundkvist J, et al : Notch and the birth of glial cells. Trends Neurosci 24 : 492-494, 2001.
PubMed
8) Dezawa M, et al : Specific induction of neuronal cells from bone marrow stromal cells and application for autologous transplantation. J Clin Invest 113 : 1701-1710, 2004.
PubMed
9) Lowell S, et al : Notch promotes neural lineage entry by pluripotent embryonic stem cells. PLoS Biol 4 : 805-818, 2006.
 
10) Bankiewicz KS, et al : Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP). Life Sci 39 (1) : 7-16, 1986.
PubMed
11) Nagane K, et al : Practical induction system for dopamine-producing cells from bone marrow stromal cells using spermine-pullulan-mediated reverse transfection method. Tissue Eng Part A, 2009. [Epub ahead of pHnt]
 
P.438 掲載の参考文献
1) Freed CR, et al : Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 : 710-719, 2001.
PubMed
2) Reynolds BA, Weiss S : Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255 : 1707-1710, 1992.
PubMed
3) Sanchez-Pernaute R, et al : In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res 65 : 284-288, 2001.
PubMed
4) Jiang Y, et al : Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418 : 41-49, 2002.
PubMed
5) Dezawa M, et al : Specific induction of neuronal cells from bone marrow stromal cells and application fbr autologous transplantation. J Clin Invest 113 : 1701-1710, 2004.
 
6) Shintani A, et al : Protection of dopamine neurons by bone marrow stromal cells. Brain Res 1186 : 48-55, 2007.
PubMed
7) Bjorklund LM, et al : Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 99 : 2344-2349, 2002.
 
8) Lee SH, et al : Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 18 : 675-679, 2000.
PubMed
9) Kawasaki H, et al : Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 : 31-40, 2000.
PubMed
10) Kim JH, et al : Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature 418 : 50-56, 2002.
 
11) Takahashi K, Yamanaka S : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 : 663-676, 2006.
PubMed
12) Wering M, et al : Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci USA 105 : 5856-5861, 2008.
 
13) Fiona D : Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97 : 703-716, 1999.
 
14) Yamashita T, et al : Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 26 : 6627-6636, 2006.
PubMed
15) de Chevigny A, et al : Fate Mapping and lineage analyses demonstrate the production of a large number of striatal neuroblasts after transforming growth factor-alpha and noggin striatal infusions into the dopamine-depleted striatum. Stem Cells 26 : 2349-2360, 2008.
PubMed
P.443 掲載の参考文献
1) Freed CR, et al : Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 344 : 710-719, 2001.
PubMed
2) Olanow CW, et al : A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 54 : 403-414, 2003.
PubMed
3) Li JY, et al : Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med 14 : 501-503, 2008.
PubMed
4) Kordower JH, et al : Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 14 : 504-506, 2008.
PubMed
5) Mendez I, et al : Dopamine neurons implanted in people with Parkinson's disease survive without pathology for 14 years. Nat Med 14 : 507-509, 2008.
PubMed
6) Kawasaki H, et al : Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron 28 : 31-40, 2000.
PubMed
7) Lee SH, et al : Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol 18 : 675-679, 2000.
PubMed
8) Takagi Y, et al : Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 115 : 102-109, 2005.
 
9) Fukuda H, et al : EACS-based purification of ES cell-derived neural precursors averts tumor formation after transplantation. Stem Cells 24 : 763-771, 2006.
 
10) Drukker M, et al : Characterization of the expression of MHC proteins in human embryonic stem cells. Proc Natl Acad Sci USA 99 : 9864-9869, 2002.
PubMed
11) Nakajima F, et al : Human leukocyte antigen matching estimations in a hypothetical bank of human embryonic stem cell lines in the Japanese population for use in cell transplantation therapy. Stem Cells 25 : 983-985, 2007.
 
12) Takahashi K, Yamanaka S : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 : 663-676, 2006.
PubMed
13) Takahashi K, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 : 861-872, 2007.
PubMed
14) Park IH, et al : Disease-specific induced pluripotent stem cells. Cell 134 : 877-886, 2008.
PubMed
15) Wernig M, et al : Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats With Parkinson's disease. Proc Natl Acad Sci USA 105 : 5856-5861, 2008.
PubMed
P.447 掲載の参考文献
1) Muramatsu S, et al : Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Exp Opin Biol Ther 5 : 663-671, 2005.
 
2) Muramatsu S, et al : Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 13 : 345-354, 2002.
 
3) Bankiewicz KS, et al : Convection-enhanced delivery of AAV vector in parkinsonian monkeys ; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164 : 2-14, 2000.
PubMed
4) Bankiewicz KS, et al : Long-term clinical improvement in MPTP-lesioned primates after gene therapy with AAV-hAADC. Mol Ther 14 : 564-570, 2006.
PubMed
5) Eberling JL, et al : Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70 : 1980-1983, 2008.
PubMed
6) Li XG, et al : Viral-mediated temporally controlled dopamine production in a rat model of Parkinson disease. Mol Ther 13 : 160-166, 2006.
 
P.451 掲載の参考文献
1) During MJ, et al : Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12 : 1589-1591, 2001.
PubMed
2) Muramatsu S, et al : Gene therapy for Parkinson's disease using recombinant adeno-associated viral vectors. Exp Opin Biol Ther 5 : 663-671, 2005.
 
3) Kreitzer AC, et al : Striatal plasticity and basal ganglia circuit function. Neuron 60 : 543-554, 2008.
PubMed
4) Kaplitt MG, et al : Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease : an open label, phase I trial. Lancet 369 : 2097-2105, 2007.
PubMed
5) Feigin A, et al : Modulation of metabolic brain networks after subthalamic gene therapy for Parkinson's disease. Proc Natl Acad Sci USA 104 : 19559-19564, 2007.
PubMed
6) Emborg ME, et al : Subthalamic glutamic acid decarboxylase gene therapy : changes in motor function and cortical metabolism. J Cereb Blood Flow Metab 27 : 501-509, 2007.
PubMed
P.454 掲載の参考文献
1) Lin LF, et al : GDNF : a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260 : 1130-1132, 1993.
PubMed
2) Treanor JJ, et al : Characterization of a multicomponent receptor for GDNF. Nature 382 : 80-83, 1996.
PubMed
3) Tomac A et al : Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373 : 335-339, 1995.
PubMed
4) Gash DM, et al : Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380 : 252-255, 1996.
PubMed
5) Bilang-Bleuel A, et al : Intrastrialal injecdon of an adenoviral vector expressing glial-cell-linededved neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 94 : 8818-8823, 1997.
 
6) Date I, et al : Grafting of encapsulated genetically modified cells secreting GDNF into the striatum of parkinsonian model rats. Cell Transplant 10 : 397-401, 2001.
PubMed
7) Yasuhara T, et al : Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease. J Neurosurg 102 : 80-89, 2005.
 
8) Muraoka K, et al : The high integration and differentiation potential of autologous neural stem cell transplantation compared with allogeneic transplantation in adult rat hippocampus. Exp Neurol 199 : 311-327, 2006.
PubMed
9) Kameda M, et al : Adult neural stem and progenitor cells modified to secrete GDNF can protect, migrate and integrate after intracerebral transplantation in rats with transient forebrain ischemia. Eur J Neurosci 26 : 1462-1478, 2007.
PubMed
10) Muraoka K, et al : Comparison of the therapeutic potential of adult and embryonic neural precursor cells in a rat model of Parkinson disease. J Neurosurg 108 : 149-159, 2008.
 
11) Gill SS, et al : Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9 : 589-595, 2003,
PubMed
12) Lang AE, et al : Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59 : 459-466, 2006.
PubMed
13) Kordower JH, 0lanow CW : Regulatable promoters and gene therapy for Parkinson's disease : is the only thing to fear, fear itself? Exp Neurol 209 : 34-40, 2008.
 
14) Ozawa K : Gene therapy using AAV. Uirusu 57 : 47-55, 2007.
PubMed
15) Arjona V, et al : Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 53 : 321-328 ; discussion 328-330, 2003.
 
P.459 掲載の参考文献
1) 野尻晋一, 山永裕明 : 図説パーキンソン病の理解とリハビリテーション (その17). 地域リハビリテーション 3 (5) : 420-423, 2008.
 
2) 阿部和夫 : 特集・治療の最前線 (1) : パーキンソン病リハビリテーションの役割. Brain Medical 14 (2) : 45-53, 2002.
 
3) 野尻晋一 : リハビリテーションからみた介護技術, p45-66, 107-118, 中央法規出版, 2006.
 
4) 柳澤信夫 : パーキンソン病との上手なつき合い方, 日本ベーリンガーインゲルハイム, 2001.
 
5) 野尻晋一, 山永裕明 : 図説パーキンソン病の理解とリハビリテーション (その18). 地域リハビリテーション 3 (6) : 514-517, 2008.
 
6) 白坂康俊 : 治療とリハビリテーション-機能訓練-言語聴覚士のための運動障害性構音障害, p264-314, 医歯薬出版, 2001.
 
7) 白坂康俊 : 代替コミュニケーションツール (AAC) の適応と限界. 音声言語医学 48 : 248-252, 2007.
Medical*Online

VI 治療上の問題点と対策

P.465 掲載の参考文献
1) Olanow CW, et al : An algorithm (decision tree) for the management of Parkinson's disease (2001) : Treatment guidelines. Neurology 56 (Suppl 5) : S1-S88, 2001.
 
2) 村田美穂 : L-Dopa血中濃度測定の臨床的意義. 内科 83 : 491-493, 1999.
 
3) 日本神経学会治療ガイドラインAd Hoc委員会 : パーキンソン病治療ガイドライン2002. 臨床神経 42 : 421-494, 2002.
 
4) Pincus JH, Barry K : Protein redistribution diet restores motor function in patient with dopa-resistant off periods. Neurology 38 : 481-483, 1988.
PubMed
P.468 掲載の参考文献
1) Fabbrini G, et al : Levodopa-induced dyskinesia. Mov Disord 22 : 1379-1389, 2007.
PubMed
2) Bezard E, et al : Pathophysiology of levodopa-induced dyskinesia : potential for new therapies. Nat Rev Neurosci 2 : 577-588, 2001.
PubMed
3) Parkinson Study Group : Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 39 : 37-45, 1996.
 
4) Schrag A, Schott JM : Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism. Lancet Neurol 5 : 355-363, 2006.
PubMed
5) Chase TN, et al : Striatal glutamatergic mechanisms and extrapyramidal movement disorders. Neurotox Res 5 : 139-146, 2003.
PubMed
6) Olanow CW, et al : Drug insight : Continuous dopaminergic stimulation in the treatment of Parkinson's disease. Nat Clin Pract Neurol 2 : 382-392, 2006.
PubMed
7) Metman LV, et al : Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 24 : 163-169, 2001.
PubMed
8) Thomas A, et al : Duration of amantadine benefit on dyskinesia of severe Parkinson's disease. J Neurol Neurosurg Psychiatry 75 : 141-143, 2004.
PubMed
9) Durif F, et al : Clozapine improves dyskinesia in Parkinson's disease : a double-blind, placebo-controlled study. Neurology 62 : 381-388, 2004.
PubMed
10) Vitek JL, et al : Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. Ann Neurol 53 : 558-569, 2003.
PubMed
11) de Bie RM, et al : Unilateral pallidotomy in Parldnson's disease : a randomized, single-blind, multicentre trial. Lancet 354 : 1665-1669, 1999.
PubMed
12) Burchiel KJ, et al : Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease : results of randomized, blinded pilot study. Neurosurgery 45 : 1375-1382, 1999.
PubMed
13) Kleine-Fisman G, et al : Subthalamic nucleus deep brain stimulation : summary and meta-analysis of outcomes. Mov Disord 21 (Suppl 14) : 290-304, 2006.
 
P.474 掲載の参考文献
1) Giladi N, Hausdorff JM : The role of mental function in the pathogenesis of freezing of gait in Parkinson's disease. J Neurol Sci 248 (1-2) : 173-176, 2006.
 
2) Giladi N, et al : Freezing of gait : prospective assessment in the DATATOP cohort. Neurology 56 : 1712-1721, 2001.
PubMed
3) Giladi N, et al : Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 12 (3) : 302-305, 1997.
PubMed
4) Schaafsma JD, et al : Characterization of freezing of gait subtypes and the response of each to levodopa on Parkinson's disease. Eur J Neurol 10 : 391-398, 2003.
PubMed
5) Amboni M, et al : Freezing of gait and executive functions in patients with parkison's disease. Mov Disord 23 : 395-400, 2007.
 
6) Bartels AL, Leenders KL : Brain imaging in patients with freezing of gait. Mov Disord 23 (Suppl 2) : S461-S467, 2008.
 
7) 岡田雅仁, 黒岩義之 : パーキンソン病及びパーキンソン症候群におけるすくみ足症例の画像的特徴. 横浜医学 56 : 97-100, 2005.
 
8) Hanakawa T, et al : Enhanced lateral premotor activity during paradoxical gait in Parkinson's disease. Ann Neurol 45 : 329-336, 1999.
PubMed
9) Nieuwboer A, et al : Electromyographic profiles of gait prior to onset of freezing episodes in patients with Parkinson's disease. Brain 127 : 1650-1660, 2004.
PubMed
10) Giladi N : Medical treatment of freezing of gait. Mov Disord 23 (Suppl 2), S482-S488, 2008.
 
11) Rascol O, et al ; LARGO study group : Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trail. Lancet 365 (9463) : 947-954, 2005.
 
12) Giladi N, et al : Freezing of gait in patients with advanced Parkinson's disease. J Neural Transm 108 : 53-61, 2001.
PubMed
13) Yener GG, et al : Improvement in Tc-99m HMPAO brain SPECT findings during donepezil therapy in a patient with pure akinesia. Ann Nucl Med 19 : 607-609, 2005.
 
14) Narabayashi H, et al : Analysis of L-threo-3, 4 dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease. No To Shinkei 43 : 263-268, 1991.
PubMed
15) Kitagawa M, et al : Effects of caffeine on the freezing of gait in Parkinson's disease. Mov Disord 22 : 710-712, 2007.
PubMed
16) Pollak L, et al : Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl (72) : 145-148, 2007.
 
17) Giladi N, Honigman S : Botulinum toxin injections to one leg alleviate freezing of gait in a patient With Parkinson's disase. Mov Disord 12 : 1085-1086, 1997.
 
18) Gurevich T, et al : The effect of injecting botulinum toxin type a into the calf muscles on freezing of gait in Parkinson's disease : a double blind placebo-controlled pilot study. Mov Disord 22 (6) : 880-883, 2007.
PubMed
19) Yokoyama T, et al : Subthalamic nucleus stimulation for gait disturbance in Parkinson's Disease. Neurosurgery 45 : 41-47, 1999.
PubMed
20) Moreau C, et al : STN-DBS frequency effects on freezing of gait in advanced Parkinson disease. Neurology 71 : 80-84, 2008.
PubMed
21) 岡田雅仁, 松本俊介 : パーキンソン病症例に対する線状レーザー発光器とりつけ杖を用いたすくみ足軽減の試み, 第41回リハビリテーション医学会学術集会, 2004.
 
22) 林明人ほか : パーキンソン病の音楽療法 : その有用性とアンケート調査結果, 第47回日本神経学会総会, 2006.
 
P.478 掲載の参考文献
1) Shaheda N, et al : Camptocormia ; pathogenesis, classification, and response to therapy. Neurology 65 : 355-359, 2005.
 
2) Djaldetti R, et al : Camptocormia (bent spine) in patients with Parkinson's disease ; characterization and possible pathogenesis of an unusual phenomenon. Mov Disord 14 : 443-447, 1999.
PubMed
3) Duvoisin RC, Marsden CD : Note on the scoliosis of parkinsonism. J Neurol Neursurg Psychiatry 38 : 787-793, 1975.
 
4) Ekbom K et al : New dystonic syndrome associated with butyrophenone therapy. Z Neurol 202 : 94-103, 1972.
PubMed
5) 原田研一, 齋藤利和 : Pisa症候群. 別冊日本臨牀 精神医学症候群I, p 199-202, 日本臨牀社, 2003.
 
6) Yokochi F : Lateral fleXion in Parkinson's disease and Pisa syndrome. J Neurol 253 (Suppl 7) : VII17-VII20, 2006.
 
7) Solla P, et al : Lateral trunk flexion and Pisa syndrome in Parkinson's disease. Are they really always different conditions although denoting similar features? J Neurol 255 : 450-451, 2008.
PubMed
8) Quinn N : Disproportionate antecollis in multiple system atrophy. Lancet i : 844, 1989.
PubMed
9) Kollensperger M, et al : Red flags for multiple system atrophy. Mov Disord 23 : 1093-1099, 2008.
PubMed
10) Kashihara K, et al : Dropped head syndrome in Parkinson's disease. Mov Disord 21 : 1213-1216, 2006.
PubMed
11) Fujimoto K : Dropped head in Parkinson's disease. J Neurol 253 (Suppl 7) : VII21-VII26, 2006.
 
12) Wunderlich S, et al : Camptocormia in Parkinson's disease mimicked by focal myositis of paraspinal muscles. Mov Disord 17 : 598-624, 2002.
PubMed
13) Katz JS, et al : Isolated neck extensor myopathy : a common cause of dropped head syndrome. Neurology 46 : 917-921, 1996.
PubMed
14) Melamed E, Djaldetti R : Camptocormia in Parkinson's disease. J Neurol 253 (Suppl 7) : VII14-VII16, 2006.
 
15) Ungerstedt U : Striatal dopamine release after amphetamine or nerve degeneration revealed by rotational behaviour. Acta Physiol Scand Suppl 367 : 49-68, 1971.
 
P.482 掲載の参考文献
1) Delay J, Deniker P : Drug-induced extrapyramidal syndromes. In : Handbook of Clinical Neurology Vol 6, Diseases of the Basal Ganglia (ed by Vinken PJ, Bruyn GW), p 248-266, North Holland Publishing Co, Amsterdam, 1968.
 
2) Samie MR : Neuroleptic malignant-like syndrome induced by metoclopramide. Mov Disord 2 : 57-60, 1987.
PubMed
3) Cohen S, et al : A case of non-neuroleptic malignant syndrome. J Clin Psychiatry 48 : 287-288, 1987.
 
4) Brennan D, et al : Neuroleptic malignant syndrome without neuroleptics. Br J psychiatry 152 : 578-579, 1988.
PubMed
5) Henderson VW, Wooten GF : Neuroleptic malignant syndrome : a pathogenic role for dopamine receptor blockade? Neurology 31 : 132-137, 1981.
 
6) Toru M, et al : Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs. J Nerv Ment Dis 169 : 324-327, 1981.
PubMed
7) Friedman JH, et al : A neuroleptic malignant-like syndrome due to levodopa therapy withdrawal. JAMA 254 : 2792-2795, 1985.
 
8) Ananth J, et al : Neuroleptic malignant syndrome and atypical antipsycotic drugs. J Clin Psychiatry 65 : 464-470, 2004.
 
9) Susman VL : Clinical management of neuroleptic malignant syndrome. Psychiatr Q 72 : 325-336, 2001.
PubMed
10) Addonizio G, et al : Neuroleptic malignant syndrome : review and analysis of 115 cases. Biol Psychiatry 22 : 1004-1020, 1987.
PubMed
11) Lazarus A : Neuroleptic malignat syndrome and amantadine withdrawal. Am J Psychiatry 142 : 142, 1985.
 
12) Pope GH, et al : Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Pschiatry 143 : 1227-1233, 1986.
 
13) Levinson DF, Simpson GM : Neuroleptic-induced extrapyramidal symptoms in fever. Arch Gen Psychiatry 43 : 839-848, 1986.
PubMed
14) Pfeeffer RF, Sucha EL : On-off induced malignant hyperthermia. Mov Disord 4 : 338-341, 1989.
 
15) Mizuta E, et al : Neuroleptic malignant syndrome in a parkinsonian woman during the premenstrual period. Neurology 43 : 1048-1049, 1993.
 
P.487 掲載の参考文献
1) The global Parkinson's disease survey (GPDS) steering committee : Factors impacting on quality of life in Parkinson's disease : results from an international survey. Mov Disord 17 : 60-67, 2002.
 
2) Marsh L, et al : Provisional diagnostic criteria for depression in Parkinson's disease : report of an NINDS/NIMH work group. Mov Disord 21 : 148-158, 2006.
PubMed
3) Kirsch-Darrow L, et al : Dissociating apathy and depression in Parkinson disease. Neurology 67 : 33-38, 2006.
PubMed
4) Schrag A, et al : Depression rating scales in Parkinson's disease : critique and recornmendations. Mov Disord 22 : 1077-1092, 2007.
 
5) Miyasaki JM, et al : Practice parameter : evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review) : report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 : 996-1002, 2006.
 
6) Levy R, Czernecld V : Apathyと基底核. パーキンソン病-臨床の諸問題 (山本光利編), p 201-216, 中外医学社, 2006.
 
7) 山本光利 (編) : パーキンソン病におけるうつ. パーキンソン病-認知と精神医学的側面, p38-53, 中外医学社, 2003,
 
8) Slaughter JR, et al : Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 13 : 187-196, 2001.
PubMed
9) Reijnders JS, et al : A systemic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23 : 183-189, 2008.
 
10) Remy P, et al : Depression in Parkinson's disease : loss of dopamine and noradrenaline innervation in the limbic system. Brain 128 : 1314-1322, 2005.
PubMed
11) 日本神経学会「パーキンソン病治療ガイドライン」作成小委員会 : 抗うつ薬. パーキンソン病治療ガイドライン-マスターエデイション, p187-208, 医学書院, 2003.
 
12) Treatment of depression in idiopathic Parkinson's disease. Mov Disord 17 (Suppl 4) : S112-S119, 2002.
 
13) Ghazi-Noori S, et al : Therapies for depression in Parkinson's disease (Cochrane Review). In : the Cochrane Library, Issue 4, John Wiley & Sons, Ltd, Chichester, 2003.
 
14) Weintraub D, et al : Antidepressant studies in Parkinson's disease : areview and meta-analysis. Mov Disord 20 : 1161-1169, 2005.
 
15) Richard IH, Kurlan R, the Parkinson Study Group : A survey of antidepressant drug use in Parkinson's disease. Neurology 49 : 1168-1170, 1997.
 
16) 菊地誠志ほか : パーキンソン病のうつ症状に対する薬物治療-EBM (Evidence Based Medicine) の立場から-. パーキンソン病におけるうつ. パーキンソン病-認知と精神医学的側面 (山本光利編), p146-158, 中外医学社, 2003.
 
17) Leentjens AF, et al : SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 18 : 552-554, 2003.
PubMed
18) van de Vijver, et al : Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 54 : 168-170, 2002.
PubMed
19) Barone P, et al : Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter parallel-group randomized study. J Neurol 253 : 601-607, 2006.
PubMed
P.492 掲載の参考文献
1) Lippa CF, et al : DLB and PDD boundary issues : diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68 : 812-819, 2007.
PubMed
2) Aarsland D, et al : A systematic review of prevalence studied of dementia in Parkinson's disease. Mov Disord 10 : 1255-1263, 2005.
 
3) Hobson P, et al : Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord 9 : 1043-1049, 2004.
 
4) Riedel O, et al : Cognitive impairment in 873 patients with idiopathic Parkinson's disease. J Neurol 255 : 255-264, 2008.
PubMed
5) Truong DD, et al : Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 266 : 216-228, 2008.
PubMed
6) 丸山哲弘 : Parkinson病と関連疾患. 神経内科 68 (Suppl 5) : 123-133, 2008.
 
7) Zgaljardic DJ, et al : A review of the cognitive and behavioral sequelae of Parkinson's disease : relationship to frontostriatal circuitry. Cogn Behav Neurol 16 : 193-210, 2003.
PubMed
8) Caballol N, et al : Cognitive dysfunction and dementia in Parkinson disease. Mov Disord 22 (Suppl 17) : S358-S366, 2007.
 
9) Jellinger KA, et al : Prevalence and impact of vascular and Alzheimer pathologies in Lewyy body disease. Acta Neuropathol 115 : 427-436, 2008.
PubMed
10) Braak H, et al : Cognitive decline correlates with neuropathological stage in Parkinson's disease. J Neurol Sci 248 : 255-258, 2006.
PubMed
11) Horstink M, et al : Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II : late (complicated) Parkinson's disease. Eur J Neurol 13 : 1186-1202, 2006.
PubMed
12) Pagonabarraga J, et al : Parkinson's disease-cognitive rating Scale : anew cognitive scale spechic for Parkinson's disease. Mov Disord 23 : 998-1005, 2008.
 
13) Matsui H, et al : Heterogeneous factors in dementia with Parkinson's disease : IMP-SPECT study. Parkinsonism Relat Disord 13 : 174-181, 2007.
PubMed
14) Gomperts SN, et al : Imaging amyloid deposition in Lewy body disease. Neurology 71 : 903-910, 2008.
PubMed
P.496 掲載の参考文献
1) Goetz CG, Stebbins GT : Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43 : 2227-2229, 1993.
PubMed
2) Melamed E, et al : Psychosis : impact on the patient and family. Neurology 52 (7 Suppl 3) : S14-16, 1999.
 
3) Celesia GG, Barr AN : Psychosis and other psychiatric manifestations of levodopa therapy. Arch Neurol 23 : 193-200, 1970.
PubMed
4) Fenelon G, et al : Hallucinations in Parkinson's disease : prevalence, phenomenology and risk factors. Brain 123 : 733-745, 2000.
PubMed
5) Hely MA et al : Sydney multicenter study of Parkinson's disease : non-L-dopa-responsive problems dominate at 15 years. Mov Disord 20 : 190-199, 2005.
 
6) Goetz CG, et al : Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord 21 : 267-270, 2006.
PubMed
7) Wada-Isobe K, et al : Assessment of hallucinations in Parkinson's disease using a novel scale. Acta Neurol Scand 117 : 35-40, 2008.
 
8) Wolters EC : Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol 248 (Suppl 3) : 22-27, 2001.
 
9) Fenelon G, et al : Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66 : 93-98, 2006.
PubMed
10) Parkinson Study group : Low-dose clozapine fbr the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 : 757-763, 1999.
 
11) Rabinstein AA, Shulmann LM : Management of behavioral and psychiatric problem in Parkinson's disease. Parkinsonism Relat Disord 7 : 41-50, 2001.
 
12) Frieling H, et al : Treating dopamimetic psychosis in Parkinson's disease : structured review and meta-analysis. Eur Neuropsychopharmaco1 17 : 165-171, 2007.
PubMed
13) Melamed E, Djaldetti R : パーキンソン病でみられるpsychosisの発生機序および管理. パーキンソン病-認知と精神医学的側面 (山本光利編), p112-121, 中外医学社, 2003.
 
14) Factor SA, et al ; Parkinson Study Group : Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 60 : 1756-1761, 2003.
 
15) Goetz CG, Stebbins GT : Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45 : 669-671, 1995.
PubMed
P.501 掲載の参考文献
1) Tandberg E, et al : A community-based study of sleep disorders in patients with Parkinson's disease. Mov Disord 13 : 895-899, 1998.
PubMed
2) Tse W, et al : Clinical usefulness of the Parkinson's disease sleep scale. Parkinsonism Relat Disord 11 : 317-321, 2005.
PubMed
3) Porter B, et al : The frequency and nature of sleep disorders in a community-based population of patients with Parkinson's disease. Eur J Neurol l5 : 50-54, 2008.
 
4) Diederich NJ, et al : Progressive sleep'destructuring, in Parkinson's disease. A polysomnographic study in 46 patients. Sleep Med 6 : 313-318, 2005.
PubMed
5) Tan EK, et al : Evaluation of somnolence in Parkinson's disease : comparison with age-and sexmatched controls. Neurology 58 : 465-468, 2002.
PubMed
6) Ondo WG, et al : Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology 57 : 1392-1396, 2001.
PubMed
7) Ghorayeb I, et al : A nationwide survey of excessive daytime sleepiness in Parkinson's disease in France. Mov Disord 22 : 1567-1572, 2007.
PubMed
8) Arnulf I, et al : Parkinson's disease and sleepiness : an integral part of PD. Neurology 58 : 1019-1024, 2002.
PubMed
9) Fronczek R, et al : Hypocretin (orexin) loss in Parkinson's disease. Brain 130 : 1577-1585, 2007.
PubMed
10) Thannickal TC, et al : Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130 : 1586-1595, 2007.
PubMed
11) Frucht S, et al : Falling asleep at the wheel : motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52 : 1908-1910, 1999.
PubMed
12) Boeve BF, et al : Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 130 : 2770-2788, 2007.
PubMed
13) 立花直子 : レム睡眠行動異常症の歴史的展開とその病態生理BRAIN and NERVE 61 : 2009. (in press)
 
14) Wetter TC, et al : Sleep and periodic leg movement patterns in drug-free patients with Parkinson's disease and multiple system atrophy. Sleep 23 : 361-367, 2000.
PubMed
15) 立花直子 : 睡眠障害. Journal of Clinical Rehabilitation 17 : 241-249, 2008.
Medical*Online
P.509 掲載の参考文献
1) 融道男ほか (監訳) : ICD-10 精神および行動の障害 臨床記述と診断ガイドライン, p219-210, 医学書院, 1993.
 
2) 高橋三郎ほか (訳) : DSM-IV-TR精神疾患の診断・統計マニュアル, p 638-641, 医学書院, 2002.
 
3) Voon V, et al : Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 66 (11) : 1750-1752, 2006.
PubMed
4) 斉藤学 : 強迫的 (病的) 賭博とその治療-病的賭博スクリーニング・テスト (修正SOGS) の紹介をかねて-. アルコール依存とアディクション 13 : 102-109, 1996.
 
5) Evans AH, et al : Punding in Parkinson's disease : its relation to the dopamine dysregulation syndrome. Mov Disord 19 : 397-405, 2004.
 
6) Molina JA, et al : Pathologic gambling in Parkinson's disease : a behavioral manifestation of phamlacologic treatment? Mov Disord 15 : 869-872, 2000.
PubMed
7) Giovannoni G, et al : Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry 68 : 423-428, 2000.
PubMed
8) Koob GF, Le Moal M : Drug abuse : hedonic homeostatic dysregulation. Science 278 : 52-58, 1997.
PubMed
9) 黒木俊秀 : 分子レベルにおける快感の基礎. 快の行動学 (中尾弘之, 田代信雄編), p34-53, 朝倉書店, 1998.
 
10) Wolters ECh, et al : Parkinson's disease-related disorders in the impulsive-compulsive spectrum. J Neurol 255 (Suppl 5) : 48-56, 2008.
 
11) Driver-Dunckley E, et al : Pathological gambling associated with dopamine agonist therapy in Parkinson's disease. Neurology 61 : 422-423, 2003.
PubMed
12) Dodd ML, et al : Pathological gambling caused by drugs used to treat Parkinson disease. Arch Neurol 62 : 1377-1381, 2005.
PubMed
13) Weintraub D, et al : Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 : 969-973, 2006.
PubMed
14) Szarfman A, et al : Association between pathologic gambling and parkinsonian therapy as detected in the Food and Drug Administration Adverse Event database. Arch Neurol 63 : 299-300, 2006.
PubMed
15) Avanzi M, et al : Prevalence of pathological gambling in patients with Parkinson's disease. Mov Disord 21 : 2068-2072, 2006.
PubMed
16) Grosset KA, et al : Problematic gambling on dopamine agonists : Not such a rarity. Mov Disord 21 : 2206-2208, 2006.
PubMed
17) Gallagher DA, et al : Pathological gambling in Parkinson's disease : risk factors and differences from dopamine dysregulation. An analysis of published case series. Mov Disord 22 : 1757-1763, 2007.
PubMed
18) Stamey W, Jankovic J : Impulse control disorders and pathological gambling in patients with Parkinson disease. Neurologist 14 : 89-99, 2008.
PubMed
19) Cloninger CR : A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 44 : 573-588, 1987.
PubMed
20) Menza MA, et al : Dopamine-related personality traits in Parkinson's disease. Neurology 43 : 505-508, 1993.
PubMed
21) Blum K et al : The D2 dopamine receptor gene as a determinant of reward deficiency syndrome. J R Soc Med 89 : 396-400, 1996.
PubMed
22) Comings DE, et al : A study of the dopamine D2 receptor gene in pathological gambling. Phamlacogenetics 6 : 223-234, 1996.
PubMed
23) Ricketts MH, et al : Association of long variants of the dopamine D4 receptor exon 3 repeat polymorphism with Parkinson's disease. Clin Genet 54 : 33-38, 1998.
PubMed
24) Bonelli RM, Cummings JL : Frontal-subcortical circuitry and behaVior. Dialogues Clin Neurosci 9 : 141-151, 2007.
PubMed
25) Masterman DL, Cummings JL : Frontal-subcortical circuits : the anatomic basis of executive, social and motivated behaviors. J Psychopharmacol 11 : 107-114, 1997.
PubMed
26) Spinella M : Neurobehavioral correlates of impulsivity : evidence of prefrontal involvement. Int J Neurosci 114 : 95-104, 2004.
PubMed
27) Tanabe J, et al : Medial orbitofrontal cortex gray matter is reduced in abstinent substancedependent individuals. Biol Psychiatry 65 : 160-164, 2009.
PubMed
28) Forbush KT, et al : Neuropsychological characteristics and personality traits in pathological gambling. CNS Spectr 13 : 306-315, 2008.
PubMed
29) Brand M, et al : Decision-making impairments in patients with Parkinson's disease. Behav Neurol 15 : 77-85, 2004.
PubMed
30) Kobayakawa M, et al : Decision making in Parkinson's disease : Analysis of behavioral and physiological patterns in the Iowa gambling task. Mov Disord 23 : 547-552, 2008.
PubMed
31) Pagonabarraga J, et al : Controlled study of decision-making and cognitive impairment in Parkinson's disease. Mov Disord 22 : 1430-1435, 2007.
PubMed
32) Mimura M, et al : Impaired decision-making in Parkinson's disease. Parkinsonism Relat Disord 12 : 169-175, 2006.
PubMed
33) Thiel A, et al : Activation of basal ganglia loops in idiopathic Parkinson's disease : a PET study. J Neural Transm 110 : 1289-1301, 2003.
PubMed
34) Cilia R, et al : Functional abnorrnalities underlying pathological gambling in Parkinson disease. Arch Neurol 65 : 1604-1611, 2008.
PubMed
35) Suhara T, et al : Dopamine D2 receptors in the insular cortex and the personality trait of novelty seeking. Neuroimage 13 : 891-895, 2001.
PubMed
36) Kaasinen V, et al : Insular dopamine D2 receptors and novelty seeking personality in Parkinson's disease. Mov Disord 19 : 1348-1351, 2004.
 
P.516 掲載の参考文献
1) Edwards LL, et al : Gastrointestinal symptoms in Parkinson's disease. Mov Disord 6 : 151-156, 1991.
PubMed
2) Edwards LL, et al : Gastrointestinal dysfunction in Parkinson's disease : frequency and pathophysiology. Neurology 42 : 726-732, 1992.
PubMed
3) Singer C, et al : Autonomic dysfunction in men With Parkinson's disease. Eur Neurol 32 : 134-140, 1992.
PubMed
4) Martignoni E, et al : Autonomic disorders in Parkinson's disease. J Neural Transm Suppl 45 : 11-19, 1995.
PubMed
5) Jost WH, Eckardt W : Constipation in idiopathic Parkinson's disease. Scand J Gastroenterol 38 : 681-686, 2003.
 
6) Byrne KG, et al : Gastrointestinal dysfunction in Parkinson's disease. A report of clinical experience at a single center. J Clin Gastroenterol 19 : 11-16, 1994.
 
7) Krogh K, et al : Clinical aspects of bowel symptoms in Parkinson's disease. Acta Neurol Scand 117 : 60-64, 2008.
PubMed
8) Jost WH, Schimrigk K : Constipation in Parkinson's disease. Min Wochenschr 69 : 906-909, 1991.
 
9) Braak H, et al : Idiopathic Parkinson's disease : possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 110 : 517-536, 2003.
PubMed
10) Wakabayashi K, et al : Parkinson's disease : the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (Berl) 76 : 217-221, 1988.
 
11) Kupsky WJ, et al : Parkinson's disease and megacolon : concentric hyaline inclusions (Lewy bodies) in enteric ganglion cells. Neurology 37 : 1253-1255, 1987.
PubMed
12) Singaram C, et al : Dopaminergic defect of enteric nervous system in Parkinson's disease patients with chronic constipation. Lancet 346 : 861-864, 1995.
PubMed
13) Wang L et al : Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 19 : 873-876, 2008,
 
14) Edwards L, et al : Gastrointestinal symptoms in Parkinson disease : 18-month follow-up study. Mov Disord 8 : 83-86, 1993.
PubMed
15) Stowe RL, et al : Dopamine agonist therapy in early Parkinson's disease. Cochrane Database Syst Rev : CD006564, 2008.
PubMed
16) Ueki A, Otsuka M : Life style risks of Parkinson's disease : association between decreased water intake and constipation. J Neurol 251 (Suppl 7) : vii 18-23, 2004.
 
17) Abbott RD, et al : Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57 : 456-462, 2001.
PubMed
18) Pfeiffer RF : Gastrointestinal dysfunction in Parkinson's disease. Clin Neurosci 5 : 136-146, 1998.
PubMed
19) Liu Z, et al : Mosapride citrate, a novel 5-HT4 agonist and partial 5-HT3 antagonist, ameliorates constipation in parkinsonian patients. Mov Disord 20 : 680-686, 2005.
PubMed
20) Neira WD, et al : The effects of cisapride on plasma L-dopa levels and clinical response in Parkinson's disease. Mov Disord 10 : 66-70, 1995.
PubMed
21) Jost WH : Gastrointestinal motility problems in patients with Parkinson's disease. Effects of antiparkinsonian treatment and guidelines for management. Drugs Aging 10 : 249-258, 1997.
PubMed
22) Sullivan KL, et al : Tegaserod (Zelnorm) for the treatment of constipation in Parkinson's disease. Mov Disord 21 : 115-116, 2006.
PubMed
23) 山下太郎ほか : Parkinson病患者の便秘症状に対するpolycarbophil calciumの効果. 神経治療 23 : 445-449, 2006.
Medical*Online
24) Zangaglia R, et al : Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 22 : 1239-1244, 2007.
PubMed
25) Sakakibara R, et al : Dietary herb extract dai-kenchu-to ameliorates constipation in parkinsonian patients (Parkinson's disease and multiple system atrophy). Mov Disord 20 : 261-262, 2005.
PubMed
26) Mathers SE, et al : Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease : a dystonic phenomenon? JNeurol Neurosurg Psychiatry 51 : 1503-1507, 1988.
PubMed
27) Ashraf W, et al : Anorectal manometry in the assessment of anorectal function in Parkinson's disease : a comparison with chronic idiopathic constipation. Mov Disord 9 : 655-663, 1994.
PubMed
28) Albanese A, et al : Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoXin A Am J Gastroenterol 98 : 1439-1440, 2003.
PubMed
P.522 掲載の参考文献
1) Chaudhuri KR, et al : Non-motor symptoms of Parkinson's disease : diagnosis and management. Lancet Neurol 5 : 235-245, 2006.
PubMed
2) 服部孝道ほか : 神経疾患による排尿障害ハンドブック, 三輪書店, 1998.
 
3) de Groat WC : Integrative control of the lower urinary tract : preclinical perspective. Br J Pharmacol 147 (Suppl 2) : S25-40, 2006.
 
4) Kavia RBC, et al : Functional imaging and the central control of the bladder. J Comp Neurol 493 : 27-32, 2005.
PubMed
5) Sakakibara R, et al : Micturition-related electrophysiological properties in the substantia nigra pars compacta and the ventral tegmental area in cats. Auton Neurosci 102 : 30-38, 2002.
PubMed
6) Kitta T, et al : Brain activation during detrusor overactivity in patients with Parkinson's disease : a positron emission tomography study. J Urol 175 : 994-998, 2006.
PubMed
7) Yamamoto T, et al : Striatal dopamine level increases in the urinary storage phase in cats : an in vivo microdialysis study. Neuroscience 135 : 299-303, 2005.
 
8) Yoshimura N, et al : Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway. Br J Pharmacol 139 : 1425-1432, 2003.
PubMed
9) Sakakibara R, et al : Effects of subthalamic nucleus stimulation on the micturation reflex in cats. Neuroscience 120 : 871-875, 2003.
PubMed
10) Sakakibara R, et al : SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction. J Neurol Sci 187 : 55-59, 2001.
PubMed
11) Seif C, et al : Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol 55 : 118-120, 2004.
PubMed
12) Sakakibara R, et al : Bladder and bowel dysfunction in Parkinson's disease. J Neural Transm 115 : 443-460, 2008.
PubMed
13) Aranda B, Cramer P : Effects of apomorphine and L-dopa on the parkinsonian bladder. Neurourol Urodyn 12 : 203-209, 1993.
PubMed
14) Kuno S, et al : Effects of pergolide on nocturia in Parkinson's disease : three female cases selected from over 400 patients. Parkinsonism Relat Disord 10 : 181-187, 2004.
PubMed
15) Scheife R, Takeda M : Central nervous system safety of anticholinergic drugs for the treatment of overactive bladder in the elderly. Clin Ther 27 : 144-153, 2005.
PubMed
P.527 掲載の参考文献
1) Parkinson J : An essay on the shaking Palsy, p 1-66, Sherwood, Neely and Jones, London, 1817. (Arch Neurol Psychiat 7 : 681-710, 1922に再録).
 
2) 岩本俊彦 : 嚥下障害の評価-慢性期合併症の落とし穴. 脳卒中診療のコツと落とし穴 (峰松一夫編), p200-201, 中山書店, 2003.
 
3) 切替一郎, 野村恭也 (編) : 咽喉科学総論. 新耳鼻咽喉科学, p527, 南山堂, 1985.
 
4) 山脇正永 : 失調症以外の症候. 脊髄小脳変性症のすべて (水澤英洋編), p 35, 日本プランニングセンター, 2006.
 
5) Logemann JA, et al : Editorial : Dysphagia in parkinsonism. JAMA 231 : 69-70, 1975.
PubMed
6) 磯崎栄治 : 多系統萎縮症における上気道閉塞. 神経研究の進歩 50 : 409-419, 2006.
 
7) Simpson DM, et al : Laryngeal dystonia in multiple system atrophy. Muscle Nerve 15 : 1213-1215, 1992,
PubMed
8) Kipps CM, et al : Movement disorder emergencies. Mov Disord 20 : 322-334, 2005.
PubMed
9) Logemann JA (編) : パーキンソン病Logemann摂食・嚥下障害, p 272-273, 医歯薬出版, 2000.
 
10) Martin BJ, et al : Normal laryngeal valving patterns during three breath-hold maneuvers : a pilot investigation. Dysphagia 8 : 11-20, 1993.
PubMed
11) Logemann JA, Kahrilas PJ : Relearning to swallow after stroke-apPlication of maneuvers and indirect biofeedback : a case study. Neurology 40 : 1136-1138, 1990.
PubMed
12) Nagaya M, et al : Effect of swallowing training on swallowing disorders in Parkinson's disease. Scand J Med 32 : 11-15, 2000.
 
13) 清水充子 : 直接訓練の一般的事項. 嚥下障害の臨床-リハビリテーションの考え方と実際 (小椋脩ほか編), p241, 医歯薬出版, 1999.
 
14) 中馬孝容, 眞野行生 : パーキンソン病に対するリハビリテーション. パーキンソン病のすべて (「脳の科学」編集委員会編), p393-399, 星和書店, 2004.
 
15) Bine JE, et al : Dysphagia and dementia in subjects with Parkinson's disease, Dysphagia 10 : 160-164, 1995.
PubMed
P.531 掲載の参考文献
1) Bannister R, Mathias CJ (ed) : Clinical features and evaluation of the primary chronic autonomic failure syndromes. In : Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System, 4th ed, p 307-316, Oxford University Press, Oxford, 1999.
 
2) 若林孝一 : パーキンソン病の全身病理. パーキンソン病病理学, 自律神経系研究の進歩 (山本光利編), p2-16, 中外医学社, 2004.
 
3) Braak H, et al : Gastric alpha-synuclein immunoreaction inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson s disease-related brain pathology. Neurosci Lett 396 : 67-72, 2006.
 
4) Wenning GK, et al : Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes : aclinicopathological study. J Neurol Neurosurg Psychiatry 67 : 620-623, 1999.
 
5) Goldstein DS : Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 16 : 46-54, 2006.
PubMed
6) Orimo S, et al : Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson's disease. Brain Pathol 17 : 24-30, 2007.
PubMed
7) 宇尾野公義 : パーキンソニズムと自律神経障害. 自律神経 10 : 163-170, 1973.
 
8) van Dijk JG, et al : Autonomic nervous system dysfunction in Parkinson's disease : relationships with age, medication, duration, and severity. J Neurol Neurosurg Psychiatry 56 : 1090-1095, 1993.
PubMed
9) Oka H, et al : Characteristics of orthostatic hypotension in Parkinson's disease. Brain 130 : 2425-2432, 2007.
PubMed
10) 新美由紀 : Parkinson病の起立性低血圧. 神経内科 66 : 30-37, 2007.
 
11) Goldstein DS, et al : Orthostatic hypotension from sympathetic denervation in Parkinson's disease. Neurology 58 : 1247-1255, 2002.
PubMed
12) Keenan RE : The Eaton Collaborative Study of levodopa therapy in parkinsonism : a summary. Neurology 20 : 46-59, 1970.
PubMed
13) 日本神経学会 : パーキンソン病治療ガイドライン2002. 臨床神経学 42 : 430-494, 2002.
 
14) Martignoni E, et al : Cardiovascular dysautonomia as a cause of falls in Parkinson's disease. Parkinsonism Relat Disord 12 : 195-204, 2006.
PubMed
15) Schoffer KL, et al : Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 22 : 1543-1549, 2007.
PubMed
P.535 掲載の参考文献
1) 宇尾野公義 : パーキンソニズムと自律神経障害. 自律神経 10 : 163-170, 1973.
 
2) Brewer M, Stacy M : Sildenafil citrate therapy in men with Parkinson's disease. Mov Disord 13 : 860, 1998.
 
3) Brown RG, et al : Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry 53 : 480-486, 1990.
 
4) Sakakibara R, et al : Questionnaire-based assessment of pelvic organ dysfunction in Parkinson's disease. Auton Neurosci 92 : 76-85, 2001.
PubMed
5) Papatsoris AG, et al : Erectile dysfunction in Parkinson's disease. Urology 67 : 447-451, 2006.
 
6) Barone P, et al : Pramipexole versus sertraline in the treatment of depression in Parkinson's disease. A national multicenter pararell-group randomized study. J Neurol 253 : 601-607, 2006.
 
7) Shapiro SK : Hypersexual behavior complicating levodopa (L-Dopa) therapy. Minn Med 56 : 58-59, 1973.
PubMed
8) Uitti RJ, et al : Hypersexuality with antiparkinsonian therapy. Clin Neuropharmacol 12 : 375-383, 1989.
PubMed
9) Mendez MF, et al : Hypersexuality after right pallidotomy for Parkinson's disease. J Neuropsychiatry Clin Neurosci 16 : 37-40, 2004.
PubMed
10) Klos KI, et al : Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy. Parkinsonism Relat Disord 11 : 381-386, 2005.
 
11) Voon V, et al : Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology 67 : 1254-1257, 2006.
PubMed
12) Voon V, Fox SH : Medication-related impulse control and repetitive behaviors in Parkinson disease. Arch Neurol 64 : 1089-1096, 2007.
PubMed
13) Weintraub D, et al : Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol 63 : 969-973, 2006.
PubMed
14) Kanovsky P, et al : Penile erections and hypersexuality induced by pergolide treatment in advanced, fluctuating Parkinson's disease. J Neurol 249 : 112-114, 2002.
PubMed
15) Wittstocket M, et al : Cabergoline can increase penile erections and libido. Neurol 58 : 831, 2002.
 
16) 井上尚英ら : プラミペキソールやペルゴリドにより誘発された性欲亢進. 神経内科 64 : 444, 2006.
 
17) Shapiro MA, et al : Hypersexuality and paraphilia induced by selegiline in Parkinson's disease : Report of 2 cases. Parkinsonism Relat Disord 12 : 392-395, 2006.
PubMed
P.539 掲載の参考文献
1) Curtis MA, et al : Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 315 : 1243-1249, 2007.
 
2) Daniel SE, Hawkes CH : Preliminary diagnosis of Parkinson's disease by olfactory bulb pathology. Lancet 340 : 186, 1992.
PubMed
3) Doty RL, et al : University of Pennsylvania smell identhication test : Arapid quantative olfactory function test for the clinic. Laryngoscope 94 : 176-178, 1984.
 
4) Doty RL, et al : Development of the 12-item cross-cultural smell identification test (CC-SIT). Laryngoscope 106 : 353-356, 1996.
PubMed
5) Saito S, et al : Development of a smell identification test using a novel stick-type odor presentation kit. Chem Senses 31 : 379-391, 2006.
PubMed
6) 持尾聰一郎ほか : Parkinson病の嗅覚障害に関する検討-線香を用いた簡便法-. 神経内科 68 : 389-392, 2007.
 
7) Sengoku R, et al : Incidence and extent of Lewy body-related alpha-synucleinopathy in aging human olfactory bulb. J Neuropathol Exp Neurol 67 : 1072- 1083, 2008.
 
8) Fumimura Y, et al : Analysis of the adrenal gland is usefu1 for evaluating pathology of the peripheral autonomic nervous system in lewy body disease. J Neuropathol Exp Neurol 66 : 354-362, 2007.
PubMed
P.544 掲載の参考文献
1) 日本神経学会パーキンソン病治療ガイドライン作成小委員会 : パーキンソン病治療ガイドライン2002 臨床神経 42 : 430-494, 2002.
 
2) 日本神経学会 : ドパミンアゴニスト使用上の注意2007年5月22日. http://www.neurology-jp.org/news/0704_dopamin/index.html
 
3) Zanettini R, et al : Valvular heart disease and the use of dopamine agonists for Parkinson's disease. N Engl J Med 356 : 39-46, 2007.
PubMed
4) Yamamoto M, et al : Dopamine agonists and cardiac valvulopathy in Parkinson disease. A case-control study. Neurology 67 : 1225-1229, 2006.
PubMed
5) Yamashiro K, et al : The frequency of cardiac valvular regurgitation in Parkinson's disease. Mov Disord 23 : 935-941, 2008.
PubMed
6) Kerner Y, et al : Predictors of sudden onset of sleep in Parkinson's disease. Mov Disord 19 : 1298-1305, 2004.
 
7) Szarfman A, et al : Association between pathological gambling and Parkinsonian therapy as detected in the food and drug administration adverse event database. Arch Neurol 63 : 299-300, 2006.
PubMed
8) 太田晃一, 篠原幸人 : 麦角系アゴニスト服用パーキンソン病患者の心弁膜症の問題について. 第49回日本神経学会総会プログラム抄録集, p202, 2008.
 
9) 吉川純一編 : 僧帽弁疾患, 大動脈弁疾患. 臨床心エコー図学, p67-111, 文光堂, 1991.
 

VII QOL

P.550 掲載の参考文献
1) 津山直一 : 標準リハビリテーション医学, p 173-205, 医学書院, 2006.
 
2) Mahoney FI, Barthel DW : Functional evaluation : The Barthel index. Md State Med J 14 : 61-65, 1965.
PubMed
3) Hoehn MH, Yahr MD : Parkinsonism : onset, progression, and mortality. Neurology 17 : 427-442, 1967.
 
4) Schwab RS, England AC : Projection technique for evaluating surgery in Parkinson's Disease. In : Third Symposium on Parkinson's Disease (ed by Gillingham FJ, Donaldson IML), p 152-157, E. & S. Livingstone, Edinburgh, London, 1969.
 
5) Fahn S, Elton RL, and Member of The UPDRS Development Commitee : Unified Parkinson's disease rating scale. In : Recent Developments in Parkinson's Disease, Vol II (ed by Fahn S, et al), p 153-163, Macmillan Healthcare Information, Florham Park, New Jersy, 1987.
 
6) Goetz CG, et al : Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) : Process, format, and clinimetric testing plan. Mov Disord 22 : 41-47, 2007.
PubMed
P.561 掲載の参考文献
1) グラフでみるパーキンソン病患者の実態報告書, 全国パーキンソン病友の会, 2007/05/18発行.
 
2) パーキンソン病患者の自由への扉 脳深部刺激術 (DBS) 体験記集, APPLE運営仲間の会, 2004/01/30発行.
 
3) http://www9.ocn.ne.jp/~pdiyasi/
 
4) 特定疾患対策懇談会における議論の整理について http://www.mhlw.go.jp/shingi/2006/12/dl/s1211-3h.pdf
 
5) 特定疾患QOL向上研究班調査報告書, パーキンソン病のQOLに占める医療・経済問題, 全国パーキンソン病友の会, 2004/03発行.
 
P.568 掲載の参考文献
1) 中島健二ほか : 鳥取県米子市のパーキンソン病の疫学 (第二報). 厚生労働科学研究費補助金 (難治性疾患克服研究事業) 神経変性疾患に関する調査研究班平成18年報告書, p124-126, 2007.
 
2) Nagayama, et al : Initial symptoms of Parkinson's disease With elderly onset Gerontology 46 : 129-132, 2000.
PubMed
3) 秋下雅弘 : 高齢者における安全な薬物療法のポイント. 日本医事新報 4381 : 57-61, 2008.
Medical*Online
4) 村田美穂 : パーキンソン病における併用療法のあり方と注意点. Geriatric Medicine 46 : 365-369, 2008.
Medical*Online
5) Marras C, et al : Predicting motor decline and disability in Parkinson disease : a systematic review. Arch Neurol 59 : 1724-1728, 2002.
PubMed
6) 日本神経学会 : パーキンソン病治療ガイドライン2002. 臨床神経 42 : 430-494, 2002.
 
7) 梅村淳ほか : 75歳以上のパーキンソン病に対する視床下核刺激療法の適応についての再考. 機能的脳神経外科 47 : 80-81, 2008.
 
8) 鈴木隆雄 : 転倒外来の実際臨床医 28 : 1830-1833, 2002.
 
9) 葛原茂樹 : パーキンソン病の自然経過-高齢者の特徴-. Gerontology New Horizon 13 (増刊号) : 39-44, 2001.
 

書評

最近チェックした商品履歴

Loading...